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Summary 
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Summary 
The development of immunotherapies against viral infections and cancer requires a better 
understanding of the key parameters that control T cell-mediated immune responses, such as 
TCR-ligand binding avidity. The overall aim of this thesis was to improve our knowledge 
regarding the contribution of TCR binding avidity in mediating the functional potency and 
maintaining the long-term memory of antigen-specific CD8 T cells. We first performed a 
comprehensive study of TCR-pMHC binding avidity (i.e. off-rates) combined with various 
functional assays on large libraries of tumor- and virus-specific CD8 T cell clones from 
melanoma patients and healthy donors. We demonstrated that TCR-pMHC off-rates accurately 
predicted the functional potential of antigen-specific CD8 T cells. Our data also confirmed the 
superior binding avidities of virus-specific compared with tumor–specific T cell clonotypes. 
The TCR-pMHC off-rate is a more stable and robust biomarker of CD8 T cell potency than 
frequently used functional assays that depend on multiple parameters, including T cell 
activation state. Together, our data show that the TCR-pMHC binding avidity is a reliable 
biophysical parameter for patient monitoring during immunotherapy. In the second part of 
this thesis, we investigated whether TCR-ligand avidity is a determining factor for the clonal 
selection and evolution of antigen-specific T cells over time. We studied TCRαβ clonotype 
composition and persistence over a period of 15 years combined with TCR-pMHC binding 
avidity analyses on large repertoires of cytomegalovirus (CMV)- and Epstein-Barr virus (EBV)-
specific CD8 T cell clones from healthy donors. Within CMV-specific T cell repertoires, we 
observed the progressive contraction of clonotypes of higher TCR-pMHC avidity and lower 
CD8 binding dependency during chronic antigen exposure. Strikingly, we identified a unique 
transcriptional signature preferentially expressed by high-avidity T cell clonotypes, including 
elevated expression of the inhibitory receptor LILRB1.  Enhanced proliferative capacity was 
also observed upon LILRB1 blockade. This was not the case for the EBV-specific T cell clonal 
composition and distribution that, once established, displayed an unprecedented stability for at 
least 15 years, independently of TCR-pMHC avidity. Our findings reveal an overall long-term 
avidity decline of CMV- but not EBV-specific T cell clonal repertoires, highlighting the 
differing role played by TCR-ligand avidity over the course of these two latent herpesvirus 
infections. We propose that the mechanisms regulating the long-term outcome of CMV- and 
EBV-specific memory CD8 T cell responses in humans are distinct. 
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Résumé 
Le développement des immunothérapies ciblant les infections virales et les cancers requiert une 
meilleure compréhension des paramètres-clés qui contrôlent les réponses cellulaires T, tel que 
l’avidité des TCRs pour leur ligand. L’objectif global de cette thèse était d’améliorer nos 
connaissances sur la contribution de l’avidité du TCR à la médiation des fonctions cellulaires 
et au maintien de la mémoire à long terme des cellules T CD8. Nous avons initialement mené 
une étude analytique sur l’avidité du TCR combinée à divers essais fonctionnels sur des 
lymphocytes T CD8 dirigés contre des antigènes viraux et tumoraux chez des donneurs sains 
et des patients atteints de mélanome. Nous avons démontré que l’avidité du TCR prédisait avec 
précision les fonctions cellulaires des cellules T CD8. Nos résultats confirment également que 
les cellules T CD8 spécifiques pour les antigènes viraux sont de plus haute avidité que celles 
spécifiques pour les antigènes tumoraux. De plus, l’avidité du TCR est un biomarqueur de la 
capacité fonctionnelle des cellules T, qui est plus stable et robuste que les tests fonctionnels 
habituellement utilisés. Dans l’ensemble, nos résultats montrent que l’avidité du TCR est un 
paramètre biophysique fiable pour le suivi des patients traités par immunothérapie. Par la suite, 
nous avons évalué si l’avidité du TCR était un facteur déterminant pour la sélection clonale des 
cellules T CD8 au cours du temps. Sur une période de 15 ans, nous avons étudié la composition 
et la persistance des répertoires clonotypiques dirigés contre le cytomégalovirus (CMV) et 
l’Epstein-Barr virus (EBV) ainsi que l’avidité du TCR chez des donneurs sains. Dans le cas de 
la réponse lymphocytaire T contre le CMV, nous avons observé la contraction progressive des 
clonotypes de plus haute avidité et peu dépendants de l’interaction avec le corécepteur CD8, 
au cours du temps. Nous avons identifié une signature transcriptionnelle distincte chez les 
clonotypes de plus haute avidité, avec notamment de l’expression élevée du récepteur inhibiteur 
LILRB1. Une augmentation de la capacité proliférative des cellules T a également été observée 
lors du blocage de LILRB1. Cela n’était pas le cas des répertoires des cellules T CD8 dirigées 
contre l’EBV qui, une fois établis, sont maintenus de façon stable pendant au moins 15 ans, 
indépendamment de l’avidité du TCR. Nos résultats révèlent un déclin global à long terme de 
l'avidité des répertoires clonaux de lymphocytes T spécifiques du CMV, mais non de l'EBV, 
soulignant le rôle différent joué par l'avidité des TCRs au cours des infections latentes induites 
par ces deux virus. Nous suggérons que des mécanismes distincts régulent l’évolution à long 
terme des réponses lymphocytaires mémoires T CD8 spécifiques du CMV et de l’EBV chez 
l'homme. 
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Abbreviations 
2D  Two-dimensional 
3D  Three-dimensional 
AIDS  Acquired immune deficiency syndrome 
AP-1  Activator protein 1 
APC  Antigen presenting cell 
C  Constant 
CARs  Chimeric antigen receptors 
CCR7  C-C motif chemokine receptor 7 
CD  Cluster of differentiation 
CD62L L-selectin 
CDR  Complementarity determining region 
CM  Central-memory T cell 
CMV  Cytomegalovirus 
CpG ODN CpG oligodeoxynucleotides  
CTLA-4 Cytotoxic T lymphocyte antigen 4 
D  Diversity 
DN  Double negative  
DNA  Deoxyribonucleic acid 
DP  Double positive 
EBV  Epstein–Barr virus 
EC50   Half maximal effective concentration 
EM  Effector-memory T cell 
EMRA Effector-memory CD45RA+ or Effector T cell 
hCMV  Human cytomegalovirus 
HCV  Hepatitis C virus 
HIV  Human immunodefiency virus 
HLA  Human leukocyte antigen 
ICAM-1 Intercellular adhesion molecule 1 
IE1  Immediate-early protein 1 
IFA  Incomplete Freund’s adjuvant 
IFN   Interferon 
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IL  Interleukin 
IM  Infectious mononucleosis 
IS  Immunological synapse 
ITAM  Immunoreceptor tyrosine-based activation motif 
ITIM  Immunoreceptor tyrosine-based inhibitory receptor  
J  Joining 
KD  Dissociation equilibrium constant  
KLRG1 Killer-cell lectin like receptor G1  
koff  Dissociation rate 
kon  Association rate 
LAG-3 Lymphocyte-activation gene-3 
LAT  Linker of activated T cells 
Lck  Lymphocyte-specific protein tyrosine kinase 
LCMV  Lymphocytic choriomeningitis virus 
LFA-1  Lymphocyte function-associated antigen 1 
LILRB1 Leukocyte immunoglobulin-like receptor subfamily B member 1 
MCMV Mouse cytomegalovirus 
MHC  Major histocompatibility complex 
MP-SPR  Multiparametric surface plasmon resonance 
N  Naive T cell 
NFAT  Nuclear factor of activated T cells 
NFkB  Nuclear factor-kappa B 
NK  Natural killer 
NTA  Nitrilotriacetic acid 
NTAmers NTA-His tag-containing multimer 
NY-ESO-1  New York esophageal squamous cell carcinoma 1 
PD-1  Programmed cell death 1 
PDL-1  PD ligand-1 
pMHC  Peptide-MHC complex 
pp65  65kDa phosphoprotein 
RAG  Recombination-activating gene 
RNA  Ribonucleic acid 
RNASeq RNA sequencing 
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RSS  Recombination signal sequences 
SHP  Src homology region 2 domain-containing phosphatase 
SLO  Secondary lymphoid organ 
SLP-76 SH2 domain containing leukocyte protein of 76kDa 
SP  Single positive 
SPR  Surface plasmon resonance 
t1/2  Half-time 
TCR  T cell receptor 
TGF-b Tumor growth factor b 
TIGIT  T cell immunoreceptor with Ig and ITIM domains 
TNF  Tumor necrosis factor 
TRAV  T cell receptor alpha variable 
TRBV  T cell receptor beta variable 
Treg  Regulatory T cell 
V  Variable 
VLA-1  Very late antigen-1  
VZV  Varicella-Zoster Virus 
WT  Wild-type 
ZAP-70 Zeta-chain-associated protein kinase 70 
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Introduction 
1. T cell immunity 
1.1. T cells in the immune system 
The human immune system comprises organs, cells and molecules, which serve to defend the 
body against invasion and infection by foreign pathogens and molecules. The immune system 
can be divided into an innate immune component, which acts rapidly and in a non-adaptive 
way, and the adaptive immune component, which takes days to develop but may provide 
lifelong protection against a particular pathogen. The two systems work closely together to 
shape an efficient immune response against a foreign organism whilst each having distinct 
functions (reviewed in [1]).  
The innate immune system provides the first line of defense against pathogens, through 
anatomical and physiological barriers and innate immune cells such as macrophages, dendritic 
cells, neutrophils or natural killer (NK) cells. These cells provide an immediate response by 
detecting and neutralizing or eliminating invading pathogens as well as alerting other 
components of the immune system. In addition, humoral innate immune proteins, such as the 
complement proteins, can recognize and induce the destruction of foreign organisms. 
On the other hand, adaptive immune responses are mediated by T and B lymphocytes, which 
recognize components of pathogens or abnormal self-cells (known as antigens) in a highly 
specific manner through their cell surface T and B cell receptors, respectively. T and B 
lymphocytes collectively possess an enormous repertoire of specificities enabling recognition 
of virtually any antigen they could encounter. Upon antigen recognition, they proliferate to 
generate large pools of lymphocytes sharing the same antigen specificity (i.e. clonal selection 
and expansion). B lymphocytes will then differentiate into plasma cells to produce antibodies, 
which neutralize extracellular pathogens and facilitate their elimination by other components 
of the immune system. T lymphocytes can be divided into either cytotoxic T cells (CD8+ T 
cells, CD stands for Cluster of Differentiation), able to directly kill infected or abnormal cells, 
or helper T cells (CD4+ T cells), able to secrete cytokines and to regulate the response of other 
immune cells. A subgroup of CD4+ T cells named regulatory T cells (Tregs) serve to prevent 
and limit the extent of immune activation. Some activated B and T cells will persist after the 
Introduction 
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resolution of the infection and differentiate into memory cells. In the case of a second exposure 
to the same antigen, memory cells are capable of generating an immune response that is faster 
and of greater amplitude, in order to efficiently eliminate the pathogen.  
1.2.  T cell development 
B and T lymphocytes are derived from multipotent hematopoietic stem cells in the bone 
marrow. Whilst B cells undergo a large part of their development there, T cells must migrate 
from the bone marrow to the thymus in order to undergo thymocyte differentiation (reviewed 
in [2]). They first start as CD4-CD8- double negative (DN) cells in the thymic cortex, then 
either evolve into the minor population of g:d T cells or into the major population of α:β T 
cells we will focus on hereafter. α:β T cells then enter a double positive (DP) thymocyte stage, 
during which they express both CD4 and CD8 coreceptors. Finally, they mature into CD4+ or 
CD8+ single positive (SP) cells while entering the thymic medulla. This step of maturation is 
driven by the capacity of T cells to interact via the T cell receptor (TCR) with self-peptide 
presented in the major histocompatibility complex (MHC) class I and MHC class II, expressed 
by thymic epithelial cells. DP thymocytes that interact optimally with self-MHC will receive 
essential survival signals and further mature. This process is known as positive selection. DP 
thymocytes that are positively selected by interacting with MHC class I will differentiate into 
CD8+ SP, while thymocytes optimally interacting with MHC class II will differentiate into 
CD4+ SP (Figure 1). Thymocytes also undergo negative selection which eliminates those that 
recognize self-antigens too strongly, by apoptosis [3]. This process prevents autoimmune 
responses in the periphery. Both positive and negative selection, collectively known as central 
tolerance, lead to the death of the majority of thymocytes and it is estimated that only 2% of 
mature naive T cells will exit the thymus to form the peripheral T cell repertoire. Nonetheless, 
some self-reactive T cells specific for self-antigen (such as Melan-A, [4]), although of low 
affinity, survive negative selection and migrate to the periphery. However, these cells only rarely 
generate auto-immune responses, demonstrating the existence of mechanisms of peripheral 
tolerance that limit their activation. Such mechanisms can be clonal deletion of self-reactive T 
cells or their conversion into Tregs by antigen presenting cells (APCs) that present self-antigen 
in secondary lymphoid organs, or the depletion of the growth-factor interleukin-2 (IL-2) from 
the environment and secretion of immuno-suppressive cytokines, such as IL-10 and tumor 
growth factor β (TGF-β) by Tregs [5].  
Introduction 
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Figure 1: T cell development in the thymus. Haematopoietic precursors migrate from the bonne marrow to the thymus, 
where T cell lineage commitment occurs. They first start as CD4-CD8- double negative (DN) cells in the thymic cortex, then 
enter a CD4+CD8+ double positive (DP) thymocyte stage, and finally mature into CD4+ or CD8+ single positive cells 
while entering the thymic medulla. Mature single positive T cells have been positively and negatively selected to generate self-
tolerant CD4+ helper T cells and CD8+ cytotoxic T cells. Adapted from Zúñiga-Pflücker 2004 [2]. 
 
1.3. The T cell receptor and co-receptors 
During T cell development, the TCR undergoes a process of gene-segment rearrangement to 
give rise to a heterodimer consisting of two transmembrane glycoprotein chains, the α and β 
chains. Both α and β chains are composed of a variable region, a constant region, a 
transmembrane region and a short cytoplasmic tail. The TCRα gene locus contains several 
variable (V) and joining (J) gene segments and one constant (C) region, whereas the TCRβ 
locus contains two diversity (D) gene segments in addition to several V and J gene segments 
and two C regions (Figure 2). The gene segments of each chain are randomly combined. First, 
Introduction 
 9 
in double negative thymocytes, the β chain gene undergoes Dβ-Jβ rearrangement followed by 
Vβ-DβJβ rearrangement. Next, Vα-Jα rearrangement takes place in double positive thymocytes. 
Gene rearrangements are driven by the recognition of recombination signal sequences (RSS), 
which flank all TCR gene segments, by the recombination-activating genes RAG1 and RAG2. 
After the introduction of double strand breaks in RSS by RAG1/2, DNA repair machinery 
completes the recombination process [6]. During gene rearrangement, the diversity of the 
receptors is further increased by the addition and deletion of nucleotides at the junction 
between the Vα-Jα and Vβ-Dβ-Jβ gene segments. Finally, the rearranged VJα and VDJβ regions 
are transcribed and spliced to join their respective C regions. After translation, the two chains 
pair to form the α:β T cell receptor, which is expressed at the cell surface. The whole process 
of combinatorial and junctional diversity, as well as the random α:β chain pairing, leads to a 
high diversity of sequences especially in the so-called complementarity determining regions 
(CDRs) that make up the antigen binding site. The CDR1 and CDR2 are generated by the 
recombination of the two variable regions Vα and Vβ, and make contact mostly with the MHC 
molecule. The CDR3, formed by the Jα and Dβ-Jβ regions, is the most variable part of the 
TCR and thus mainly interacts with the antigenic peptide [7]. We use the CDR3 sequence to 
define a unique TCR clonotype, which is a population of T cells that carry identical TCR α and 
β chains. 
 
 
Figure 2: T-cell receptor gene rearrangement. Variable (Va), joining (Ja) and constant (Ca) gene segments 
constitute the TCRa gene locus, whereas the TCR b locus contains diversity (D) gene segments in addition to several Vb and 
Jb and two Cb gene segments. Segments from each region are recombined, with additional nucleotide additions, to generate the 
final TCR sequence. Adapted from Nikolich-Zugich et al. 2004 [7]. 
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The recombination process has the potential to create between 1015 and 1020 different TCRs  
[7-9], though a more recent study has even estimated this number as high as 1061 [10]. However, 
due to stringent positive and negative selection, the real TCR repertoire diversity is much lower. 
In fact, while the number of T cells circulating in a human body is estimated to be between 
1012 and 1013 [11], the number of different TCRs has been shown to be between 107 [12] and 
108 [13]. This discrepancy indicates that a relatively high number of T cells bearing an identical 
TCRαβ, or clonotypes, are circulating, due to homeostatic proliferation and clonal expansion 
after antigen recognition. 
The TCR has only short cytoplasmic tails that do not allow it to directly signal after binding to 
a peptide-MHC complex (pMHC). Therefore, to be functional the TCR has to be in association 
with the CD3 molecule to form a TCR/CD3 complex [14] (Figure 3). CD3 is a protein complex 
made up of a g and a d chain, two e chains and two z chains. The g, d and e chains are cell-
surface proteins with transmembrane regions and cytoplasmic tails that contain 
immunoreceptor tyrosine-based activation motifs (ITAMs). The two z chains are mainly 
intracellular dimers linked by disulfide bonds which each contain three ITAMs. The 
transmembrane regions of the CD3 chains are negatively charged due to the presence of 
aspartate residues, a characteristic that allows these chains to associate with the positively 
charged residues in the transmembrane region of the TCR. To induce a T cell response upon 
TCR triggering, the CD3 ITAMs become phosphorylated and recruit a complex set of 
intracellular signaling molecules (the precise T cell signaling process is detailed in section 1.4).  
 
Figure 3: The T cell receptor 
complex.  The T cell receptor (TCR) 
complex comprises the TCR αβ heterodimer 
in association with the CD3 co-receptor, 
composed of six signaling chains (two e, two 
z, one g and one d). CD3 chains contain 
one to three immunoreceptor tyrosine-based 
activation motifs (ITAMs). TCR and 
CD3 chains interact via their respective 
positively and negatively charged residues. 
Adapted from Murphy 2012 [1]. 
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In addition to the interaction between the TCR and the peptide-MHC, T cell co-receptors also 
participate in interactions with the MHC to increase antigen sensitivity (Figure 4). Indeed, the 
co-receptors CD4 and CD8 are cell surface glycoproteins, which associate with the TCR 
complex on the T cell surface and bind to MHC to stabilize and increase the avidity of the 
TCR-pMHC interaction [15-17]. The CD4 is a single chain with four immunoglobulin-like 
domains including the D1 domain which interacts with the MHC class II molecule. On the 
other hand, CD8 can be found in an αα homodimeric or αβ heterodimeric form. The latter is 
found on the vast majority of T lymphocytes and we will be focused on thereafter. CD8 
interacts through its α chain with the α3 domain of MHC class I molecules. In the context of 
Human Leukocyte Antigen (HLA)-A*0201, residues 223-229 of the α3 domain have been 
shown to be of particular importance for this interaction [18]. The CD8 α chain, in addition to 
its critical role in binding MHC I, also holds the docking site for the lymphocyte-specific 
protein tyrosine kinase (Lck) p56, essential for the initiation of TCR signaling. In contrast, it is 
the β chain, and especially the palmitoylated part of its cytoplasmic tail, that partition CD8 into 
lipid rafts to bring it close to the TCR complex [19]. 
The CD28 costimulatory molecule, found in association with the TCR complex (Figure 4), is 
an important co-receptor for T cell activation and survival. It has two ligands, CD80 expressed 
on activated APCs early during an immune response, and CD86 expressed on APCs later 
during the immune response [20]. CD86 is also the ligand for the inhibitory receptor cytotoxic 
T lymphocyte antigen 4 (CTLA-4), thus playing a role in regulating T cell immune responses 
[21]. CD28 expression varies between the different T cell subsets and will be described in 
section 1.5. 
CD45 is a transmembrane tyrosine phosphatase expressed by hematopoietic cells known to 
regulate TCR-mediated signaling (Figure 4). It has been shown to be capable of both 
downregulating and enabling Lck activity [22], to facilitate T cell signaling and to suppress the 
hyperactivation of peripheral T cells, respectively. CD45 has several isoforms depending on 
the inclusion or exclusion of alternatively spliced exons, A, B and C. The different isoforms 
are specific to the stage of T cell activation and differentiation, and thus are used to identify 
different T cell subsets. For instance, the isoform containing exon A, and so called CD45RA, 
is expressed on naive T cells [23] and activated effector T cells [24]. CD45RO, which does not 
contain any of the exons, is expressed on memory T cells [25].  
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1.4. Antigen recognition and T cell signaling 
The TCR can only recognize antigen in the form of peptide properly processed and presented 
in MHC molecules at the surface of APCs. The two classes of MHC, MHC class I and MHC 
class II differ in their structure, their expression on cells and the type of antigenic peptides they 
present. MHC class I molecules comprise a transmembrane heavy chain α which contains three 
domains (α1, α2, α3) associated non-covalently with the β2 microglobulin chain. MHC class I 
molecules present peptides derived from cleaved endogenous proteins, such as self-peptides 
or viral peptides produced during viral replication, to the TCR of CD8 T cells [26]. MHC class 
I molecules are expressed by all nucleated cells with a higher expression on immune cells such 
as dendritic cells or B and T cells. MHC class I molecules are encoded, in humans, by three 
main genes HLA-A, -B, and -C. The HLA genes are highly polymorphic resulting in a unique 
set of HLA alleles in each individual, with the exception of identical twins [27]. MHC class II 
molecules consist of two transmembrane chains, α and β, each containing two domains (α1, 
α2, β1, β2), encoded by the HLA-DR, -DP and -DQ genes. They are specialized in the 
presentation of extracellular antigens derived from proteins degraded in the endocytic pathway 
of APCs, to the TCR of CD4 T cells [28]. Therefore, MHC II expression is highly restricted to 
phagocytic APCs such as dendritic cells, macrophages or B cells. 
After recognition by the TCR of a peptide presented by MHC molecules, a protein 
reorganization occurs at the interface of the T cell and APC to form an immunological synapse 
(IS) (Figure 4). This is a tight molecular junction whose formation is driven by the engagement 
of adhesion receptors such as the T cell integrin Lymphocyte Function-associated Antigen 1 
(LFA-1) to its ligand, Intercellular Adhesion Molecule 1 (ICAM-1) on the APC [29, 30]. This 
organized interface also contains diverse regulatory elements that fine-tune T cells activation, 
such as the coreceptor CD45 [31] or the inhibitory receptors PD-1 (Programmed Cell Death 
1) or CTLA-4 [32]. 
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Figure 4: Immunological synapses 
between T cells and antigen presenting 
cells. A representative view of the antigen 
recognition signal (TCR-peptide/MHC), co-
stimulatory (shown in blue) and -inhibitory (shown 
in yellow) molecules found in an immunological 
synapse and involved in T-cell recognition. 
Adapted from Huppa and Davis, 2003 [33]. 
 
 
 
 
 
 
Following TCR-pMHC interaction and the formation of the IS, an intracellular signaling 
cascade is initiated in the T cell. In the case of naive T cells, pMHC recognition is not sufficient 
for T cell activation, and requires the additional engagement of CD28 costimulatory receptors 
by cognate ligand expressed on APCs (Figure 4). In the absence of such costimulation, naive 
T cells will become anergic and will not be able to proliferate or to differentiate. Anergy is one 
of the processes that induces tolerance and prevents excessive self-reactivity of T cell-based 
immune responses, as CD80 and CD86 are mainly expressed on activated APCs during 
infection. For effector T cells, on the other hand, TCR-pMHC interaction is sufficient to 
initiate T cell activation. TCR-mediated cell signaling starts with the activation of the Src-family 
Lck and Fyn kinases by the tyrosine phosphatase CD45, which removes their inhibitory 
phosphatase groups. Lck and Fyn then phosphorylate the ITAMs of the CD3 chains of the 
TCR complex, which results in the recruitment of the Syk-family zeta-chain-associated protein 
kinase 70 (ZAP-70) [34]. After being activated by Lck, ZAP-70 will phosphorylate the 
transmembrane proteins LAT (linker of activated T cells) and SLP-76 (SH2 domain containing 
leukocyte protein of 76kDa), which together activate phospholipase C-g (PLC-g) [35]. The 
activation of PLC-g leads to the activation of three distinct signaling branches, culminating 
with the transcription factors (i) nuclear factor-kappa B (NFkB), (ii) nuclear factor of activated 
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standard cooled charge coupled device (CCD) camera18.
In this way, it is possible to count the exact number of
ligands that a T cell encounters on another cell, and
then monitor the consequences of that interaction with
respect to the increase of intracellular calcium concen-
tration and the behaviour of different GFP-labelled
proteins. In this way, it was shown that at least some
CD4+ T-cell blasts can respond to even a single ligand,
by stopping and fluxing calcium weakly (FIG. 2a). Two
ligands in the interface produce a more sustained rise
in calcium and ten or more ligands produce a maximal
response and promote the formation of a stable
synapse. Parallel experiments using two different cyto-
toxic T-cell models give a similar dose-response curve
(M. Purbhoo et al., unpublished observations). So, in at
least four T-cell model systems, T cells can detect just
one ligand, but all require about ten to increase and
maintain calcium levels fully (FIG. 2b). Increased calcium
levels are pivotal to T-cell activation, as this induces the
nuclear localization of nuclear factor of activated T cells
(NFAT) — a transcription factor that is responsible for
many of the gene-expression changes associated with
activated TH cells19.
Importantly, 25–30 peptide–MHC complexes were
required at the interface to induce T cells to stop and
flux calcium when CD4 was blocked (FIG. 2b). These data
indicate that CD4 is intimately involved in detecting
antigens at low surface densities, which prompted
Ligand threshold for synapse formation
T cells are highly sensitive to antigen, with estimates
ranging from 1–400 specific peptide–MHC complexes
on a presenting cell required to activate fully at least
some T cells in a population13–15. There are major uncer-
tainties with these studies however: they rely on average
values of peptide loading on a given MHC molecule
and there is no way of measuring just how much surface
area is ‘surveyed’by a given T cell and how far it gets in
the activation process. To illustrate the limitations of this
bulk-cell population approach (as opposed to a single-
cell approach), suppose you had detected full activa-
tion in a few T cells at an average of 100 peptides per
APC. Not only will you have outliers in the APCs that
might have 300 peptides per cell (and which might be
responsible for most of the activation events when 
peptide is limiting), but it also matters a great deal
whether the T cell surveys 1% of the APC surface or 50%.
An important recent advance has been the develop-
ment of a new approach that provides more precise
information about T-cell sensitivity and the nature of
T-cell responsiveness to different numbers of ligands16.
Here, the peptide extends out of the peptide-binding
groove and is labelled on an amino-terminal biotin with
a streptavidin–phycoerythrin conjugate. Phycoerythrin
is a large (240 kDa) multimeric protein that contains
~34 chromophores17. Because of its brightness, it is pos-
sible to visualize single phycoerythrin molecules with a
FLUORESCENCE RESONANCE
ENERGY TRANSFER
(FRET).An imaging technique
to analyse intermolecular
distances based on the transfer
of energy from a donor molecule
to an acceptor molecule without
the emission of a photon.
CTLA4
TCR
CD4/CD8
CD45
CD45
CD44
CD43
ICAM1
CD28 CD80/CD86
LFA1
LCK
CD3
ZAP70
PI3K
SHP2
APC
T cell
CD2–CD48/CD59
LCK
CD4
CD45*
TCR–CD3–peptide
–MHC
CD28–CD80/CD86
CTLA4–CD80/CD86
Agrin
PKC-θ
CD43
Talin
LFA1–ICAM1
CD45 CD44
a b
Peptide–
MHC
CD2 CD48/CD59
Figure 1 | Overview of a mature T-cell synapse. a | A profile view showing a selection of the key ligand pairs and signalling
molecules that are involved in T-cell recognition. The stimulatory peptide–MHC molecule is shown in red, activating/co-stimulatory
molecules are blue, inhibitory molecules are yellow and molecules that are not contributing to signalling are grey. The arrow indicates
converging signals that lead to T-cell activation. b | The face on view of the synapse with the characteristic ‘bulls-eye’ zone pattern,
including the central region of the supra-molecular activation complex (cSMAC) (yellow), the peripheral ring surrounding the cSMAC
(pSMAC, green) a d the region distal t  the synapse outside t e pSMAC (dSMAC, grey) as well the molecules/ligand pairs that are
found enriched within. APC, antigen-presenting cell; CTLA4, cytotoxic T lymphocyte antigen 4; ICAM1, intercellular adhesion molecule
1; LFA1, leukocyte function-ass ciated antigen 1; PI3K, phosphatidylinosit l 3-kinase; SHP2, SRC homology 2-domain-containing
protein tyrosine phosphatase 2; TCR, T-cell receptor; ZAP70, ζ-chain-associated protein 70. *CD45 enters the cSMAC at later stages.
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T-cells (NFAT) and (iii) activator protein 1 (AP-1) [36]. These transcription factors regulate 
gene transcription involved in cell activation, proliferation, and differentiation.  
1.5. CD8 T cell differentiation and subsets 
Following activation, naive T cells will rapidly proliferate to generate a large pool of effector 
cells with the same antigen specificity, a process known as clonal expansion. At the end of the 
primary response, the majority of effector T cells will die by apoptosis and only a small fraction 
will remain as long-term memory T cells. During a second exposure to the same antigen, 
memory T cells are mobilized in a recall response that is faster and more efficient than the 
primary response [37]. The different subsets of T cells (naive, memory and effector) can be 
distinguished based on their differential expression of cell-surface molecules.  
Naive (N) T cells express high levels of homing receptors such as L-selectin (CD62L) and C-
C motif chemokine receptor 7 (CCR7), which promote T cell trafficking to secondary lymphoid 
tissues where they encounter activated APCs. Thus, N T cells are generally defined as 
CD62L+CCR7+ and CD45RA+. 
Effector T cells lose the capacity to migrate to lymph nodes and are thus defined as CCR7-, 
CD62L-, and CD45RA+ and are termed EMRA T cells. EMRA T cells preferentially home to 
peripheral tissues and exhibit strong effector functions such as cytokine production and killing 
capacity to eliminate infected or abnormal cells. Expression of the coreceptor CD28, involved 
in T cell co-stimulation, further defines intermediate stages of differentiation of EMRA T cells. 
EMRA CD28+ (EMRA28+) T cells display phenotypic and functional features that are 
intermediate between naive and differentiated effector, while EMRA CD28-  (or EMRA28-) T 
cells is a subset evolving toward a more differentiated effector stage [38].  
The memory CD8 T cell subset also consists of a highly heterogeneous population of cells that 
differ in phenotype, function and response to a particular antigen. Sallusto et al. [39] were the 
first to discriminate two types of CD8 memory T cells based on their expression of CCR7: the 
central-memory (CM) cells which are CCR7+ and the effector-memory (EM) cells which are 
CCR7-. CM T cells lack immediate effector function but recirculate between blood and 
lymphoid tissues to eventually re-encounter antigen and rapidly proliferate at high magnitude. 
In response to antigen re-encounter they will differentiate into effector or effector-memory T 
cells. EM T cells circulate between blood and peripheral tissues where they can exert effector 
Introduction 
 15 
functions. Based on expression of the costimulatory receptor CD28, EM T cells subset can be 
further divided in two subsets [40]. CD28 expressing memory cells or EM28+, resemble CM 
T cells with a short replicative history, low expression of effector molecules, but an increase 
survival potential. On the other hand, CD28- memory cells or EM28-, express more cytokines 
and have an advanced replicative history, thus being closer to effector T cells [40]. Finally, 
several other memory T cell subsets have been more recently described, such as tissue-resident 
memory T cells, which stably occupy peripheral tissues and do not re-enter blood circulation. 
They exert effector functions to provide immediate protection against local infection at body 
surfaces to accelerate pathogen clearance (reviewed in [41]). 
1.6. CD8 T cell effector functions 
As previously described, following antigenic challenge, naive CD8 T cells undergo a program 
of clonal expansion and differentiation, during the course of which they acquire effector 
functions to become cytotoxic T cells and kill infected or tumor cells [42]. One way for CD8 
T cells to exert their cytotoxic function is by delivering cytotoxins, mainly perforin and 
granzyme, to target cells. Perforin generates pores in the target cell membrane, and granzyme, 
a serine protease, enters target cells via perforin-mediated pores to induce apoptosis. These 
proteins are synthesized and stored in granules inside CD8 T cells. To avoid damage to 
surrounding tissue that effector molecules could induce, cytolytic granules are released within 
an immunological synapse between the T cell and the target cell [43]. Activated CD8 T cells 
also express the transmembrane protein Fas ligand, which can bind to Fas expressed on target 
cells. This interaction leads to the death of the target cell by apoptosis through the death 
domain of the cytoplasmic tail of Fas [44]. Finally, CD8 T cells can also act by releasing 
cytokines such as interferon-g (IFNg), tumor necrosis factor α and β (TNFα and TNFβ) [45]. 
IFNg inhibits viral replication, and increases the expression of MHCI as well as the 
presentation of viral peptides. IFNg  also recruits and activates macrophages to act as 
phagocytes and antigen presenting cells. TNFα and TNFβ cytokines are as well able to activate 
macrophages and can directly kill target cells by apoptosis through the interaction with TNF 
receptor-I.  
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2. Non-self and self T cell-specific immune responses 
2.1. Anti-viral versus anti-tumoral responses 
From an immunological point of view, chronic infections and cancer are comparable in many 
ways. In addition to giving rise to a specific immune response, they are also characterized by 
continuous antigenic stimulation of immune cells. They are also known to escape immune 
control through various mechanisms such as the downregulation of immunogenic antigens, as 
well as MHC downregulation. The drastic difference between the viral and tumoral context is 
the ability of the immune system to efficiently control chronic infections, while tumor cells are 
often invasive and can only rarely be spontaneously controlled. In fact, while cancer vaccines 
in melanoma patients have shown successful induction of T cells at high frequencies and with 
similar phenotype and effector characteristics to those associated with long-lasting, protective 
anti-viral responses [46-48], they have so far obtained only limited clinical success. This could 
be due to the persistence of an immunosuppressive tumor microenvironment [49, 50]. Indeed, 
tumors induce strong local immune suppression through several mechanisms such as the 
secretion of immunosuppressive factors including the cytokines TGF-b [51] or IL-10, or by 
the depletion of nutrients essential for CD8 T cell activity [52, 53]. Another major difference 
between chronic viral infections and tumors is the origin of their respective antigens. Virally 
infected cells are recognized by T cells through the presentation of non-self antigens, while 
tumor-specific T cells respond to self-antigen, and are therefore largely eliminated by both 
central and peripheral tolerance mechanisms to prevent auto-immunity. As a result, tumor-
specific CD8 T cells typically exhibit weaker TCR-pMHC binding avidity (dissociation 
equilibrium constant (KD) between 300-10 µM) compared to pathogen-specific CD8 T cells 
(KD of up to 1 µM) [54, 55]. 
Despite the differences described hereabove, chronic viral infections such as Epstein-Barr virus 
(EBV) and Cytomegalovirus (CMV) have proven to be essential tools in the study of highly-
efficient memory T cell responses, and for the identification of T-cell correlates of protection 
in humans. 
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2.2. T cell-based parameters for protective immunity 
The development of immunotherapies, such as adoptive cell transfer, for the treatment of 
cancer and viral infection has been of growing interest in recent decades. To better exploit the 
therapeutic potential of T cells, numerous studies have focused on defining key parameters and 
their synergy for an optimal protective immune response (Figure 5, reviewed in [56, 57] and 
[58]). After being activated by their cognate antigen, T cells must proliferate to reach high 
frequencies. The magnitude of the response is, in part, driven by naive CD8 T cell frequencies, 
which have been correlated with the number of CD8 T cells generated upon primary antigenic 
challenge (reviewed in [59]), though this finding remains controversial [60-62]. Similarly, it is 
not clear whether the magnitude of the response is a protective parameter as it has been 
associated with protection in some studies [63-65], while this is not the case in others reports 
[66, 67]. In addition, the affinity of a given peptide-MHC interaction has been shown to shape 
the magnitude of the response and has been associated with efficient protection [68, 69].  
Importantly, the magnitude of a T-cell response does not necessarily reflect its 
functional potential. In this regard, T cell functional avidity, which describes how well a T cell 
responds in vitro to its cognate antigen, has been used to assess the quality of a T cell response. 
It is defined by functional readouts such as cytokine production, target cells lysis or 
proliferation at different doses of peptide antigen [70]. Numerous studies have associated high 
T cell functional avidity with efficient viral control and clearance in both animal models [71-
73] and patients with human immunodeficiency viruses (HIV) [74, 75] and hepatitis C (HCV) 
[76-78] infections. In addition, T cell functional avidity has been associated with better tumor 
control in mice [79, 80] and in melanoma patients [81, 82]. On the other hand, high functional 
avidity T cells may be more prone to activation-induced cell death, senescence, or exhaustion 
(reviewed in [70]). Nonetheless, a greater proportion of polyfunctional CD4 or CD8 T cells 
(i.e. which exert multiple effector functions) have been observed in HIV [83, 84], hepatitis C 
[85] and CMV [86] patients with controlled infection, compared to patients with progressive 
disease. The functional avidity of T cells is primarily controlled by the strength of TCR-pMHC 
interactions (or TCR–pMHC binding affinity/avidity), and this key parameter will be 
extensively discussed in section 3.  
The quality of a T cell response also depends on the T cell capacity to migrate to the tumor or 
infection sites, as well as to survive and persist over time. Finally, it is generally accepted that 
greater diversity of the TCR repertoire is associated with better protection [87], as a polyclonal 
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response targeting multiple epitopes should ensure long-term protection even if some 
clonotypes are poorly functional or do not survive. In addition, it helps minimize opportunities 
for mutation-driven pathogen or tumor escape [88]. A relatively diverse TCR repertoire has 
been shown to be a predictor of better disease outcome in mouse models [89], whereas in 
humans the advantage of having a diverse repertoire is not always apparent, especially during 
viral infection. Indeed, highly skewed repertoires with clonotypes shared between individuals 
have been observed in EBV, CMV [90-92] or HIV [93] patients who show disease control. 
This non-exhaustive list of criteria and their importance for a protective immune response can 
greatly vary depending on many parameters such as the type of infection or malignancy, as well 
as the patient HLA background and immunocompetent status.  
 
 
 
Figure 5: Identifying T cell correlates of protection for adoptive cell transfer immunotherapy. 
Selection of autologous T cells from a patient based on correlates of protection such as TCR affinity/avidity, T cell frequency, 
poly-functionality, poly-clonality, capacity to migrate to the tumor or sites of infection, as well as survival. After in vitro selection 
and expansion, T cells are re-infused to the patient. Adapted from Hebeisen et al. [94]. 
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3. TCR-pMHC binding affinity/avidity 
3.1. Definitions 
The strength and kinetics of TCR-pMHC recognition are central parameters that impact 
numerous aspects of T cell biology. Due to technological limitations, these parameters are often 
translated in terms of functional avidity, which is the antigen sensitivity measured by functional 
readouts such as cytotoxic activity, proliferation or cytokine production. These functional 
assays are often limited to experiments of fixed stimulation doses and do not directly measure 
the TCR-pMHC affinity/avidity. In addition, many parameters can influence functional assays 
such as the chosen readouts, the activation state of the cells as well as intra-experimental 
variability. 
In contrast to functional avidity, the structural binding strength of the TCR to pMHC is defined 
as the TCR affinity or avidity (Figure 6). The TCR-pMHC affinity refers to the strength with 
which a monovalent receptor binds to its ligand, in this case a single TCR to a peptide–MHC 
complex [95], and this value is inversely proportional to the dissociation equilibrium constant 
KD. At steady-state, KD is defined as the ratio of the dissociation rate (koff) and association rate 
(kon). The dissociation rate koff, or the speed at which the TCR dissociates from the pMHC 
complex can also be expressed as a half-life (t1/2), by the equation t1/2 = ln2 / koff [96]. 
Conversely, TCR-pMHC avidity is the association constant of multiple TCRs bound to their 
respective pMHC complexes, in the cellular context [70]. This measure takes into account the 
potential contribution of co-receptors, TCR density on the cell surface or the T cell activation 
state [94]. TCR-pMHC avidity was commonly assessed by multimers while monomeric pMHC-
TCR dissociation kinetic measurements are assessed by reversible multimers such as 
Nitrilotriacetic acid (NTA)-His tag-containing multimer (NTAmers) [97, 98] or Streptamers 
[99] and define TCR structural or binding avidity. 
Introduction 
 20 
 
Figure 6: Parameters of the TCR-pMHC interaction. The TCR-pMHC affinity refers to the association constant 
of a monovalent receptor bound to its ligand, while TCR-pMHC structural avidity is the association constant of multiple 
TCRs bound to their respective pMHC complexes in the cellular context. Functional avidity depends on the antigen sensitivity 
translated into functional readouts such as proliferation, cytokine production or cytotoxic function. Adapted from Nikolich-
Zugich et al. 2004 [7]. 
 
3.2. Measurement of TCR-pMHC binding affinity/avidity 
TCR-pMHC affinity kinetics (i.e. kon, koff and KD) were first assessed by surface plasmon 
resonance (SPR). SPR assays require the production of soluble TCRs which are perfused 
through a three-dimensional (3D) space to interact with pMHC attached to a sensor chip (also 
defined as 3D interactions) (Figure 7A). A major limitation of this technique is the expensive 
and laborious production of soluble molecules. Moreover, SPR measurements do not take into 
account the contribution of the CD8 coreceptor to TCR–pMHC binding strength. Novel 
technologies have been more recently developed to measure association and dissociation 
constants in a more physiological way, at the interface between a living T cell and an APC or a 
membrane linked pMHC at the two-dimensional (2D) level [100, 101], using fluorescent-based 
or micropipette adhesion frequency assays (Figure 7B). 2D interaction analyses have been 
© 2004 Nature Publishing Group
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diversification in and outside of the thymus, and to
what extent functional features are programmed by
TCR-independent events. The one feature that is
influenced by TCR avidity (and thereby indirectly by
diversity) seems to be the skewing of T helper 1
(TH1)/TH2-cell responses, where higher avidity and
longer TCR–pMHC contacts have been linked to
TH1-cell unc ion47. It will be of interest to extend
such studies to other functions, including migration,
proliferation and secretion of other cytokines.
Muddying the waters: TCR crossreactivity. An impor-
tant factor at the interface of structural and functional
diversity is TCR crossreactivity — the ability of a TCR
to recognize several different peptides bound to self-
MHC molecules (BOX 2). (TCR crossreactivity on non-
self MHC molecules is outside the scope of this
review). One problem facing the immune system is
how to use a finite TCR repertoire, distributed on a
finite number of T cells, to deal with a very large num-
ber of epitopes. It is essential for immune defence that
sufficient numbers of cells are deployed to combat
infection. Simultaneously, specificity of recognition
must be high enough for the repertoire to respond to
foreign, but not to self, peptides. These conditions
could be m t by a large, diverse and highly el ctive
Negative selection could also theoretically promote
some structural and functional diversification through
r ceptor editing, whereby serial TCR-α rearrangements
are induced by negatively selecting ligands42,43, replacing
the original TCR-α chain with other chains. So, instead
of one specificity that would have been negatively
selected, several could be generated by receptor editing.
These effects have be n observed in some TCR-transgenic
models42,43, but not in others44, and, therefore, the
physiological significance of this mechanism remains
incompletely understood.
The examples mentioned illustrate instances of
structural changes to the TCR repertoire induced by
positive or negative selection. Moreover, there are many
examples in which TCR contact with self-peptide–MHC
results in the functional modification of T-cell reactivity.
These include downregulation of important cell-surface
molecules such as TCRs, CD4 or CD8 (REFS 45,46) or
functional anergy, all of which have been observed in
TCR-transgenic systems.
With the TCR repertoire being set by these forces,
T cells that have left the thymus are now charged with
the crucially important task: protection against patho-
ge s.At this point, functional diversity after contact with
antigen is established3–6. It is still unclear to what extent
TCR structur  and avidity can determine functional
T cell
APC
TCR
CD4/CD8MHC
Affinity Structural avidity Functional avidity
Cytolytic function
Proliferation
Cytokine production
Figure 3 | Overview of the concepts of affinity and avidity. Affinity refers to the steady-state association constant between 
a monovalent receptor and its ligand, in this case a single T-cell receptor (TCR) and peptide–MHC (pMHC) complex. Structural
avidity is the steady-state association constant between multiple cell-bound receptors and ligands and is determined by the
direct binding affinities of multiple TCRs to their pMHC complexes. Functional avidity depends on the relative kinetics of
signalling that translate into measurable biological functions such as proliferation, cytokine production or cytolytic function.
APC, antigen-presenting cell.
Affinity Avidity Functional avidity
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shown to correlate well with functional avidity of T cells [102, 103], however they require highly 
specialized equipment and are time-consuming.  
TCR-pMHC avidity was originally estimated based on the staining intensity of soluble pMHC 
multimers of well-defined valencies (Figure 7C) directly on living cells [98, 104]. However, 
pMHC multimer staining intensity does not consistently correlate with the TCR-pMHC 
affinity/avidity [79, 105, 106]. In the past, these discrepancies were overcome by performing 
multimeric association and dissociation rate measurements on living T cells, monitored by flow 
cytometry generally during several hours. Nonetheless, multimeric off-rate does not 
consistently correlate with functional capacity and in vivo protection [79, 106], mainly due to 
the multivalent nature of pMHC complexes and their capacity to rebind TCRs during 
dissociation assays [107]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Representation of TCR-pMHC binding affinity/avidity measurements. TCR-pMHC affinity 
refers to the association constant of a monovalent receptor bound to its ligand and can be assessed by (A) 3D interactions 
(commonly done by SPR) or (B) directly at the interface between a living T cell and an APC or a membrane linked pMHC 
at the 2D level. TCR-pMHC avidity is the association constant of multiple TCRs bound to their respective pMHC complexes 
in the cellular context using multimers with defined valency (C). Due to the caveats induced by the multivalency of multimers, 
reversible multimers have been developed to assess TCR structural avidity defined as the strength of interaction between 
monovalent TCR-pMHC complexes at the cellular level (D). Adapted from Hebeisen et al. [94]. 
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To overcome these limitations and to measure TCR structural avidity at the monomeric level, 
reversible multimers such as NTAmers [97, 98] and Streptamers [99] have recently been 
developed. These complexes consist of fluorescently labelled pMHC monomers linked 
together in a multimeric complex that can be disrupted upon addition of a stimulus (Figure 
7D). Reversible multimers allow the quantitative and reproducible measurements of 
monomeric TCR-pMHC dissociation kinetics (koff) on living T cells. In the case of Streptamers, 
multimer complexes dissociate following addition of D-biotin through a binding site 
competition process that can take up to 60 seconds to reach total complex disruption. 
Monomeric dissociation rate of pMHC from TCRs can be then monitored as a decay in 
fluorescence measured by real-time microscopy [99]. The more recently developed reversible 
multimers, NTAmers [97], are made of pMHC monomers bearing Cy5-labeled b2m complexed 
with PE-streptavidin carrying an engineered NTA linker (Figure 8). These complexes are highly 
stable but rapidly decay to monomers in several seconds (2-3 sec) upon addition of imidazole. 
 
 
 
Figure 8: Representation of reversible NTAmer-based dissociation assay. Individual antigen-specific CD8 
T cell clones were stained with HLA-A0201 antigen-specific NTAmers composed of a PE-labeled backbone (grey) and Cy5-
labeled monomers (brown) carrying imidazole-sensitive Ni2þ-NTA4 moieties. Upon addition of imidazole, the NTAmer 
multimeric complex rapidly dissociates into Cy5-labeled pMHC monomers and Cy5 fluorescent decay can be measured by flow 
cytometry over time. Adapted from Hebeisen et al. 2015 [108]. 
 
Owing to the faster decay of the multimeric complex into monomeric pMHC when compared 
with Streptamers, NTAmers offer an increased sensitivity to detect T cells with low avidity 
TCRs (reviewed in [94]), such as those typically found in self/tumor–specific CD8 T cell 
repertoires. Our lab recently showed that NTAmer-based dissociation rates strongly correlate 
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with the killing capacity of TCR-engineered and natural tumor-specific human CD8 T cells 
[108, 109].  
3.3. Relationship between TCR avidity and function 
The strength of TCR-pMHC interaction has been shown to influence multiple facets of T cell 
activity, including thymic selection, priming by APCs, activation, proliferation and 
differentiation. During priming in secondary lymphoid organs (SLOs), T cells expressing high 
avidity TCRs engage in longer interactions with APCs than do their low avidity counterparts 
[110]. Such high avidity T cell-APC interactions lead to a greater degree of expansion within 
SLOs, and to a slower acquisition of effector functions compared to low avidity T cells [110, 
111]. Thus, high-avidity T cells exit the lymphatic system and enter blood circulation later but 
in greater number and with superior effector functionality [111]. This mechanism allows for a 
rapid response to early infection by low avidity T cells, followed by more robust control 
mediated by high avidity T cells. Indeed, it has been shown that greater diversity of recruited 
TCR affinities is associated with improved host protection in mice [111, 112].  
Using various engineered models, such as affinity-optimized TCR variants or altered peptide 
ligands, several studies have shown that within the physiological affinity range (KD 100–1 µM), 
strong TCR-pMHC interactions correlate with enhanced T cell responsiveness (e.g. cell 
activation, signaling, proliferation, cytokine/chemokine secretion, and target cell killing) [113-
118]. Furthermore, seminal clinical trials demonstrated the importance of TCR-pMHC 
affinity/avidity in cancer patients treated with engineered T cells of enhanced TCR affinity 
(reviewed in [119]). Clinical studies performed with affinity-enhanced T cells against the cancer 
testis HLA-A2/NY-ESO-1157-165 (NY-ESO-1 stands for “New York esophageal squamous cell 
carcinoma 1”) antigen provided augmented in vivo functional capacity and improved tumor 
growth control [120-122]. 
However, most of these reports including the clinical studies are based on artificial models 
(e.g., using affinity-optimized TCR variant panels or altered peptide ligand models), and thus 
only limited information is available on the overall impact and clinical relevance of TCR-pMHC 
binding avidity or kinetics (e.g. off-rates) in the context of naturally occurring antigen-specific 
CD8 T cell responses. Using Streptamers, Nauerth et al. have shown that virus-specific CD8 T 
cells bearing TCRs of high affinity conferred better protection against Listeria monocytogenes 
infection in mice [99]. Moreover, in the tumor model, our group recently documented that the 
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half-lives determined by NTAmers accurately predicted the killing capacities of large panels of 
tumor-specific T cell clones that were isolated prospectively from patients with cancer [108] as 
well as following therapeutic vaccination [109].  
Thus, whilst T cells bearing both low and high affinity TCRs are likely crucial for an efficient 
immune response in vivo, high affinity T cells are essential for complete and/or prolonged 
pathogen control. Moreover, identifying and selecting TCRs of higher avidity may be of 
particular importance in the tumoral setting, since most high avidity/affinity self/tumor 
antigen–reactive T cells are naturally eliminated or silenced by mechanisms of central and 
peripheral tolerance, emphasizing the need to select the remaining rare high-avidity cells for 
immunotherapy. 
4. Herpes virus 
Herpes viruses are genetically stable, large double stranded DNA viruses. Following 
primary/replicative infection in a permissive cell type, they are able to establish lifelong latency 
in a second cell type. g herpesviruses, such as EBV, use the proliferative capacity of the latently 
infected cell to amplify their stable reservoir, while α and β herpesviruses, such as CMV, do 
not have this capacity. In hosts able to mount a proper immune response, herpesviruses are 
generally well controlled reflecting the fine balance between host immune mechanisms and the 
capacity of the virus to evade those controls. 
4.1. Biology of infection of the Epstein-Barr Virus 
EBV infection is restricted to human beings and characterized by latent infection in B cells. 
EBV is mainly transmitted in saliva and is wide spread, with more than 95% of adults over 30 
being seropositive in Europe and North America [123, 124]. Primary infection typically occurs 
in childhood and is usually asymptomatic. However, in adolescents or adults primary EBV 
infection may lead to symptomatic infection (known as infectious mononucleosis (IM)) in 25% 
to 70% of cases [125, 126], characterized by fever, sore throat, enlarged lymph nodes in the 
neck, and tiredness. Following oral transmission, the virus undergoes lytic replication in oral 
epithelial cells and locally-infiltrating B lymphocytes associated with lytic gene expression 
programs. Two immediate early proteins (acting as transcriptional activators) are first 
expressed, followed by several early proteins (essential for viral DNA replication) and finally 
several late proteins (mainly virus structural components). At the same time, the virus induces 
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a growth-transforming infection in B cells leading to their expansion in lymphoid tissues and 
blood. Some of these cells will survive the immune response and allow the virus to established 
a life-long persistence in the circulating memory B cell pool. This latent phase is associated 
with a highly restricted latent gene expression profile which serves to avoid immune detection 
by minimizing antigen exposure [127]. Periodically, EBV virus can re-enter into the lytic phase, 
leading to host cell lysis and the release of new virions. 
4.2. EBV-associated diseases 
EBV is characterized as an oncogenic virus. However, while it is never cleared by the immune 
system after primary infection, it is well controlled and immunocompetent individuals usually 
carry it as a lifelong asymptomatic infection. Nonetheless, in an immunosuppressive context, 
such as HIV infection or autoimmune disease treatment, EBV infection can lead to severe and 
life-threatening disease and malignancy. Since epithelial cells and B cells are the primary target 
cells, most common EBV-derived cancers are nasopharyngeal carcinomas and B cell 
lymphomas such as Burkitt’s lymphoma as well as Hodgkin’s and non-Hodgkin’s lymphoma. 
Moreover, EBV is one of the major causes of post-transplant lymphoproliferative disorder due 
to the use of immunosuppressive drugs leading to donor- or recipient-derived EBV 
reactivation. To date, no antiviral drugs have been approved for the specific treatment of EBV 
infection, yet several candidates have proven to inhibit EBV replication in vitro [128]. 
4.3. Immune control of EBV 
The immune response to EBV comprises, primarily, the induction of cellular immunity 
mediated by T and NK cells, as well as humoral immunity mediated by antibody-secreting B 
cells. During the acute phase of infection, NK cells significantly expand, in parallel with the 
viral load [129]. They mediate control over primary EBV infection by targeting lytically-infected 
cells to limit virus replication, but can also prevent or delay B cell transformation by EBV [130, 
131]. 
During the lytic phase, a dramatic expansion of specific CD8 T cells is observed in the 
periphery, with responses to any one lytic epitope accounting for up to 50% of the circulating 
CD8+ population. CD8 immunodominance follows the sequential pattern of expression of 
lytic proteins in target cells, with immediate early and some early antigens dominating over late 
antigens. This suggests that CD8 T cell responses are mounted through direct contact with 
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lytically infected cells. During the lytic phase, a significantly smaller population of CD8 T cells 
(up to 5% of the circulating pool) [132] is directed against latent antigens, especially epitopes 
from the EBNA3 family. At the end of the acute phase and with the decline in viral load, lytic 
and latent antigen specific CD8 T cells contract to below 2% and 0.5% of the circulating CD8+ 
T cell compartment, respectively [133-135]. 
CD4 T cell expansion also occurs during the acute phase of the infection but to a lesser extent, 
and it is mainly directed against latent epitopes, though CD4 T cells respond to a broader range 
of available lytic and latent antigens. Finally, the host humoral response consists mainly of the 
production of antibodies against a wide range of lytic antigens such as viral capsid antigens and 
early antigens which are highly immunogenic [136].  
4.4. Biology of infection of the Cytomegalovirus 
Human cytomegalovirus (hCMV) is a b herpesvirus infecting between 60% and 90% of the 
population worldwide, with higher frequencies found in developing countries [137]. The virus 
is spread between individuals via body fluids such as saliva, blood, breast milk, via sexual 
contact or from an infected mother to her child during pregnancy. Primary infection is usually 
asymptomatic in immunocompetent hosts, with rare cases of infectious mononucleosis 
symptoms. After primary infection, the virus establishes a lifelong asymptomatic latency in the 
host, through a fine homeostatic balance between viral determinants and immune surveillance. 
Following transmission, the virus infects mainly epithelial and endothelial cells [138] but also 
several other cell types such as smooth muscle cells, fibroblasts, leukocytes and dendritic cells 
[139, 140]. However, it establishes a lifelong latency in vascular endothelial cells, epithelial cells 
and primarily in immature cells of the myeloid lineage [141, 142], the latter are found in the 
bone marrow and in blood circulation. These infected cells can spread the latent infection by 
circulating and infiltrating many organs. Reactivations from the latent state occur regularly and 
studies have shown that inflammation was the leading cause. Indeed, in an inflammatory 
context, cells from the myeloid lineage are stimulated and will differentiate into macrophages 
or dendritic cells where reactivation can occur [143, 144]. These constant CMV reactivations 
throughout life require constant and efficient immune control to keep the host disease free.  
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4.5. CMV-associated diseases 
CMV infection can cause severe and sometimes fatal disease in immunocompromised 
individuals or neonates. Indeed, hCMV is a major infectious cause of congenital abnormalities, 
including hearing loss, visual impairment, mental retardation or morbidity, and it is estimated 
to affect 1 to 5% of all live births in developed countries [145]. In adults, severe cases of CMV-
associated disease occur in the majority of acquired immune deficiency syndrome (AIDS) 
patients without anti-CMV prophylactics, with the most common being retinitis and 
subsequent blindness. Transplant patients are also at high risk of CMV reactivation and 30 to 
75% of organ recipients will develop symptomatic disease during the year following transplant 
[146, 147]. The risk of fatal disease depends on the type of transplantation. For example, bone 
marrow transplants have a much higher risk of fatal pneumonia compared to kidney transplants 
[148, 149]. Many other pathologies are related to CMV-infection such as colitis, hepatitis or 
central nervous system disease. These risks can be significantly reduced with the prescription 
of anti-viral prophylactics. However, they have been associated with toxicity, and patients can 
still develop late-onset CMV diseases when the treatment is stopped [150]. As T cell-mediated 
immunity is the main correlate of protection (detailed in section 4.6), adoptive transfer of 
CMV-specific T cells in immunocompromised patients has been investigated. Several clinical 
trials have established the safety and efficacy of simultaneous adoptive transfer of both CMV-
specific CD8 and CD4 T cells for prophylaxis and treatment of CMV infection following 
transplant [151-154]. Finally, CMV infection is thought to increase the risk of development of 
other fungal and bacterial infections [155] as CMV interferes with the host immune system, 
especially in the more impaired immune systems of older individuals [156]. Aging of the 
immune system with CMV infection will be discussed in more details in section 5.6.  
4.6. Immune control of CMV 
hCMV infection induces a robust immune response where both the innate and adaptive 
immune systems play a role. The innate immune system, especially NK cells, provides the first 
line of defense by eliminating infected cells to contain the infection. The adaptive immune 
system then comes into play, in the form of both humoral and cell-mediated immunity. 
Antibodies neutralize viral proteins and prevent viral entry into new cells, and are thought to 
be essential to limit viral dissemination and symptomatic infection [157, 158]. On the other 
hand, CMV-specific CD4 and CD8 T cells play a critical role in the control of latent and 
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reactivating CMV. It has been shown in mouse CMV (MCMV) models that while CD8 T cells 
and NK cells are sufficient to control lytic infection in most organs, CD4 T cells are essential 
for the control of viral replication in the salivary glands [159, 160]. CMV-specific T cells can 
recognize over 150 antigens but are mainly directed against two dominant epitopes, the 65kDa 
phosphoprotein (pp65), derived from the virus matrix, and the immediate-early protein 1 (IE1), 
presented by HLA-A2 and HLA-B7, respectively [161, 162]. The magnitude of the CD8 
response is highly variable between individuals, but CMV-specific CD8 T cells represent on 
average 5% and up to 35% of the circulating pool of CD8 T cells in seropositive healthy adults 
[162]. Indeed, it has been shown that CMV-specific CD8 T cells generally persist in large 
numbers after the contraction phase and, in the case of certain specificities, can even slowly 
accumulate over time in a process that has been termed “memory inflation” [163-165].  
The phenomenon of memory inflation has been primarily described in the MCMV model, 
where “conventional CD8 T cells” contract following the acute phase, resulting in a pool of 
memory T cells stably maintained during the latent phase. In contrast, CD8 T cells specific for 
certain antigens such as M38316–323, m139419–426, IE3416–423, IE3461–475, M102486–500, accumulate 
gradually over time during the latent phase and, as such, are termed “inflationary CD8 T cells” 
[163, 166, 167]. In human CMV, some epitope-specific CD8 T cell responses have also been 
shown to increase in magnitude with age [168-170]. The distinct frequency and phenotypic 
patterns of conventional versus inflationary CD8 T cell responses against CMV are represented 
in Figure 9.  
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Figure 9: CMV-specific T cell response dynamics. Representative kinetics of CMV-specific T cells during the 
acute and latent phases of infection. While non-inflationary T cells contract following the acute phase, inflationary T cells 
continuously accumulate during the latent phase aided by regular viral transcriptional activity and T cell stimulation. Adapted 
from O’Hara G et al. 2012 [171]. 
 
While long-lived classical memory CD8 T cells are mainly maintained over time with a central 
memory T cell phenotype, inflationary effector-memory cells are usually terminally 
differentiated, characterized by the downregulation of co-receptors such as CD27 and CD28 
as well as homing receptors like CD62L and CCR7 (Figure 9 and 10). They also express several 
inhibitory receptors such as killer-cell lectin like receptor G1 (KLRG-1) [166] and leukocyte 
immunoglobulin-like receptor subfamily B member 1 (LILRB1, also known as CD85j or ILT-
2) [172], but not PD-1 [173] (Figure 9 and 10). In addition, they maintain their effector 
functions, secrete cytotoxins such as perforin and granzyme [174] and are able to proliferate 
[173, 175], in contrast to the features of exhausted T cells generally observed in other persistent 
chronic viral infections such as HIV or hepatitis B and C virus [176]. 
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Figure 10: Classical and non-classical CMV-specific CD8 T cells. Long-term conventional memory CD8 T 
cells are maintained with a central memory T cell phenotype, while inflationary T cells (non-classical memory) have an effector-
memory phenotype characterized by the downregulation of co-receptors such as CD27 and CD28 as well as homing receptors 
like CD62L and CCR7 and the maintenance of effector functions. Adapted from Klenerman and Oxenius, 2016 [177]. 
 
While CMV reactivation events are well controlled by humoral and cell-mediated immunity, 
resulting in the virtual absence of new virion production unless the infected host is severely 
immunocompromised [178], the main driver of memory inflation is thought to be repetitive 
antigen exposure via detection of transcriptional reactivation [179]. Indeed, when MCMV-
specific CD8 T cells were transferred into naive hosts, they failed to divide and persist, 
suggesting that antigen stimulation is required for their accumulation and maintenance at high 
frequencies [173]. Mouse models have also demonstrated that CM T cells are a primary source 
of new EM T cells, thus sustaining memory inflation (Figure 10). MCMV-specific CM T cells 
are thought to be re-activated both in SLOs, by non-hematopoietic, latently infected cells [180], 
as well as in blood circulation, by latently infected vascular endothelial cells [181] (Figure 11). 
After reactivation, they undergo proliferation and differentiation and ultimately accumulate in 
peripheral tissues where they can exert effector functions (Figure 11).   
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Figure 11: Model of CMV-inflationary cell activation and maintenance. Non-hematopoietic latently infected 
cells present viral antigens to inflationary central memory (CM) T cells in lymph nodes or in the vasculature. Activated CM T 
cells proliferate and differentiate into inflationary effector memory T cells and ultimately accumulate in peripheral tissues where 
they can exert effector functions. Adapted from Klenerman and Oxenius, 2016 [177]. 
 
Despite mounting a strong response, the immune system is not able to eliminate the infection 
due to its latency and the multiple immune-evasion strategies employed by hCMV. Indeed, of 
the 751 CMV proteins thus far identified in infected cells [182] only a few are essential for viral 
replication. The vast majority are thought to be immune evasion proteins, which profoundly 
interfere with both the innate and adaptive components of the host, impeding viral clearance 
[183]. For example, the hCMV US11, US2 and US3 proteins down-regulate MHC-I and MHC-
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II molecules on T cells and APCs, while hCMV-UL18 is a surface-expressed MHC-I 
homologue. The expression of such viral proteins in infected cells avoids immune recognition 
by CD4 and CD8 T cells, as well as NK cells [184-187]. Furthermore, CMV-UL111.5A is a 
potent immunosuppressive interleukin homologous to IL-10, that has been demonstrated to 
suppress anti-CMV immunity [188]. Finally, many hCMV proteins also inhibit the activation 
of NK cells by blocking activatory receptors or preventing the expression of activatory ligands 
[184, 187]. 
5. Memory CD8 T cell immune response to EBV and CMV 
5.1. Differences in frequency and phenotype between EBV- and CMV-specific 
memory CD8 T cells 
As previously mentioned, some CMV-specific memory CD8 T cells can go through memory 
inflation during the latent phase of infection, resulting in a continuous expansion overtime. 
Conversely, irrespective of their antigen specificity, the pool of EBV-specific memory CD8 T 
cells remains relatively stable over time. Nonetheless, CD8 T cells specific for EBV lytic 
antigens are found in higher frequencies and harbor a more terminally differentiated phenotype 
(i.e. CCR7-, CD62L- and CD45RA+) compared to EBV latent antigen-specific CD8 T cells 
which are largely CD45RA- and express higher levels of CCR7 and CD62L. However, even 
CD8 T cells specific for EBV lytic antigens remain generally less differentiated than CMV-
specific CD8 T cells, being CD27high and CD27low, respectively [189-192]. In addition, CMV-
specific memory T cells generally exhibit high levels of expression of CD57, a marker of 
replicative senescence [193, 194]. These phenotypic differences are not reflected by functional 
capacity, since both CMV- [173] and EBV-specific [195] memory T cell clones are cytotoxic 
and have the capacity to secrete cytokines such as TNFα, and IFNγ as well as perforin.  
These differences in frequency and phenotype between EBV- and CMV-specific 
memory CD8 T cells could, in part, be due to differences in the biology of the two viruses. 
Indeed, during latency, EBV reactivation in B cells occurs only sporadically, leading to cycles 
of T cell rest and stimulation thus maintaining a pool of functional CD8 T cells over time. 
Conversely, CMV latent infection is characterized by continuous low level of transcriptional 
activity leading to the constant stimulation of CD8 T cells with infrequent rest [196, 197].  
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5.2. TCR repertoire characteristics of EBV- and CMV-specific responses 
One way to study T cell immune responses against specific epitopes is to assess the TCR 
repertoire diversity in terms of the number, the frequency and the distribution of clonotypes 
within an antigen-specific T cell pool. T cell clonotypes are defined as the progeny of a given 
naive precursor cell sharing the same antigen-specific TCRα and β chains. Several studies have 
shown that the degree of diversity in the EBV- [90-92, 198-203] and CMV-specific [91, 199, 
202, 204, 205] TCR repertoires is generally highly restricted, ranging from 1 to 16 clonotypes, 
though some studies suggest that this number may be somewhat higher [206]. This discrepancy 
depends, at least in part, on the targeted epitope and the method used to study the repertoire. 
Indeed, TCR repertoires are often studied based on either the β or the α chain sequence of the 
clonotypes and not both, thus potentially incorporating a bias in the estimated diversity. 
Preferential T cell receptor beta variable (TRBV) and alpha variable (TRAV) gene segment 
usage (according to Arden’s nomenclature [207]) has been observed in epitope-specific TCR 
repertoires, such as the large proportion of TR-BV2, -BV4, -BV16, -BV22 and TRAV15 in 
EBV A2/GLC-specific CD8 T cell clonotypes [90, 91, 201-203]. Similarly, the CMV A2/NLV-
specific repertoire has been associated with a biased usage of TRBV and TRAV genes segments 
including TR-BV8, -BV13 and TRAV18 [91, 199, 202, 205]. Finally, so-called “public” TCRs 
against CMV and EBV have been reported in several studies, based on the shared TCRa or b 
chain rearrangements or features between various individuals [204, 205, 208-211]. Clonotypes 
bearing such public TCRs have been shown in some cases to preferentially expand [205, 208], 
possibly because public TCRs may be evolutionarily selected for optimum interactions with 
certain viral epitopes. However, “true” public TCRs defined as the exact same TCRαβ found 
in unrelated individuals may be relatively rare [208]. 
5.3. TCR repertoire selection of EBV- and CMV-specific responses between 
acute and latent phases 
Upon primary viral infection, antigen-specific T cells expand during the acute phase, followed 
by a contraction phase when the viral load decreases. During the contraction phase, 90% of T 
cells are lost and the remaining cells constitute the memory pool and will persist into the latent 
phase of the infection. The parameters driving the selection of certain T cells from the acute 
to the chronic phase remain elusive.  
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In the context of hCMV infection, data describing the T cell repertoire between the acute and 
chronic phases are very limited, since the primary infection is generally asymptomatic. One 
study, however, including both patients after organ transplant as well as rare cases of 
symptomatic primary hCMV infection, has shown that the diversity of the polyclonal CD8 T 
cell response rapidly diminishes when entering the chronic phase. The TCR repertoire is then 
limited to the usage of only a few TCR Vb segments within which dominant clones frequently 
had public TCR usage [212]. This observation was reinforced in the context of hCMV 
reactivation and/or chronic inflammation. In this clinical setting, a dramatic clonal focusing of 
HLA-A*0201/NLV-pp65-specific T cells has been observed, with selection of single 
clonotypes displaying similar public TCR features in several patients [205].  
As EBV primary infection is more often symptomatic, in the form of infectious 
mononucleosis, compared to hCMV primary infection, several studies have investigated the 
repertoire evolution between IM and the latent phase of the infection.  Some studies observed 
a relative conserved TRBV usage, yet with significative dominance shift [213, 214]. Others have 
shown at the clonotype level that highly dominant CD8 T cell clonotypes present during acute 
IM are poorly represented [215], if at all [90]  in the chronic phase and are often overtaken or 
replaced by other clonotypes specific for the same epitope after 1 to 2 years after the primary 
infection. 
Together, these studies suggest that a change of repertoire occurs in human CMV and EBV 
infections between the two phases, with some clones being less likely to contribute to the 
memory pool during latency. However, the repertoires in these studies are mostly based on 
TRBV staining and on very few TCR sequences at the clonotype level. A more recent study 
using tetramer sorting and next-generation sequencing found that, in both hCMV- and EBV-
infection in renal transplant recipients, the CD8 T cell clonal repertoires in the early phase of 
infection were mostly similar to those found after one year, both in terms of clonal composition 
and dominance hierarchy [216].  
Collectively, whether the TCR repertoire is conserved or undergoes selection during the 
transition from the acute to the latent phase of EBV and CMV infections still remains 
controversial.  
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5.4. TCR repertoire evolution of EBV and CMV specific responses over time 
during the latent phase 
Several studies have focused on the maintenance of the clonal repertoire during the latent phase 
of herpes virus infection. In both hCMV and EBV infection, it has been demonstrated that, 
once established, the CD8 T cell clonal composition appears to be relatively stable for at least 
several years with only minor alterations in dominance [91, 198, 212, 216, 217]. Nevertheless, 
it is important to note that the maximal time span analyzed in those studies was of about 5 
years, whereas hCMV and EBV immune responses persist for decades and small changes in 
the repertoire may only be observed over longer periods of time. In this regard, Miles and 
colleagues [92] have observed in two EBV-positive donors, the persistence of single CD8 T 
cell clonotypes against the HLA B*0801/FLR and HLA B*4405/EEN epitopes for 18 and 11 
years, respectively. However, in most reported cases, EBV specific responses are oligoclonal, 
and the long-term (i.e. more than 5 years) persistence and shift in dominance between 
clonotypes has thus far not been extensively investigated.  
Collectively, following primary infection and initial TCR repertoire focusing, herpes virus-
specific T cell responses revealed a high stability of the TCR clonotype repertoire over time 
[216] as well as during homeostatic immune reconstitution [218]. Nonetheless, in depth analysis 
of the precise clonotype composition, as defined by both TCR α and β chains, and its 
persistence over long periods of time in healthy humans with chronic infection are still required 
to better understand long-term memory T cell responses.  
5.5. Impact of TCR-pMHC affinity/avidity on clonal repertoire selection 
Despite major efforts, the parameters underlying the clonal selection after the acute phase to 
enter the memory pool as well as the long-term maintenance of virus-specific CD8 T cell 
repertoires remain poorly understood. 
Several studies have proposed the TCR-pMHC affinity/avidity as a major determinant of the 
TCR repertoire selection and dominance in virus-specific CD8 T cell responses. Indeed,  Day 
and colleague have shown that hCMV-specific dominant clones selected from the acute phase 
into the memory pool showed higher functional avidity (based on half maximal effective 
concentration or EC50 from target cell lysis assays) compared to contracted clones, suggesting 
a functional avidity threshold to enter the memory pool [212]. These results were reinforced in 
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the context of hCMV reactivation and/or chronic inflammation, where it has been shown that 
the preferentially expanded and dominant clonotypes were of higher avidity for their cognate 
antigen compared to subdominant clonotypes, based on CD8-mutated tetramer binding and 
tetramer dissociation rates [205, 219]. On the other hand, one study has shown that CD8 T cell 
repertoires against the EBV HLA-B8/RAKFKQLL epitope displayed no significant 
differences in terms of global avidity (measured by tetramer staining and dissociation kinetics) 
between the acute and chronic phases of infection, thus contrasting with the concept of avidity 
maturation observed in CMV infection [220].  
Similarly, the impact of TCR-pMHC affinity/avidity has been investigating for the persistence 
of CMV- and EBV-specific clonal repertoire during latency. While the repertoire is kept stable 
for several years, dominant and subdominant clonotypes appear to have comparable functional 
avidity but display heterogeneous levels of CD8 binding dependency. This suggests a 
compensatory role for the CD8 co-receptor to preserve clonotypic diversity while maintaining 
high functional capacity [91, 198, 202, 212]. The impact of the TCR avidity on long-term 
evolution of the repertoire and eventual shift in clonal dominance has been so far mainly 
estimated by mathematical models. Indeed, Davenport et al. [220] have proposed a model to 
predict the evolution of EBV-specific T cell repertoires throughout the course of an infection. 
This model takes into account variations in TCR avidity and thus in cell division rate of the 
different clonotypes, but also integrated a decline in survival with increased cell division 
number. This senescence model is characterized by a primary contribution from several clones, 
the gradual senescence of high-avidity T cell clones, and their slow replacement by clones of 
intermediate avidity (in a process termed clonal succession) during life-long latent infection. 
This theory was partially supported in hCMV infection by the more recent work of Griffiths 
and colleagues, who reported that highly differentiated CMV/pp65-specific CD8 T cells that 
re-express CD45RA and which are of relatively low avidity (based on CD8-null tetramer 
binding) are significantly more prevalent in older individuals [221]. In addition, Ouyang et al. 
have observed a large expansion of functionally impaired CD8 T cells directed against a CMV 
epitope in the elderly, which was not observed in younger donors [222]. These data suggest a 
skewing of the T cell repertoire avidity during aging. 
Nonetheless, further investigations are needed to determine the precise criteria for antigen-
specific CD8 T cell repertoire selection into the memory pool following acute infection as well 
as their evolution during lifelong latency. 
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5.6.  Immune responses with aging 
It is commonly accepted that human aging is characterized by an increased vulnerability to 
infection and a decrease in vaccine efficacy [223, 224] due a deterioration of the immune 
system, also termed immunosenescence [225]. One of the main features of the cellular 
immunity with aging is the change in T-cell composition. In both blood and SLOs, the 
proportion of naive T cells in older individuals has been shown to be markedly decreased in 
the CD4 and CD8 T cell compartments [226, 227], mainly due to thymic involution. This age-
related decrease of thymic output of naive T cells, in addition to an age-related loss in the 
capacity to prime naive T cells [228], reduces the hosts ability to respond to novel antigen 
encounter, thus rendering them more prone to a variety of diseases [229].  
Concurrent with the decrease of the naive T cell pool, the relative proportion of other subsets, 
especially effector-memory T cells, increases [230]. Moreover, the phenotype of T cells has 
been shown to evolve with increasing age, with the gradual loss of the costimulatory receptors 
CD28 and CD27, while the expression of markers such as CD57 and KLRG1 is enhanced with 
aging. In addition, telomere length of T cells also tends to decrease with time [231]. This 
phenotype has been associated with T cell senescence, characterized by a low or inexistent 
proliferative capacity, despite high functional properties. The overall decline of the immune 
system with aging is also characterized by low-grade inflammation in the absence of explicit 
infection (or inflamm-aging). Inflamm-aging and immunosenescence are interrelated processes 
[232] that may be reinforced by many factors such as metabolic changes, tissue injury or latent 
infections. 
Latent infections with continued T cell stimulation, such as CMV, is believed to accelerate the 
aging of the immune system and thus to compromise its ability to control new infections or 
latent reactivation in the elderly. As previously mentioned, in normal aging the proportion of 
naive CD4 T cells decreases, whereas this does not hold true for the absolute number of naive 
CD4 T cells. However, in CMV seropositive individuals a decrease in the absolute number of 
naive CD4 T cells is observed [227]. On the other hand, for CD8+ cells, a reduction in the 
absolute number of CD8 naive-T cells in older individuals has been reported [229] regardless 
of their CMV serostatus [233], probably due to decreased homeostatic proliferation [234, 
235]. Proportionally, the increase in effector-memory T cells is more pronounced in CMV+ 
individuals than in their seronegative counterparts. This is in part due to the phenomenon of 
memory inflation over time and the accumulation of CMV-specific memory T cells [177]. 
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Latent hCMV infection, especially with significant memory inflation, is suspected to accelerate 
immunosenescence in seropositive elderly individuals. Moreover, since CMV-specific 
inflationary T cells are generally terminally differentiated, with low proliferative potential but 
high functional capacity, their large contribution to the T cell pool could also be responsible 
for the observed global increase of senescent- and/or exhausted- like T cells in the elderly. 
Indeed, several studies have shown that persistent viral infections such as HIV [174, 236-238], 
HCV [239], and CMV [224, 240] correlate with an increased proportion of highly differentiated, 
exhausted and/or senescent T cells already in early life and with time. This phenomenon was 
not observed in latent EBV or Varicella-Zoster Virus (VZV) infections, probably due to a less 
stringent and continued T cell stimulation.  
While a modest age-related decrease in TCR repertoire diversity has been demonstrated [13, 
241-243], the large expansion of oligoclonal hCMV-specific CD8 T cells during memory 
inflation has been proposed to further constrain the overall T cell repertoire diversity [244], 
although the physiological impact of this change remains unclear [245]. Whether the 
persistence of CMV infection over time reduces the hosts ability to mount an effective and 
protective immune response to other pathogens, or increases the risk of cancer or other 
diseases, remains to be elucidated. On one hand, CMV-infection has been associated with an 
increased risk of cardiovascular disease in elderly individuals through several mechanisms, 
including direct vascular damage due to infection of vascular endothelial cells [246], or by 
increasing the background level of inflammation thus enhancing inflammation-mediated 
vascular pathology [247]. Large cohort studies have also associated high levels of CMV-specific 
immunoglobulin G with mortality in the elderly [247, 248]. On the other hand, CMV infection 
has been shown to be beneficial in aged mice, by conferring an increased resistance to bacterial 
infection through the mobilization of a broader TCR repertoire [249] and a higher basal 
activation state of the innate immune system [250, 251]. Finally, conflicting studies have 
reported both a beneficial [252] and detrimental [253] impact of latent hCMV infection on 
influenza vaccination, further confounding our understanding of the effect of chronic CMV 
infection on human immune system potency. 	  
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Objectives 
This thesis is divided into two main objectives. The first objective focusses on the impact of 
TCR-ligand binding avidity on T cell functional potency among viral and tumor-specific CD8 
T cells. This part has been recently published in Allard M, Couturaud B et al., JCI Insight 2017 
[254] (see Manuscript 1 in the results section). The second objective addresses the impact of 
TCR-ligand binding avidity on the evolution of human CD8 TCR repertoires specific for 
persistent herpes viruses over extended periods of time. The data collected from the second 
aim are compiled into a manuscript in preparation (see Manuscript 2 in the results section).  
1. Impact of TCR binding avidity on CD8 T cell function among different 
antigenic specificities 
In the last few decades, immunotherapy has played a leading role in innovative treatments 
against cancers such as melanoma, or viral infections such as CMV. In most immunotherapy-
related strategies, cytotoxic CD8 T-cells play a central role, due to their capacity to kill tumor 
or infected cells. Therefore, extensive research has been undertaken to investigate which 
properties of these cells are essential to generate protective and durable immune responses. In 
that regard, high T cell functional avidity, which is the antigen sensitivity measured by 
functional readouts, has been associated with better control of viral infections in both animal 
models [71-73] and humans [74-78], as well as better tumor control in mice [79, 80] and 
melanoma patients [81, 82]. However, ex vivo functional avidity and polyfunctional assessments 
remain laborious and time consuming, and are often not possible because relatively large 
number of cell numbers must be withdrawn from patients. Furthermore, the TCR-pMHC 
binding avidity remains often neglected, mainly due to technical limitations. In fact, TCR-ligand 
avidity may offer a better biometric by which the quality of the antigen-specific T cell response 
can be directly evaluated, since it controls numerous aspects of T cell biology such as T-cell 
activation, differentiation, and functional efficacy (reviewed in [255]) as well as Listeria 
monocytogenes infection control in mice [99].  
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1.1. Strong relationships between TCR-pMHC binding avidity and T cell 
functional potency 
To better characterize the relationship between the physical interaction of the TCR-pMHC 
complex and the ensuing T cell activation, we used the recently developed NTAmer 
technology. This novel flow cytometry-based approach allows for the quantification of 
monomeric TCR-pMHC dissociation kinetics (koff) directly on living antigen-specific CD8 T 
cells. Using this technology, our group documented robust correlations between NTAmer 
kinetic values (koff) and those obtained by SPR [108]. Moreover, we showed that NTAmer-
based koff measurements strongly correlate with the killing capacity of TCR-engineered CD8 T 
cells [108] as well as following therapeutic vaccination [109]. In the latter study, we found 
differences in TCR-pMHC binding avidity depending on the type of Melan-A26-35 peptide used 
for vaccination [109]. To elucidate the precise causality between TCR-pMHC binding avidity 
and the overall CD8 T cell functional profile, NTAmer-based koff  measurements of antigen-
specific CD8 T cell clones were combined with multiple functional assays including killing 
capacity, CD107a degranulation, cytokine production, proliferation, costimulatory and 
inhibitory receptor expression, as well as the ability of  tumor-specific CD8 T cells to control 
tumor growth in vivo. This part of the study was performed on large libraries of HLA-A*0201–
restricted effector-memory CD8 T cell clones specific for self/tumor antigen (i.e. Melan-A26-35 
and NY-ESO-1157-165) and viral antigen (i.e. CMV/pp65495-504 and EBV/BMFL1259-267). Results 
obtained from these experiments show that TCR-pMHC off-rate is a major determinant 
controlling the functions of CD8 T cells in vitro and in vivo. These observations further enhance 
our understanding of the impact of TCR avidity on CD8 T cell activation and function. 
1.2. Variations of TCR-pMHC avidity according to the antigenic specificity of 
CD8 T cells 
Only limited information is available on the overall quality of TCR-pMHC binding avidity of 
self/tumor–specific versus non–self/pathogen–specific CD8 T cell repertoires [54, 55]. The 
most detailed study investigating this question was carried out by Aleksic et al. [55] who 
compared the TCR affinities of 14 tumor-specific TCRs directed against various tumor 
antigens, versus 10 TCRs that bind to different viral antigens. Using the SPR approach, they 
observed that TCRs that bind viral antigens fall within a higher affinity range than those that 
bind cancer-related antigens [55]. However, one of the major caveats of SPR analysis is that it 
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ignores the contribution of CD8 coreceptor and/or other molecules present in the vicinity of 
the TCR to the overall TCR-pMHC avidity. In addition, this study focused on only one TCR 
sequence per antigenic specificity due to technical limitations (i.e. the laborious and expensive 
production of soluble TCRs and their cognate pMHC), thus introducing a strong selection bias, 
as it is known that TCRs directed against the same epitope can cover a large range of TCR 
affinities [256]. To better address the question of whether or not TCR avidity depends on the 
antigenic origin (i.e. self/tumor versus non-self/viral), we performed a comprehensive analysis 
of TCR-pMHC off-rates using the novel NTAmer technology on large panels of effector-
memory CD8 T cell clones (n = 414) specific for (i) the differentiation antigen A2/Melan-A26-
35, (ii) the cancer testis antigen A2/NY-ESO-1157-165, (iii) the viral A2-CMV/pp65495-504 antigen 
and (iv) the viral A2-EBV/BMFL1259-267 antigen isolated from five melanoma patients and two 
healthy donors. In addition, we investigated potential differences in terms of TCR binding 
avidity between the type of tumor antigen (i.e. Melan-A versus NY-ESO-1) as well as following 
peptide vaccination in combination with CpG oligodeoxynucleotides (CpG ODN) and 
incomplete Freund’s adjuvant (IFA) (i.e. Melan-A) or from patients with naturally occurring 
anti-tumoral T cell responses (i.e. NY-ESO-1). Our data highlight superior TCR-ligand binding 
avidities of virus-specific T cell repertoires compared with self/tumor-specific T cell ones. 
Moreover, higher avidity T cells were found in melanoma patients with natural responses 
against NY-ESO-1 tumor antigen than following therapeutic vaccination with the Melan-A 
peptide. Nevertheless, several clones with enhanced TCR binding avidity could still be detected, 
indicating the presence of rare self/Melan-A-specific CD8 T cells that are selected upon 
vaccination, emphasizing the relevance of therapeutic vaccination approaches in enhancing the 
quality of a tumor-specific repertoire.    
1.3. Stability and robustness of TCR-pMHC off-rates 
T cell functional avidity can greatly vary depending on the chosen functional readouts and the 
laboratory protocols used to assess them, the activation state of the T cells, their differentiation 
status or the expression of inhibitory and costimulatory receptors [70]. In this regard, the TCR-
pMHC off-rate may provide a more reliable biophysical parameter to assess T cell potency. To 
investigate this question, we assessed the reproducibility of NTAmer-derived TCR-pMHC off-
rate measurements in parallel with T cell functional capacities, in separate experiments. In 
addition, we investigated the impact of the T cell activation state on TCR-pMHC off-rate and 
on T cell functional avidity. Our results revealed that the TCR-pMHC off-rate is a more stable 
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and robust biomarker of CD8 T cell potency than the frequently used functional 
assays/metrics, that depend on T cell activation state, and therefore show major intra- and 
inter-experimental variability. The identification of novel T cell-based parameters able to 
overcome some of the limitations associated with functional assays, and thus to resolve the 
lack of universal standards of T cell potency assessment, is of great interest. Indeed, the 
efficient and reproducible identification and isolation of high avidity T cells is of significant 
value to improve the therapeutic potential of T cells for immunotherapy. In this line, TCR-
pMHC off-rate represents an interesting candidate as a biomarker of T cell therapeutic efficacy. 
2. Impact of TCR-ligand binding avidity on the persistence of viral-
specific CD8 T cell clonotypes over time 
2.1. Progressive fluctuations over time of CMV- but not EBV-specific memory 
CD8 T cell clonotype repertoires  
Whether CD8 memory T cell repertoires are stably maintained over prolonged periods, 
periodically “renewed”, or slowly remodeled remains a matter of debate. It is a particularly 
difficult question to address in humans, since it requires in-depth longitudinal analysis of 
protective immune responses over extended periods of time. In this regard, the unique 
signature of a TCR defined by its α and β chain sequences is an excellent marker to track 
individual clonotypes and follow antigen-specific responses in a straightforward manner over 
time [257]. Antigen- specific CD8 T cell repertoires are generally composed of highly frequent 
(also defined as dominant) as well as less frequent (defined as non-dominant) T cell clonotypes 
[202]. In humans, changes in TCRαβ clonotype dominance have been observed between the 
acute and the chronic phases of persistent EBV and CMV infection [90, 198, 212]. In addition, 
several studies have revealed the persistence of dominant and non-dominant CMV and EBV-
specific T cell clonotypes in healthy donors over periods of 2 to 5 years [91, 198, 212, 216, 
217]. However, the repertoires in most of these studies were mostly based on TRBV staining 
and on very few TCR sequences at the clonotype level. In addition, fluctuations in the 
repertoires may be observed only after longer periods of time.  
To reinforce our knowledge about the precise persistence of dominant and non-dominant 
CMV- and EBV-specific CD8 T cell clonotypes over extended periods of time in asymptomatic 
virus-infected individuals, we studied the TCRαβ clonotype composition and selection of large 
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panels of CMV- and EBV-specific CD8 T-cell clones from six healthy donors over a period of 
15 years, i.e. between early (2002) and late (2017) time-points. The TCRαβ repertoires were 
assessed by several techniques to minimize experimental bias. These analyses allowed us to 
examine whether the presence of continuous antigenic stimulation (i.e. during latent CMV 
infection) versus sporadic stimulation (i.e. during latent EBV infection) over extended periods 
of time leads to intermittent shifts in the dominance hierarchy of TCR clonotypes. Whereas T 
cell clonal repertoires against HLA-A2/pp65 (i.e. CMV) were highly restricted (i.e. 2 to 6 
clonotypes), the clonal T cell repertoires for EBV (HLA-A2/BMFL1) showed more diversity 
(i.e. 15 to 25 co-dominant clonotypes), in agreement with our previous report [91]. We found 
that the TCRαβ clonotype composition of both CMV- and EBV-specific T cell responses 
remains remarkably stable over the 15 years. Nevertheless, significant fluctuations within the 
CMV-specific clonotype repertoires were observed during this observed period of time, highly 
contrasting to the great stability of the EBV-specific ones.  
2.2. Progressive long-term avidity decline of CMV- but not EBV-specific 
memory CD8 T cell clonotype repertoires 
We next investigated how TCR-pMHC binding parameters could influence T cell selection, 
expansion and persistence over extended periods of time (i.e. 15 years). As previously 
described, several studies have linked clonal selection and expansion during infection and the 
respective TCR-pMHC binding affinity/avidity. While some studies have shown the selective 
expansion of particular TCR clonotypes of high avidity for virus-specific MHC following 
secondary acute virus infection in mice [258-260], others have found an enrichment of virus-
specific CD8 T cells of low affinity/avidity in older individuals, suggesting a T cell repertoire 
skewing towards an overall lower avidity during aging [221, 222, 256]. However, all of these 
studies are based on classical multimer staining and functional assays and mostly characterized 
T cell clonotypes at the TCR-Vβ level, without including accurate measurements of the TCR-
pMHC binding affinity/avidity or kinetics, nor the complete TCRαβ clonotype repertoire 
analysis. Importantly, almost no longitudinal studies of more than 5 years have been carried 
out in humans. Thus, available data on long-term repertoire and overall avidity evolution is 
limited to studies comparing groups of individuals of different age. Therefore, the precise 
impact of TCR-pMHC-CD8 avidity on well-defined virus-specific T cell clonotype selections 
and their persistence in humans remains largely unknown.  
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In our study, we took advantage of NTAmer based off-rate measurements on CMV- and EBV-
specific clones from the repertoires of our healthy donors followed during 15 years, as well as 
TCR avidity measurements on total CMV-specific CD8 T cell populations at the two time 
points (i.e. 2002 versus 2017). We also studied the contribution of CD8 binding to the overall 
TCR-pMHC binding avidity of each co-dominant clonotypes, using NTAmers bearing the 
D227K/T228A mutations in the HLA-α3 domain preventing CD8 binding (i.e. CD8-null 
NTAmers; [108]). Within the CMV-specific TCRαβ clonotype repertoires, we observed the 
preferential selection and expansion over time of clonotypes of lower TCR-pMHC binding 
avidity and higher CD8 binding dependency. In contrast, the clonal evolution of the EBV-
specific clonotype repertoires was highly preserved, with the same clonotype distribution (i.e. 
dominant versus sub-dominant, low versus high TCR avidity, CD8 binding-independent versus 
-dependent) during the observation period of 15 years. Interestingly, for the EBV model, TCR-
pMHC off-rates correlated to distinct TRBV family usage (e.g. TRBV20 versus TRBV29) 
rather than to individual clonotype selection, as it is the case for the CMV-specific T cell 
responses. Similar data were found when we performed off-rate measurements on global virus-
specific T cell populations from 2002 versus 2017, with an overall avidity decline over time of 
CMV- but not of EBV-specific CD8 T cell clonotype repertoires. Together, these experiments 
allowed us to better understand to which extent structural TCR binding avidity governs the 
selection, expansion and survival of particular T cell clonotypes over extended periods of time, 
as well as the evolution of overall TCR avidity of the repertoire during EBV- and CMV latency. 
Specifically, our findings revealed distinct features of the highly sophisticated control of 
persistent CMV- versus EBV-specific CD8 T cell clonotypes over extended periods of time in 
healthy adults.   
2.3. Accumulation of LILRB1 expression over time in high avidity CMV-specific 
CD8 memory T cell clonotypes 
Several studies have shown a progressive change in the phenotype of virus specific CD8 T cells 
during CMV and EBV latency, as well as in general aging. Indeed, CMV- and EBV-specific T 
cells that accumulate in older individuals have been shown to have a more differentiated 
phenotype with, for example, the re-expression of CD45RA [221]. Moreover, T cells directed 
against chronic infections such as CMV, HCV or HIV are often described as exhausted or 
senescent T cells, characterized by high expression of inhibitory receptors such as PD-1, 
CTLA-4 or KLRG1 [174, 236-240]. On the other hand, it has been shown that inhibitory 
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receptor expression depends on differentiation and activation rather than the exhausted state 
of human CD8 T cells [261]. This suggests that their sustained expression in chronic infection 
may rather reflect CD8 T cell activation and differentiation, which may need to be down-tuned 
in order to prevent chronic tissue damage [262]. 
Here, we first evaluated the functional capacity of high versus low avidity CMV and EBV-
specific CD8 T cell clones generated from our healthy donors at both time-points (i.e. 2002 
versus 2017). We found that both CMV- and EBV-specific T cell clonotypes bearing TCRs of 
higher binding avidities exhibited improved functional potential in terms of killing, and 
CD107a degranulation capacity as well as cytokine (IFNg and TNFα) production, compared 
to clonotypes of lower TCR avidities. Again, functional avidity was related in the EBV model, 
to the distinct TRBV usage, rather than to particular TCRαβ clonotypes.  
Finally, we assessed the whole gene expression from CMV-specific CD8 T cells of defined 
TCRαβ clonotypes and of known characteristics for TCR binding avidity, clonal dominance 
and persistence over time by ex vivo RNA sequencing (RNASeq). We identified a distinct 
molecular signature, including elevated expression of LILRB1, preferentially expressed by the 
high avidity T cell clonotypes in three out of the four studied donors. LILRB1/CD85j is a 
negative regulatory receptor, known to accumulate in antigen-specific CD8 T cells with aging 
[263]. The RNASeq analyses also revealed a progressive increase in LILRB1 expression in 
CMV-specific clonotypes over time. Similar observations were made when we assessed the 
surface expression of LILRB1 by flow cytometry with a preferential expression found again in 
high avidity T cell clonotypes. Finally, the functional impact of LILRB1 on proliferation and 
cytokine production was investigated in blocking experiments.  
Collectively, these experiments, combined to the careful evaluation of the clonotype repertoires 
and the overall TCR avidity evolution over time should improve our knowledge of the fine-
tuned control of protective virus-specific T cell immune responses in healthy adults over 
extended periods of time. Understanding the biological parameters (i.e. TCR-pMHC binding 
avidity, T cell functional potential, or the presence of checkpoint regulatory receptors) involved 
in the long-term persistence of CD8 T cell clonotypic responses under chronic antigen 
exposure should further help us to identify specific deficiencies in anti-tumor T cell responses, 
and thus guide the rational development of T cell-based therapies against cancer and/or 
infections. 
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Results 
1. Manuscript 1 
The following article, published in The Journal of Clinical Investigation Insight in July 2017, 
corresponds to the first aim of this thesis. This study was mainly done in collaboration with 
Dr. Mathilde Allard and supported by all co-authors. 	  
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Introduction
Cytotoxic T lymphocytes mediate immune protection against a large number of infectious diseases, and recent 
developments in oncology confirmed their ability to eliminate cancers. To achieve successful immunity, T cells 
must be activated through specific interactions between T cell receptors (TCRs) and antigenic peptides presented 
by major histocompatibility molecules (pMHC) on antigen-presenting cells. This enables T cell expansion and 
differentiation into large numbers of effector cells with various functional capacities (i.e., killing, cytokine pro-
duction, proliferation). Furthermore, T cells must migrate and localize to the infected or tumoral tissues, exert-
ing their effector function and finally acquire memory properties, assuring long-lasting immunity.
Extensive research has been undertaken to determine which T cell properties are essential to generate 
protective and durable immune responses. T cell functional avidity, which measures in vitro T cell responses 
when exposed to increasing antigen concentrations, has been largely associated with the control of  viral (1–3) 
or tumor (4, 5) load in animal models. In accordance with these observations, several findings in patients 
with HIV (6, 7) or hepatitis C (8, 9) infections further showed the key role of  CD8+ T cells of  high functional 
avidity in efficient viral control and clearance. Yet, others have challenged the functional superiority of  such 
high-avidity cells, which may be prone to increased activation-induced cell death, senescence, or exhaustion 
(reviewed in ref. 10). In the context of  antitumor responses, results obtained from melanoma patients also 
indicate that T cells of  high functional avidities are required for efficient protection (11–13). Besides func-
tional avidity, higher proportions of  polyfunctional CD8+ or CD4+ T cells were also found in HIV (14, 15) 
and hepatitis C (16) controllers, when compared with individuals with progressive disease. Moreover, some 
reports proposed a direct link between functional avidity (i.e., antigen sensitivity) and polyfunctionality (i.e., T 
cell capacity to exert multiple effector functions) (17, 18). However, the ex vivo appraisal of  T cell functional-
Despite influencing many aspects of T cell biology, the kinetics of T cell receptor (TCR) binding to 
peptide-major histocompatibility molecules (pMHC) remain infrequently determined in patient 
monitoring or for adoptive T cell therapy. Using specifically designed reversible fluorescent 
pMHC multimeric complexes, we performed a comprehensive study of TCR-pMHC off-rates 
combined with various functional assays on large libraries of self/tumor– and virus-specific CD8+ 
T cell clones from melanoma patients and healthy donors. We demonstrate that monomeric 
TCR-pMHC dissociation rates accurately predict the extent of cytotoxicity, cytokine production, 
polyfunctionality, cell proliferation, activating/inhibitory receptor expression, and in vivo 
antitumor potency of naturally occurring antigen-specific CD8+ T cells. Our data also confirm the 
superior binding avidities of virus-specific T cells as compared with self/tumor–specific T cell 
clonotypes (n > 300). Importantly, the TCR-pMHC off-rate is a more stable and robust biomarker 
of CD8+ T cell potency than the frequently used functional assays/metrics that depend on the T 
cell’s activation state, and therefore show major intra- and interexperimental variability. Taken 
together, our data show that the monomeric TCR-pMHC off-rate is highly useful for the ex vivo 
high-throughput functional assessment of antigen-specific CD8+ T cell responses and a strong 
candidate as a biomarker of T cell therapeutic efficacy.
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ity/polyfunctionality is still often limited to assays of  fixed stimulation doses and by the lack of  universal stan-
dards of  T cell assessment (reviewed in refs. 19, 20). It is therefore essential to improve our knowledge regard-
ing the contribution of  the different aspects of  T cell function to clinical efficacy and to identify additional T 
cell–based parameters that may enable overcoming some of  the limitations associated with functional assays.
The functional avidity of  T cells is primarily controlled by the strength of  TCR-pMHC interactions, 
a key parameter shown to impact on numerous aspects of  T cell biology, including their thymic selection 
(21), activation and differentiation (22), autoimmune pathogenicity (23), and protection against infection 
and cancer (24). In fact, TCR-pMHC binding avidity may offer a key metric by which the quality of  the 
T cell response can be directly evaluated, since it controls T cell activation, differentiation, and functional 
efficacy (25). Numerous studies indicate that, within the affinity range of  physiological interactions (KD 
100–1 μM), enhanced TCR-pMHC affinity or off-rate (koff) correlate with improved T cell functionality 
(26). However, most of  these reports are based on artificial models (e.g., using affinity-optimized TCR vari-
ant panels or altered peptide ligand models), and thus only limited information is available on the overall 
impact and clinical relevance of  TCR-pMHC binding avidity or kinetics (e.g., off-rates) in the context of  
naturally occurring antigen-specific CD8+ T cell responses. Moreover, identifying and selecting TCRs of  
higher avidity may be of  particular importance in the tumoral setting, since most high avidity/affinity self/
tumor antigen–reactive T cells are naturally eliminated or silenced by mechanisms of  central and peripheral 
tolerance, emphasizing the need to select the remaining rare high-avidity cells for immunotherapy.
Reversible 2-color multimer-based approaches (i.e., Streptamers, NTAmers) have been developed to 
precisely quantify monomeric TCR-pMHC dissociation rates (i.e., off-rate or koff) directly on living T cells. 
Streptamers initially revealed that virus-specific CD8+ T cells with longer off-rates conferred better in vivo 
protection than T cells with shorter off-rates (27). However, owing to the faster decay of  the multimeric 
complex onto monomeric pMHC when compared with Streptamers, NTAmers offer an increased sensitiv-
ity to detect T cells with low-avidity TCRs (26), such as those typically found in self/tumor–specific CD8+ 
T cell repertoires. Consequently, we recently showed that NTAmer-based koff strongly correlated with the 
killing capacity of  TCR-engineered and natural tumor-specific human CD8+ T cells (28, 29).
With the aim to thoroughly evaluate possible correlations between T cell function and TCR-pMHC bind-
ing kinetics, we here undertook a large-scale analysis of  combined multiple functions (i.e., killing, CD107a 
degranulation, cytokine production, proliferation, surface expression of  activating/inhibitory receptors, and 
tumor control) and optimized off-rate measurements using NTAmers to characterize large libraries of  tumor- 
and virus-specific CD8+ T cell clones isolated from melanoma patients and healthy donors. Our large data sets 
show that the TCR-pMHC off-rate is a major determinant controlling the functions of  CD8+ T cells in vitro 
and in vivo. Our findings are also of  practical importance, as we found that the TCR-ligand dissociation rate 
is a highly stable biomarker, more reliable and reproducible than the usual assessments based on multimer 
staining levels or functional T cell avidity, which may fluctuate depending on the T cell’s activation state.
Results
TCR-pMHC off-rate accurately correlates to overall T cell functional avidity. To precisely address the relationship 
between the TCR-pMHC off-rate and the overall CD8+ T cell functional profile, we generated large libraries 
of HLA-A*0201–restricted CD8+ T cell clones, by direct ex vivo sorting and cloning of self/tumor–specific 
(i.e., Melan-A26–35 and NY-ESO-1157–165) and virus-specific (i.e., cytomegalovirus CMV/pp65495–504 and Epstein-
Barr virus EBV/BMFL1259–267) effector memory (EM) T cells (Supplemental Figure 1; supplemental material 
available online with this article; https://doi.org/10.1172/jci.insight.92570DS1). We analyzed all clones for 
TCR-pMHC dissociation rates using NTAmers loaded with the native Melan-A, NY-ESO-1, EBV/BMFL1, or 
CMV/pp65 peptide because they provided a more physiological assessment of the TCR-pMHC recognition effi-
cacy as opposed to the corresponding analog peptides (as detailed in Methods). Representative koff-based panels 
of self/tumor– and virus-specific CD8+ T cell clones were further characterized at the functional level, including 
assessment of cytotoxic activity, CD107a degranulation, and production of cytokines based on peptide titration 
assays, as well as proliferation (Supplemental Figure 2). Note that, for the same antigen specificity, most of the 
different functional readouts/measures were obtained during the same nonspecific restimulation cycle to make 
use of the antigen-specific CD8+ T cell clones in a similar resting state (>15 days after restimulation).
We observed, for all antigenic specificities, statistically significant correlations between TCR-pMHC 
off-rates and various functional avidity readouts (EC50, defined as the peptide concentration producing half-
maximal response) or proliferative capacity (percentage of  divided cells) (Figure 1 and Supplemental Fig-
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ure 3, A and B). Yet, stronger correlations (P < 0.01–0.001, r > 0.5, and narrow confidence intervals) were 
generally found for self/tumor–specific (Melan-A and NY-ESO-1) than non–self/virus–specific (CMV/
pp65 and EBV/BMFL1) T cells. By contrast, no positive correlations could be observed between TCR-
pMHC off-rates and the maximally reached functions at saturating peptide doses (Bmax, maximal response) 
(Supplemental Figure 3C; data not shown). In turn, the maximal response depended on the in vivo differen-
tiation status, with stronger Th2-related cytokine production by clones derived from the early-differentiated 
EM/CD28+ cells and greater granzyme B expression and killing by those from the late-differentiated EM/
CD28– cells (Supplemental Figure 3D). Collectively, these results indicate that, within an antigen-specific 
repertoire, the kinetics of  TCR-pMHC interactions represent a major determinant of  the overall functional 
avidity of  CD8+ T cells, regardless of  their differentiation status (Supplemental Figure 3D) or function-
specific activation thresholds (killing < CD107a < IFN-γ < TNF-α < IL-2) (Supplemental Figure 4A).
TCR-pMHC off-rate closely correlates to CD8+ T cell polyfunctionality. Protective immunity against intracellular 
pathogens relies on the individual CD8+ T cell capacity to display multiple effector functions or polyfunction-
ality (10). We hypothesized that the kinetics of  TCR-pMHC interactions could also affect their polyfunction-
ality. The coexpression levels of  CD107a, IFN-γ, TNF-α, and IL-2 were characterized on a representative 
selection of  self/tumor– and virus-specific CD8+ T cell clones with relative slow or fast TCR-pMHC off-rates 
(Figure 2). For all antigenic specificities and peptide titrations tested, the fraction of  cells displaying more than 
1 single function was always greater in CD8+ T cell clones with slower TCR-pMHC off-rates than with faster 
ones (Figure 2A). In line with these observations, we found that a significant proportion of  antigen-specific 
CD8+ T cell clones with slow TCR-pMHC off-rates showed increased polyfunctional capacities (in terms 
of  EC50 titration curves) when compared with the clones having fast TCR-pMHC off-rates (Figure 2, B–D). 
However, a strict correlation between off-rates and polyfunctionality was not always found, and limited differ-
ences were mostly observed in the EBV-specific CD8+ T cell responses. Taken together, these results show that 
the TCR-pMHC off-rate not only predicts single functional avidities of  self/tumor– and virus-specific CD8+ T 
cells, but also their capacity to codevelop multiple effector functions.
TCR-pMHC off-rate closely follows costimulatory/coinhibitory receptor expression in activated CD8+ T cells. PD-1 
surface expression on CD8+ T cells has been reported to positively correlate with TCR-pMHC binding avidity 
(30) or functional avidity (31). Here, we explored the relationship between NTAmer-derived off-rates and the 
expression of  various costimulatory (CD28 and CD137) and coinhibitory (LAG-3, PD-1, TIGIT, and TIM-3) 
receptors (Figure 3). No consistent correlations were found when CD8+ T cell clones were assessed in a rest-
ing state (data not shown). In contrast, following 24 hours of  stimulation with self/tumor or viral peptides, 
we observed substantial correlations between TCR-pMHC off-rates and the extent of  increased expression of  
both costimulatory and coinhibitory receptors (Figure 3, A–F). These data indicate a direct impact of  TCR-
pMHC binding avidities on the susceptibility of  CD8+ T cells to antigen-specific activation, and consequently 
on the upmodulation of  both costimulatory and coinhibitory receptors upon stimulation.
We also investigated whether TCR-pMHC off-rates associated with CD5 expression, which is a mea-
sure of  the strength for self-pMHC selecting ligands during thymocyte development (32). At baseline, most 
virus-specific CD8+ T cell clones displayed high expression levels of  CD5, irrespective of  their TCR-pMHC 
off-rates (Figure 3G). These data are in line with previous reports proposing that T cells with greater TCR 
sensitivity to self  pMHC are most efficiently recruited in response to foreign antigens (33, 34). Positive cor-
relations were only found in the context of  self/tumor–specific CD8+ T cell clones, with slower off-rates 
associating with higher baseline levels of  CD5 (Figure 3G and Supplemental Figure 5). This latter observa-
tion suggests that the expression levels of  CD5 on self/tumor–specific T cells may also predict their capac-
ity for increased homeostatic or antigen-specific response.
TCR-pMHC off-rate predicts the in vivo functional potency of  self/tumor–specific CD8+ T cells. To further sub-
stantiate the relevance of  our in vitro observations, we evaluated the impact of  TCR-pMHC off-rates on the 
ability of  self/tumor–specific CD8+ T cells to control tumor growth in vivo. We first adoptively transferred 
A2/Melan-A26–35–specific CD8
+ T cell clones of  slow versus fast TCR-pMHC off-rates into immunodefi-
cient NSG mice bearing human melanoma Me275 tumors (Figure 4A). The transfer of  fast off-rate T cell 
clones showed intermediate tumor growth control. In contrast, T cell clones with slow off-rates mediated a 
more significant delay in tumor growth when compared with the untreated (PBS) group (Figure 4B). Fur-
thermore, a significantly prolonged survival was only observed for mice treated with A2/Melan-A26–35–spe-
cific clones of  slow TCR-pMHC off-rates (Figure 4C). To confirm those observations, we then performed 
similar experiments using the A2/NY-ESO-1 antigenic model, but this time, all mice received s.c. injec-
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tions of  human recombinant IL-2 to enhance the T cell antitumor efficacy (Figure 4D). In line with the 
observations made on Melan-A26–35–specific T cells, NY-ESO-1157–165–specific CD8
+ T cell clones of  slow 
TCR-pMHC off-rates provided a significant delay in tumor growth in comparison to the clones with fast 
off-rates (Figure 4E). Finally, we monitored the peripheral persistence of  NY-ESO-1157–165–specific T cells 
at days 2 and 14 following adoptive transfer. Analysis of  tail bleeds taken at day 2 revealed that there was 
a significantly improved engraftment of  slow off-rate T cell clones compared with fast off-rate T cell clones 
(Figure 4F). Yet, tumor-specific T cells did not persist beyond 14 days after T cell transfer (data not shown), 
in line with a previous report (35). In summary, these data provide further evidence that the TCR-pMHC 
off-rate represents an excellent biomarker to predict the immunotherapeutic potential of  tumor-specific 
CD8+ T cells, and could therefore be selectively used to enhance the efficacy of  adoptive T cell therapy (27).
TCR-pMHC off-rates vary according to the antigenic specificity of  CD8+ T cells. Only limited information is 
available on the overall quality of  TCR-pMHC binding avidity of  self/tumor–specific versus non–self/
pathogen–specific CD8+ T cell repertoires (36, 37). To address this point, we performed a comprehensive 
analysis of  TCR-pMHC off-rates on 414 EM CD8+ T cell clones specific for (a) the differentiation antigen 
A2/Melan-A26–35, (b) the cancer testis antigen A2/NY-ESO-1157–165, (c) the viral CMV/pp65495–504 antigen, 
and (d) the viral EBV/BMFL1259–267 antigen isolated from 5 melanoma patients and 2 healthy donors (Fig-
ure 5, A and B, and Supplemental Figure 6, A and B). TCR-pMHC off-rate repertoires varied according to 
the T cell antigenic specificity. As such, A2/Melan-A26–35–specific CD8
+ T cells displayed significantly fast-
er TCR-pMHC off-rates than the A2/NY-ESO-1157–165–specific ones. Moreover, both tumor-specific TCR 
repertoires exhibited significantly faster TCR-pMHC off-rates than repertoires specific for herpes virus 
antigens (A2/pp65495–504 and A2/BMFL1259–267). Due to the presence of  highly frequent TCR clonotypes 
potentially biasing the NY-ESO-1– and CMV-specific and to a lesser extent the EBV- and Melan-A–specific 
CD8+ T cell repertoires (38–40), we performed an extensive TCR-BV-CDR3 clonotyping of  353 EM CD8+ 
T cell clones (Figure 5C and Supplemental Table 1). We identified 143 individual clonotypes (specific 
for A2/Melan-A– and A2/NY-ESO-1–tumor antigens, and A2/pp65– and A2/BMLF1–viral epitopes), 
representing approximately 40% of  the clonotype diversity, and depending on the antigenic specificity 
(Melan-A26–35 > EBV/BMFL1259–267 > NY-ESO-1157–165 and CMV/pp65495–504). The same TCR-pMHC off-
rate hierarchy (virus-specific > self/tumor–specific CD8+ T cells) was observed when considering all CD8+ 
T cell clones (Figure 5B) or only the individual TCR clonotypes (Figure 5C). Finally, similar differences 
were obtained when the CD8+ T cell clones were subdivided according to their ex vivo differentiation status 
(early-differentiated EM/CD28+ or late-differentiated EM/EMRA/CD28–; Supplemental Figure 6C).
The differences found between A2/Melan-A26–35–specific and A2/NY-ESO-1157–165–specific repertoires 
may result from the fact that the A2/Melan-A26–35–specific clones were derived following peptide vaccination 
in combination with CpG and incomplete Freund’s adjuvant (IFA) adjuvant (41), when compared with the 
NY-ESO-1 repertoire obtained from patients with naturally occurring T cell responses. Thus, we investigated 
the quality of  the natural A2/Melan-A26–35–specific CD8
+ T cell repertoires found in unvaccinated melanoma 
patients (n = 2), as well as in A2-positive and A2-negative individuals without melanoma (n = 4), known to 
express an unusually large peripheral repertoire of  naive (CD45RA+CCR7+) A2/Melan-A26–35–reactive CD8
+ 
T cells (42). Unvaccinated patients exhibited differentiated A2/Melan-A26–35–specific T cell repertoires of  sig-
nificantly faster off-rates when compared with the ones derived from vaccinated melanoma patients (Figure 
5D). Strikingly, similar rapid off-rates were observed for the CD45RA+CCR7+ naive-specific T cell repertoires 
derived from unvaccinated patients as well as from A2-positive and A2-negative healthy individuals. These 
observations reveal the overall inferior quality of  the TCR-pMHC binding repertoires specific for the self–
A2/Melan-A26–35 epitope, when compared with the ones specific for the cancer testis A2/NY-ESO-1 or viral 
Figure 1. Relationship between TCR dissociation rates and functional avidity of self/tumor– and virus-specific CD8+ T cell clones. Correlations between 
EC50 values from (A) killing, (B) CD107a degranulation, (C) IFN-γ–, (D) TNF-α–, and (E) IL-2–production titration assays and NTAmer-derived TCR disso-
ciation rates (koff). (F) Correlations between percentages of proliferating cells upon antigen-specific stimulation and NTAmer-derived TCR dissociation 
rates (koff). (A–F) Antigen-specific CD8+ T cell clones were generated upon direct ex vivo sorting from effector-memory (EM)/CD28+/– and/or EMRA/CD28–
subsets. Each data point represents an A2/Melan-A26–35– (derived from patient LAU618, ○), A2/NY-ESO-1157–165– (patient LAU155, □), A2/pp65495–504–, or A2/
BMFL1259–267– (healthy donor BCL4, ◊) specific individual T cell clone. Nonfunctional clones are represented in gray boxes. The number of clones displaying 
function n, as well as Spearman’s correlation (2 tailed, α = 0.05) coefficients R and P values are indicated. Color-coded and black lines are indicative of 
regression fitting and 95% confidence intervals, respectively. Of note, only very low numbers of outliers were identified when applying the ROUT method 
and are highlighted in color (71). The representative TCR-BV-CDR3 clonotype diversity of each antigenic specificity was LAU618/Melan-A, 77%; LAU155/NY-
ESO-1, 43%; BCL4/pp65, 57%; and BCL4/BMFL1, 67%.
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antigens. Yet, several clones with slower off-rates could still be detected, indicating the presence of  rare self/
Melan-A–specific T cells of  high binding avidity within the endogenous unvaccinated repertoire. Finally, our 
data show that higher-avidity T cells can be selected following therapeutic vaccination, emphasizing the rel-
evance of  therapeutic vaccination approaches in enhancing the quality of  a tumor-specific repertoire.
TCR-pMHC off-rate is a stable and robust biomarker independent of  the activation state of  the T cell. CD8+ T 
cell functional avidity represents a biological readout that is potentially influenced by multiple factors, such 
as TCR-pMHC binding avidity, TCR and CD8 surface expression, as well as various molecules regulating 
TCR signaling and T cell function (10). In that regard, the TCR-pMHC off-rate may provide a more reli-
able biophysical parameter than the widely used functional-related methods to assess T cell potency. To 
investigate this question, we first compared the variations obtained following separate experimental mea-
surements (n = 4 to 9) of  TCR-based dissociation rates, multimer staining intensity levels, and EC50 killing 
avidity of  12 representative Melan-A–specific CD8+ T cell clones. For each individual clone, the interexper-
imental off-rate values nicely clustered together, in sharp contrast to the repeat multimer staining and func-
tional avidity experiments showing large disparities (Figure 6, A–C). Furthermore, the average dissociation 
rates of  these clones strongly correlated with average EC50 killing avidity, but not with average multimer 
staining intensity (Supplemental Figure 7A). Finally, no correlation was found between functional avidity 
and multimer staining levels, in agreement with previous reports (reviewed in ref. 26). We next performed 
longitudinal measurements of  TCR-pMHC off-rates and EC50 killing avidity on a representative panel of  
A2/Melan-A26–35–specific CD8
+ T cell clones following nonspecific in vitro stimulation with phytohemag-
glutinin (PHA) and feeder cells (Supplemental Figure 7, B and C). We observed a remarkable stability of  
TCR-pMHC off-rate measurements upon stimulation, even when tested at a 6-month interval on T cell 
clones that underwent several additional rounds of  PHA/feeder expansion (Figure 6D). In contrast and as 
previously described (43), for a given T cell clone, the killing avidity greatly varied and was augmented up 
to 10-fold, according to the time elapsed since the last stimulation (Figure 6E). These data indicate that the 
functional avidity reflects the in vitro activation status of  CD8+ T cells, in line with the upregulation of  cell-
surface expression of  TCRαβ, CD8αβ, and VLA-1 integrin, and conversely the downregulation of  VLA-4 
integrin and several coinhibitory receptors such as CD5, LAG-3, and TIGIT or the costimulatory receptor 
CD28 (Figure 6F). Importantly, the TCR-pMHC binding off-rate measurement is independent of  TCRαβ 
levels, and stands out as a more stable and reliable biomarker than the usually performed assessments of  
multimer staining levels (i.e., mean fluorescence intensity) or EC50 functional avidity.
Discussion
Several observations support the importance of  considering both quantitative (i.e., magnitude of  response) 
and qualitative (i.e., functional avidity, polyfunctionality) determinants of  the T cell response, in order to 
predict in vivo efficacy (reviewed in ref. 10). However, ex vivo functional avidity or EC50 (using titrated 
functional assays) and polyfunctionality assessments remain laborious and time consuming, and are often 
not possible because relatively large cell numbers must be withdrawn from patients. Importantly, and as 
shown in the current study, EC50 values largely depend on the T cell’s activation state, and are thus influ-
enced by intraexperimental (i.e., over-time experimental measurements following T cell stimulation) and 
interexperimental (i.e., separate experimental measurements) variability/fluctuations (Figure 6). Moreover, 
functional avidity varies greatly depending on the functional readouts (e.g., cytotoxicity versus cytokine 
production), which mostly reflects modulation of  the function-specific activation thresholds (cytotoxicity < 
cytokine production) (Figure 1 and Supplemental Figure 4A). Taken together, these observations show that 
there is a strong need to identify a T cell–based biomarker that overcomes the major limitations associated 
with functional assays and provides a reliable, simple-to-use, amenable-to-standardization immune metric 
for immunotherapy of  cancer or chronic microbial infections.
Figure 2. Relationship between TCR dissociation rates and polyfunctionality of self/tumor– and virus-specific CD8+ T cell clones. (A) CD107a, IFN-γ, 
TNF-α, and IL-2 coexpression titration assays of A2/Melan-A26–35– (derived from patient LAU618), A2/NY-ESO-1157–165– (patient LAU155), A2/pp65495–504–, or 
A2/BMFL1259–267– (healthy donor BCL4) specific clones with slow (n = 10) or fast (n = 10) TCR off-rates. Pie arcs depict the average fraction of cells displaying 
0 to 4 functions. (B and C) Individual and (D) average ± SEM polyfunctional (coexpression of CD107a, IFN-γ, TNF-α, and IL-2) titration curves obtained for 
A2/Melan-A26–35– (derived from patient LAU618), A2/NY-ESO-1157–165– (patient LAU155), A2/pp65495–504–, or A2/BMFL1259–267– (healthy donor BCL4) specific 
clones with slow (n = 10, plain symbols and solid lines) or fast (n = 10, empty symbols and dotted lines) TCR off-rates. Vertical lines indicate EC50 values. 
The P values were determined by the extra sum-of-squares F test (α = 0.05). The representative TCR-BV-CDR3 clonotype diversity of each antigenic speci-
ficity was LAU618/Melan-A, 80%; LAU155/NY-ESO-1, 45%; BCL4/pp65, 65%; and BCL4/BMFL1, 80%.
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Here, using an extensive and representative panel of  antigen-specific CD8+ T cells generated in the 
context of  natural or postvaccination immune responses, we show that the TCR-ligand dissociation rate 
globally correlated to all aspects of  CD8+ T cell functions tested (i.e., cytotoxic activity, CD107a degranu-
lation, cytokine production, proliferation and coreceptor modulation; Figures 1 and 3), including poly-
functionality (Figure 2) of  both self/tumor– and virus-specific CD8+ T cells. Nonetheless, virus-specific 
T cells displayed weaker, although statistically significant correlations, than tumor-specific T cells, which 
may in part be the consequence of  their overall slower TCR off-rates. These data nicely fit with the model 
proposing that enhanced TCR affinity or off-rate correlates with improved T cell responsiveness, but that 
this correlation is no longer linear above a certain TCR binding avidity threshold (reviewed in ref. 26). 
Specifically, using artificial affinity-enhanced TCRs, several reports (30, 44, 45) have shown that maximal 
T cell responsiveness occurs within an optimal window of  TCR-pMHC binding interactions, usually lying 
in the upper physiological affinity range (KD between 10 and 1 μM), and encompassing naturally occur-
ring non–self/virus–specific TCR repertoires (36, 37). Moreover, the monomeric TCR-pMHC off-rate also 
predicted the relative tumor control activity in vivo (Figure 4). Importantly, as a biophysical readout, the 
TCR-pMHC off-rate represents a more stable and robust parameter of  T cell potency, compared with the 
fluctuating biological metrics, such as T cell functional avidity or multimer-staining levels, which instead 
depend on the activation status of  the cell (Figure 6). Our observations are in agreement with other stud-
ies showing that functional avidity is not a constant parameter in individual T cell clones, but gradually 
increases with time after in vitro restimulation (43, 46) or during the early course of  acute viral infection in 
vivo (47). Enhanced antigen sensitivity is notably influenced by the differential expression of  TCRαβ and 
accessory molecules (i.e., increased CD8αβ and VLA-1 versus reduced CD28, LAG-3, and TIGIT expres-
sion) (Figure 6). Altogether, our data show that the TCR-pMHC off-rate stands out as a major and stable 
determinant of  CD8+ T cell function, allowing the accurate monitoring of  the quality of  naturally occur-
ring or vaccination-induced self/tumor–specific T cell responses, but also for identifying the most potent 
CD8+ T cells for adoptive transfer therapy.
Thus far, a debate remains regarding which parameter(s) of the TCR-pMHC interactions (e.g., KD, koff, kon) 
could better predict T cell activation and subsequent response potency. Several studies reported that the dissocia-
tion rate (koff) was the most significant factor (27, 45), whereas others proposed that the dissociation constant 
KD was the preeminent correlate of T cell responsiveness (44, 48). However, the association rate parameter, kon, 
may also contribute to the response potency (49, 50). In that regard, Aleksic et al. (51) and Govern et al. (52) 
proposed that these apparently contradictory observations might in fact reflect the impact of fast versus slow 
association rates on the TCR-pMHC binding duration. Indeed, at the cell interface, fast kon rates would allow 
rapid rebinding of the same TCR-ligand complex after dissociation, resulting in enhanced effective dissociation 
half-lives. Molecular TCR-pMHC binding interactions are usually assessed by surface plasmon resonance (SPR) 
measurements in solution (3D binding), which fail to take into account the kon-associated rapid rebinding effect 
of the TCR to the same pMHC. The NTAmer-based approach deviates in that regard from SPR measurements. 
Using a panel of CD8+ T cells engineered to express TCR variants of increasing affinities for pMHC, we previ-
ously observed that TCRs with fast kon had prolonged NTAmer-based dissociation half-lives compared with 
those with slow kon (28). Thus, NTAmers may somehow reflect additional membrane-associated kinetic aspects 
(i.e., impact of rebinding and CD8 coreceptor), which are typically integrated by the 2D surface–based kinetic 
analyses (reviewed in ref. 53). Despite its current limitations (T cell cloning requirement, no direct kon readouts), 
the NTAmer technology allows for rapid and accurate real-time off-rate measurements of large panels of natu-
rally occurring antigen-specific CD8+ T cells that may display a broad range of TCR-pMHC affinities, including 
weak interactions (refs. 28, 29, and current study). Finally, a tight correlation between TCR off-rates and T cell 
antigenic sensitivity was not always observed, and notably depended on the antigenic specificity of the cells, but 
Figure 3. Relationship between TCR dissociation rates and activating/inhibitory receptor expression of self/tumor– and virus-specific CD8+ T cell 
clones. Correlations between fold increases in surface expression of (A) CD28, (B) CD137, (C) LAG-3, (D) PD-1, (E) TIGIT, and (F) TIM-3 upon antigen-
specific stimulation and NTAmer-derived TCR dissociation rates (koff). (G) Correlations between baseline surface expression levels (geometric mean 
fluorescence intensity [gMFI]) of CD5 and NTAmer-derived TCR dissociation rates (koff). (A–G) Each data point represents an A2/Melan-A26–35– (derived 
from patient LAU618, ○), A2/NY-ESO-1157–165– (patient LAU155, □), A2/pp65495–504– or A2/BMFL1259–267– (healthy donor BCL4, ◊) specific individual T cell 
clone. The number of clones tested n, as well as Spearman’s correlation (2 tailed, α = 0.05) coefficients R and P values are indicated. Color-coded and 
black lines are indicative of regression fitting and 95% confidence intervals, respectively. Outliers were determined by the ROUT method and are high-
lighted in color (71). The representative TCR-BV-CDR3 clonotype diversity of each antigenic specificity was LAU618/Melan-A, 77%; LAU155/NY-ESO-1, 
43%; BCL4/pp65, 57%; and BCL4/BMFL1, 67%.
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also on the T cell functional readout (Figures 1 and 3). However, robust statistical evaluation did not identify 
consistent outlier clones (i.e., the same clone that behaved as an outlier in one functional assay was not an outlier 
in the other functional assays). Thus, the few outlier data that we observed might best be explained by the vari-
ability/fluctuations related to biological measures (Figure 6), yet we cannot entirely exclude an impact of the kon 
parameter, possibly influencing T cell responsiveness (49, 50). In-depth kon evaluation of such exceptions would 
be highly useful, although only feasible once novel technologies that can interrogate all TCR-pMHC binding 
parameters directly on living T cells become available.
Extending previous studies showing a positive correlation between PD-1 expression and TCR-pMHC avid-
ity (30) or functional avidity (31), NTAmer-based off-rates nicely predicted the upmodulation of both costimula-
tory (CD28, 4-1BB) and coinhibitory (PD-1, LAG-3, TIM-3, TIGIT) receptors upon antigen-specific stimulation 
(Figure 3). Thus, our results indicate that T cells of higher binding avidity are more susceptible to activation and 
Figure 4. Relationship between TCR 
dissociation rates and tumor control in 
immunodeficient mice upon adoptive T cell 
transfer. (A) Individual or (B) average ± SEM 
tumor growth and (C) Kaplan–Meier survival 
curves of tumor-bearing NSG mice adoptively 
transferred with PBS (control, n = 7; black 
solid lines) or 1 × 106 A2/Melan-A26–35–specific 
T cell clones with fast (n = 4; blue dotted 
lines) or slow (n = 7; blue solid lines) TCR 
off-rates. (D) Individual or (E) average ± SEM 
tumor growth curves of tumor-bearing NSG 
mice adoptively transferred twice with 1 × 
106 A2/NY-ESO-1157–165–specific T cell clones 
with fast (n = 5; green dotted lines) or slow 
(n = 5; green solid lines) TCR off-rates. Tumor 
volume and survival curve P values were 
determined by 2-way ANOVA and log-rank 
tests, respectively. (F) Representative stain-
ing and (G) absolute counts of human CD8+ T 
cells from blood taken from tail veins at day 
2 following adoptive transfer of 4 × 106 A2/
NY-ESO-1157–165–specific CD8
+ T cell clones with 
fast (n = 4; green empty circles) or slow (n = 
3; green full circles) TCR off-rates. As control, 
3 mice received PBS (n = 4; black squares). 
P values were determined by 1-way ANOVA 
multiple comparison tests.
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Figure 5. TCR dissociation rates according to the 
antigenic specificity, clonotype repertoire, and ex 
vivo differentiation status of CD8+ T cell clones. (A 
and B) NTAmer-derived TCR dissociation rates (koff) 
of EM/EMRA CD28+/– clones (n = 414) specific for the 
differentiation antigen A2/Melan-A26–35 (derived from 
melanoma patients LAU618, LAU627, and LAU818 fol-
lowing vaccination with Melan-A/peptide, incomplete 
Freund’s adjuvant, and CpG), the cancer testis A2/
NY-ESO-1157–165 (from patients LAU50 and LAU155 with 
naturally occurring T cell responses), or the persistent 
herpes viruses A2/pp65495–504 or A2/BMFL1259–267 (from 
healthy donors BCL4 and BCL6), categorized according 
to (A) the respective patients and donors or (B) antigenic 
specificity. (C) NTAmer-derived TCR dissociation rates 
(koff) of individual TCR-BV-CDR3 clonotypes specific for 
the tumor epitopes A2/Melan-A26–35 (n = 27) and A2/NY-
ESO-1157–165 (n = 24), and the persistent herpes virus epit-
opes A2/pp65495–504 (n = 37) and A2/BMFL1259–267 (n = 55). 
(D) NTAmer-derived TCR dissociation rates (koff) of A2/
Melan-A26–35–specific clones derived from HLA-A2–nega-
tive (HD1 and HD2), HLA-A2–positive (HD3 and HD4) 
healthy donors, HLA-A2–positive unvaccinated (LAU975 
and LAU1013) and A2/Melan-A26–35–vaccinated (LAU618, 
LAU627, and LAU818) melanoma patients, categorized 
according to the patient/donor groups and the differen-
tiation status of T cell clones. (A–D) Data are depicted 
as box (25th to 75th percentiles) and whisker (10th to 
90th percentiles) with the middle line representing the 
median. Numbers of clones n, as well as Kruskal-Wallis 
test (α = 0.05) derived P values are indicated. Significant 
differences between the A2/Melan-A26–35– and the A2/
NY-ESO-1157–165–specific groups were obtained by Mann-
Whitney test (2 tailed).
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subsequent upregulation of activating/inhibitory receptors than lower-avidity ones. Expression of inhibitory 
receptors such as PD-1 is usually considered a hallmark of T cell exhaustion in chronic infection and cancer, and 
consequently high-avidity T cells may be more prone to functional impairment. However, Odorizzi et al. (54) 
recently found that genetic absence of PD-1 on CD8+ T cells does not prevent exhaustion during chronic LCMV 
infection. Instead, PD-1 also plays a critical role in protecting T cells from overstimulation, excessive prolifera-
tion, and terminal differentiation (54), and identifies highly reactive antitumor T lymphocytes (55). Moreover, 
Figure 6. Interexperimental and over-time 
variations of TCR dissociation rates, pMHC 
multimer staining, and functional avidity 
assays. (A) NTAmer-derived TCR dissocia-
tion rates (koff), (B) NTAmer surface staining 
levels (geometric mean fluorescence intensity 
[gMFI]) and (C) killing avidity values (EC50) 
obtained in independent assays (n > 4) for A2/
Melan-A26–35–specific CD8
+ T cell clones with 
slow (n = 6, plain symbols and solid lines) or 
fast (n = 6, empty symbols and dotted lines) 
TCR off-rates. (A–C) Data are depicted as indi-
vidual values and boxes (minimum to maxi-
mum, with the middle line representing the 
mean). (D) NTAmer-derived TCR dissociation 
rates (koff), (E) killing avidity values (EC50), and 
(F) surface staining levels (gMFI) obtained over 
time (D10/11, D15, and D20/21; D = day) follow-
ing nonspecific stimulation (by PHA and irradi-
ated feeder cells) for A2/Melan-A26–35–specific 
T cell clones with slow (n = 6, plain symbols 
and solid lines) or fast (n = 6, empty symbols 
and dotted lines) TCR off-rates. S2 represents 
the off-rate measurements of the same clones 
6 months before the fifth round of stimula-
tion (S5). The P values were determined by the 
Friedman (α = 0.05) and Wilcoxon matched-
pair signed-rank (2-tailed) tests.
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T cell differentiation and activation are major drivers of inhibitory receptor expression (56). In line with these 
observations, the extent of coreceptor upmodulation observed following stimulation (Figure 3) likely reveals the 
overall antigen sensitivity of the T cells, which is mostly driven by TCR-pMHC binding avidity.
Another major finding is that the TCR-pMHC dissociation rate parameter allows the direct comparison 
across various antigen-specific T cell repertoires, in contrast to functional assays. The latter ones rely on the 
stability of  the pMHC complexes, which is not the case for monomeric TCR-pMHC dissociation experi-
ments. Indeed, the stability of  peptide binding to MHC may highly vary between different antigens even 
when presented by the same HLA-A*0201 molecule. This may help explaining why direct comparisons of  in 
vitro functional avidities (i.e., EC50) between tumor- and virus-specific T cell clones, or between Melan-A26–35 
and NY-ESO-1157–165 or CMV/pp65495–504 and EBV/BMFL1259–267 specificities show such divergent differences 
(Figure 1 and Supplemental Figure 4B). For instance, Melan-A– and EBV-specific T cell clones generally 
exhibit the lowest EC50 functional avidities, whereas NY-ESO-1– and CMV-specific T cell clones share the 
highest ones. In contrast, this is no longer an issue for the off-rate measurements, which rely by definition on 
the dissociation rate between the TCR and a given pMHC complex at the monomeric level. Consequently, we 
were able to directly compare large T cell clonotype repertoires (n > 300) across 4 different antigenic specifici-
ties and confirm strong binding differences between self/tumor and virus-specific CD8+ T cells (Figure 5 and 
refs. 36, 37). Specifically, virus-specific CD8+ T cell repertoires were endowed with longer TCR-pMHC disso-
ciation rates than self/tumor–specific ones. These data nicely support the concept that many tumor antigens 
are in fact self-antigens, and consequently mechanisms of  central and peripheral tolerance shape the self/
antigen-specific repertoires towards lower TCR avidities by removing high-avidity self-reactive T cells (23, 57).
Fluorochrome-conjugated pMHC reagents are widely used for the detection and analysis of antigen-specific 
CD8+ T cells. Various reports have previously shown that certain functional antigen-specific CD8+ T cells fail to 
bind tetrameric MHC ligands, which could represent up to several percent of the CD8+ T cell subset (58–60). 
Moreover, this is of particular importance when staining tumor-specific CD8+ T cells, known to express lower 
TCR-pMHC affinity/avidity repertoires than virus-specific cells (Figure 5 and refs. 36, 37). We therefore used 
pMHC multimer and NTAmer molecules to detect tumor-specific CD8+ T cells, which consistently displayed 
higher sensitivity than Streptamers or pentamers (Supplemental Figure 1A) or pMHC tetramer molecules (data 
not shown). However, we cannot entirely exclude that a sizeable fraction of antigen-specific T cells may not be 
stained by these higher-sensitivity tools and may therefore be ignored in our experimental setting.
The Melan-A/MART-126–35 antigenic peptide is among the best-studied human tumor–associated antigens. 
We have previously documented that the frequency of naive A2/Melan-A26–35–specific CD8
+ T cells is unusually 
high, because of the large numbers selected in the thymus (42). A recent study reported that medullary thymic 
epithelial cells express a truncated Melan-A transcript, which precludes clonal deletion (central tolerance) to this 
antigen due to the lack of the expression of the immunodominant 26–35 epitope (61). Another interesting expla-
nation might lay in the impact of certain germ line TCR gene segments, notably the TRAV12-2 gene dominant 
in the Melan-A antigen–specific T cell repertoire, on contributing substantial binding affinity for the HLA-A2/
Melan-A26–35 complex (62). One additional plausible cause of the presence of this large Melan-A26–35–reactive T 
cell repertoire is that it could be positively selected through the recognition of unknown Melan-A cross-reactive 
peptides expressed in the thymus (63, 64). Here, we found that naive Melan-A26–35–reactive repertoires isolated 
from either healthy individuals or unvaccinated melanoma patients depicted an overall poor TCR binding avid-
ity, when compared with the primed repertoires from vaccinated patients (Figure 5). Thus, our observations are 
compatible with central tolerance mechanisms, possibly involving other cross-reactive self-antigens, and restrict-
ing the Melan-A26–35–reactive T cell repertoire to the lower-avidity range. Yet, although rare, our large-scale study 
could identify few self/Melan-A26–35–specific naive CD8
+ T cells of higher binding avidities within healthy indi-
vidual’s and patient’s repertoires, extending and refining prior studies performed using conventional pMHC 
class-I fluorescent multimers (65). Therefore, it is possible that therapeutic vaccination allows for the selection 
and expansion of a wide Melan-A–reactive TCR avidity repertoire, which includes highly specific T cells sharing 
similar binding avidities to those present in the cancer testis A2/NY-ESO-1–specific repertoire.
Finally, our results highlight the importance of  optimizing the choice of  tumor antigens for the devel-
opment of  cancer-based immunotherapies. Notably, it remains to be determined whether T cell repertoires 
targeting tumor-derived neoantigens can display greater TCR-pMHC binding avidities than self/tumor–
antigen ones, since neoantigen-specific T cells are more likely to escape thymic negative selection (66). 
It is tempting to speculate that potent neoantigen-specific CD8+ T cells would display TCR off-rates of  a 
magnitude closer to the kinetics of  virus-specific CD8+ T cells shown in this study.
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Large-scale ex vivo assessment of  TCR-pMHC binding kinetics was until recently technically challeng-
ing, underestimating the overall impact and clinical relevance of  this biophysical parameter in the context 
of  antigen-specific CD8+ T cell repertoires. Based on monomeric TCR-pMHC off-rate measurements (i.e., 
NTAmers), we here demonstrated that the koff parameter represents a powerful biomarker to characterize 
in vitro and in vivo CD8+ T cell potency within antigen-specific CD8+ T cell responses. Yet, robust tech-
niques allowing for the rapid identification and isolation of  CD8+ T cells of  highest avidity and functions 
directly ex vivo from tissues or blood samples and at the single-cell level are still required. In that regard, 
Nauerth and colleagues (67) proposed that small polyclonal virus-specific CD8+ T cell populations could be 
analyzed directly ex vivo without the need of  previous TCR cloning or T cell sorting. The recent implemen-
tation of  an ex vivo platform allowing for the single-cell serial determination of  2D TCR-pMHC affinity 
(based on micropipette adhesion frequency) and TCR clonotyping is also highly promising (68). In conclu-
sion, recent technological breakthroughs now enable the rapid development of  TCR-pMHC binding kinet-
ics–based simple assays as sensitive and reliable biomarkers of  CD8+ T cell activity and clinical efficacy.
Methods
Patients, healthy donors, and ethics statement. Peripheral blood samples were collected from HLA-A*0201–
negative (HD1 and HD2), HLA-A*0201–positive (HD3 and HD4), HLA-A*0201–positive and CMV/EBV 
chronically infected (BCL4 and BCL6) healthy donors (HDs) (39) and from HLA-A*0201–positive stage 
III/IV metastatic melanoma patients included in immunotherapy studies (patient LAU50, NCT00112242; 
patient LAU155, NCT00002669; and patients LAU975, LAU1013, LAU618, LAU627, and LAU818, 
NCT00112229; www.clinicaltrials.gov) (38, 41, 69). Patients LAU618, LAU627, and LAU818 received 8 to 
12 monthly low-dose vaccinations injected s.c. with 100 μg high-affinity Melan-A26–35 (A27L) analog peptide 
mixed with 0.5 mg CpG 7909/PF-3512676 (Pfizer and Coley Pharmaceutical Group) and emulsified in IFA 
(Montanide ISA-51, Seppic). Peripheral blood mononuclear cells (PBMCs) centrifuged in Ficoll-Hypaque 
(Pharmacia) were cryopreserved in 10% DMSO and stored in liquid nitrogen until further use.
Generation of  antigen-specific CD8+ T cell clones. Thawed PBMCs were positively enriched using anti-CD8-coat-
ed magnetic microbeads (Miltenyi Biotec), stained in PBS, 0.2% BSA, and 5 mM EDTA with PE-labeled HLA-
A*0201 multimers (loaded with analog Melan-A26–35 (A27L), NY-ESO-1157–165 (C165A), and EBV/BMFL1259–267 
(C260A), or native CMV/pp65495–504 peptide) (TCMetrix Sàrl) at 4°C for 45 minutes, followed by cell surface 
markers (APC anti-CD28, FITC anti-CD45RA [BD Pharmingen], PE-Cy7 anti-CCR7 [BioLegend], and APC-
A750 anti-CD8 [Beckman Coulter], Supplemental Table 2) at 4°C for 30 minutes. Cells were then sorted into 
defined differentiated subpopulations (naive, CD45RA+CCR7+CD28+; EM, CD45RA–CCR7–CD28+/–; or 
EMRA, CD45RA+CCR7–CD28–) of antigen-specific CD8+ T cells on a FACSAria (BD Biosciences) or Astrios 
(Beckman Coulter) flow cytometer. Sorted cells were cloned by limiting dilution in Terasaki plates and expanded 
in RPMI 1640 medium supplemented with 8% human serum, 150 U/ml human recombinant IL-2 (gift of  
GlaxoSmithKline), 1 μg/ml PHA (Sodiag), and 1 × 106/ml 30-Gy-irradiated allogeneic PBMCs. The antigenic 
specificity of CD8+ T cell clones was controlled by HLA-A*0201/peptide multimer staining (TCMetrix Sàrl). 
Extensive TCR-BV-CDR3 clonotyping was performed on the T cells from patients LAU618, LAU155, and 
LAU50 and from healthy donors BCL4 and BCL6, as previously described (39), allowing selecting representa-
tive sets of dominant (with frequency > 5%) and nondominant TCR-BV-CDR3 clonotypes. Clonotype diver-
sity varied from 43% to 80%, depending on the antigenic specificity (Melan-A26–35 > EBV/BMFL1259–267 > NY-
ESO-1157–165 and CMV/pp65495–504) and is indicated throughout the manuscript.
NTAmer staining and dissociation kinetics measurements. The pMHC multimer and NTAmer molecules 
used in this study carry 8 to 12 pMHC monomers per conjugate, similarly to Dextramer molecules. Impor-
tantly, multimers and NTAmers provided a superior ex vivo detection of  A2/Melan-A–specific CD8+ T 
cells from PBMCs of  2 melanoma patients, when compared with pentamers (5 pMHC monomers) or 
Streptamers (5–7 pMHC monomers) (Supplemental Figure 1A). NTAmers are dually labeled pMHC mul-
timers built on NTA-Ni2+-His-tag interactions (70) and were used for dissociation kinetic measurements 
as described previously (28, 29). Briefly, individual antigen-specific CD8+ T cell clones were stained for 
45 minutes at 4°C in PBS, 0.2% BSA, and 5 mM EDTA with antigen-specific NTAmers, in which the 
HLA-A*0201 molecules were loaded with the native Melan-A26–35, NY-ESO-1157–165, EBV/BMFL1259–267, 
or CMV/pp65495–504 peptide. Of  note, Melan-A– and NY-ESO-1–specific T cells isolated from melanoma 
patients as well as EBV-specific T cells from healthy donor BCL4 were initially sorted with the analog-
peptide multimers. Yet, all Melan-A–, NY-ESO-1–, and EBV-derived T cell clones presented a high degree 
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of  cross-reactivity, since native-peptide NTAmers showed a comparable capacity to stably label each gener-
ated specific clone and thus should not have introduced a significant bias in the analysis. NTAmer staining 
was assessed at 4°C on a SORP-LSR II flow cytometer (BD Biosciences). Following 1 minute of  baseline 
acquisition, imidazole (100 mM) was added and Cy5 fluorescence measured during the following 10 min-
utes. Data were analyzed using the kinetic module of  FlowJo software (v.9.7.6, Tree Star) and modeled 
(1-phase exponential decay) using Prism software (v.6, GraphPad).
Chromium release cytolytic assay. Chromium release cytolytic assays were performed as previously 
described (13). Briefly, 51Cr-labeled HLA-A*0201–positive TAP-deficient T2 cells were pulsed with serial 
dilutions of  native Melan-A26–35, NY-ESO-1157–165, EBV/BMFL1259–267, or CMV/pp65495–504 peptides, and 
incubated with antigen-specific CD8+ T cell clones at an E/T ratio of  10:1 for 4 hours. NY-ESO-1157–165 
and EBV BMFL1259–267 peptides were preincubated for 1 hour at room temperature with 2 mM disulfide-
reducing agent tris(2-carboxyethyl)phosphine (TCEP, Pierce Biotechnology). Percentages of  specific lysis 
were calculated as 100 × (experimental – spontaneous release)/(total – spontaneous release). EC50 and Bmax 
values were derived by dose-response curve analysis (log[agonist] versus response) using Prism software. 
Non–killer clones were defined as displaying a maximal lysis less than 25% and/or for which an EC50 value 
could not be accurately determined. These non–killer clones were excluded from the statistical analyses.
CD107a degranulation and intracellular cytokine staining. HLA-A*0201–positive TAP-deficient T2 cells were 
pulsed 1 hour at 37°C with serial dilutions of  the native Melan-A26–35, NY-ESO-1157–165, EBV/BMFL1259–267, or 
CMV/pp65495–504 peptides, washed, and incubated with antigen-specific CD8
+ T cell clones at an E/T ratio of  
1:2 for 6 hours in the presence of  FITC anti-CD107a (BD Pharmingen; Supplemental Table 2) and brefeldin 
A (10 μg/ml, Sigma-Aldrich). NY-ESO-1157–165 and EBV BMFL1259–267 peptides were preincubated for 1 hour 
at room temperature with the disulfide-reducing agent TCEP (2 mM). Cells were then stained in PBS, 0.2% 
BSA, 5 mM EDTA, and 0.2% NaN3 with Pacific-Blue anti-CD8α (Beckman Coulter) at 4°C for 30 minutes, 
fixed in PBS 1% formaldehyde, 2% glucose, and 5 mM NaN3 for 20 minutes at room temperature, and finally 
stained in PBS, 0.2% BSA, 5 mM EDTA, 0.2% NaN3, and 0.1% saponin (Sigma-Aldrich) with PerCPCy5.5 
anti–IL-2, APC anti–IL-13, PE-Cy7 anti–IFN-γ, A700 anti–TNF-α (BD Pharmingen; Supplemental Table 2), 
and PE anti–IL-4 (Biolegend) for 30 minutes at 4°C before acquisition on a Gallios (Beckman Coulter) flow 
cytometer. Percentages of  CD107a/cytokine–positive T cells were analyzed using FlowJo software (v.10.0.7, 
Tree Star). EC50 and Bmax values were derived by dose-response curve analysis (log[agonist] versus response) 
using Prism software. Non-cytokine clones were defined as displaying a maximal response less than 25% and 
for which an EC50 value could not be determined accurately. These non-cytokine clones were not included in 
the statistical analyses. CD107a, IL-2, IFN-γ, and TNF-α coexpression were analyzed using SPICE software 
(v.5.35, National Institute of  Allergy & Infectious Diseases).
Proliferation assay. 30-Gy-irradiated HLA-A*0201–positive PBMCs were pulsed 1 hour at 37°C with 
native Melan-A26–35 (10 μM), NY-ESO-1157–165 (1 μM), EBV/BMFL1259–267 (1 μM), or CMV/pp65495–504 (0.01 
μM) peptides, washed, and incubated with CellTraceViolet-stained antigen-specific CD8+ T cell clones 
(Thermo Fisher Scientific) at an E/T ratio of  1:2 in RPMI 1640 medium supplemented with 8% human 
serum and 50 U/ml human recombinant IL-2. NY-ESO-1157–165 and EBV/BMFL1259–267 peptides were pre-
incubated for 1 hour at room temperature with the disulfide-reducing agent TCEP (2 mM). After 7 days, 
antigen-specific CD8+ T cell clones were acquired on the Gallios flow cytometer. Percentages of  divided 
cells were analyzed using the proliferation module of  FlowJo software (v.9.7.6).
Surface marker expression/modulation assay. For coreceptor modulation assays, antigen-specific CD8+ T cell 
clones were incubated for 24 hours in the absence or presence of  HLA-A*0201 unlabeled tetramers load-
ed with native Melan-A26–35 (1 μg/ml), NY-ESO-1157–165 (1 μg/ml), EBV BMFL1259–267 (0.1 μg/ml), or CMV 
pp65495–504 (0.01 μg/ml) peptides. Cells were then stained in PBS, 0.2% BSA, 5 mM EDTA, and 0.2% NaN3 
with (a) A488 anti-PD1 (Serotec), PE-Cy7 anti-CD5 (BD Pharmingen), APC anti-TIGIT (eBioscience), and 
BrV421 anti-CD28 (Biolegend), or with (b) FITC anti–LAG-3 (Enzo), PE anti–TIM-3 (R&D Systems), and 
APC anti-CD137 (BD Pharmingen) at 4°C for 30 minutes and acquired on the Gallios flow cytometer. Mark-
er expression (geometric mean fluorescence intensity [gMFI]) was analyzed using FlowJo software (v.10.0.7) 
and their modulation was calculated as (gMFI of  stimulated cells)/(gMFI of  un-stimulated cells).
For over-time expression assays, tumor-specific CD8+ T cell clones were stimulated and expanded 
upon PHA and irradiated feeder cells, and stained over time (at day 10, 15, and 20) in PBS, 0.2% BSA, 
5 mM EDTA, and 0.2% NaN3 with FITC anti-CD8β, PE-Cy7 anti-CD8α, PE anti–pan-TCRαβ (Beck-
man Coulter), PE anti–VLA-1, PE-Cy7 anti-CD5, APC anti–VLA-4, APC anti-CD137, BrV421 anti-PD1 
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(BD Pharmingen), APC anti-TIGIT (eBioscience), BrV421 anti-CD28 (Biolegend), or FITC anti–LAG-3 
(Enzo) at 4°C for 30 minutes, and acquired, using identical settings, on the Gallios flow cytometer. Supple-
mental Table 2 contains a detailed list and information of  all antibodies used in this study.
Adoptive T cell transfer in immunodeficient mice. NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (Jackson 
Laboratory, stock number 005557) were bred in a conventional animal facility at the University of  Laus-
anne under specific pathogen–free status. Six- to nine-week-old female mice were anesthetized with isoflu-
rane and subcutaneously injected with 1 × 106 A2/Melan-A26–35–positive and A2/NY-ESO-1157–165–positive 
human melanoma Me275 tumor cells (grown in DMEM medium supplemented with 10% FCS, and previ-
ously passed in NSG mice for A2/NY-ESO-1157–165–specific experiments). Once the tumors became pal-
pable (around day 14 to 20), 1 × 106 human tumor-specific CD8 T cell clones were injected intravenously 
in the tail vein. For A2/NY-ESO-1157–165–specific experiments, 1 × 10
6 T cell clones were administrated 
twice at day 14 and day 21, followed by 3 daily subcutaneously injections of  human recombinant IL-2 (3 × 
104 U), starting at the day of  T cell transfer. Tumor volumes were measured by caliper twice per week and 
calculated as follows: volume = length × width × width/2. Mice were sacrificed by CO2 inhalation before 
the tumor volume exceeded 1,000 mm3 or when necrotic skin lesions were observed at the tumor site. In 
separate experiments, we collected blood from tail veins at day 2 and 14 after infusion of  4 × 106 A2/NY-
ESO-1157–165–specific T cell clones and analyzed the frequency of  persisting human CD8
+ T cells by flow 
cytometry. This study was approved by the Veterinary Authority of  the Canton de Vaud (Permit number 
VD1850.5) and performed in accordance with Swiss ethical guidelines.
Statistics. Data were analyzed using Prism software (v.6, GraphPad) by nonparametric Spearman 
correlation, nonlinear regression (95% confidence intervals and 10% ROUT coefficient Q; see ref. 71), 
extra sum-of-squares F, Kruskal-Wallis, Mann-Whitney, Friedman, Wilcoxon-paired, 2-way ANOVA 
and log-rank tests. The associated P values (2-tailed and α = 0.05 when applicable), as well as numbers of  
experiments and sample sizes are indicated throughout.
Study approval. Study protocols were designed, approved, and conducted according to the relevant 
regulatory standards from (a) the ethical commission of  the University of  Lausanne (Lausanne, Switzer-
land), (b) the Protocol Review Committee of  the Ludwig Institute for Cancer Research (New-York), and 
(c) Swissmedic (Bern, Switzerland). Healthy donors and patient recruitment, study procedures, and blood 
withdrawal were done upon written informed consent.
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SUPPLEMENTAL MATERIALS  
Supplemental Table 1. List of TCR-BV-CDR3 clonotypes and their off-rate values. 
 
Antigenic Patient/
specificity Donor Clonotype BV family CDR3 (amino acids) BJ Mean koff (s-1)
A2/Melan-A LAU618 clono 1 BV3 SPPGLSGNIQ 2.4 0.03338
clono 2 BV3 SFQGVGTGEL 2.2 0.02622
clono 3 BV13 SYGPLSGAGY 1.2 0.02548
clono 4 BV13 SPGTLADTQ 2.3 0.06173
clono 5 BV13 SAGYGQPQ 1.5 0.05155
clono 6 BV14 RAGALQGEQ 2.7 0.10740
clono 7 BV14 SPAALSGAYEQ 2.7 0.10100
clono 8 BV17 SPGALNTEA 1.1 0.06438
clono 9 BV3 SFPRWGRNYSYNEQ na 0.03492
clono 10 BV14 SLSAGTGVLDTQ na 0.09449
clono 11 BV17 SIGA--EHEQ na 0.09964
clono 12 BV17 SIEALQGFTEA na 0.04187
clono 13 BV17 RWGVLNTEA na 0.01835
A2/NY-ESO-1 LAU155 clono 1 BV1 SVATGGDTQ 2.3 0.01875
clono 2 BV8 NSGSNEQ 2.1 0.02771
clono 3 BV8 SLGSTEA 1.1 0.00831
clono 4 BV8 NSGANEQ 2.1 0.02026
clono 5 BV8 RKGPNEQ 2.1 0.03529
clono 6 BV13 SYVGAAGEL 2.2 0.02918
clono 7 BV13 SLTGGLNSPL na 0.03146
clono 8 BV1 SLATGEDTQ na 0.01574
clono 9 BV13 LGDGDGAYNSPL 1.6 0.03277
LAU50 clono 10 BV8 QQGGTEA 1.1 0.01572
clono 11 BV8 SLGGTEA 1.1 0.01975
clono 12 BV13 RTGLDGY 1.2 0.03094
clono 13 BV13 SYVGGKAEA 1.2 0.02612
A2/CMV-pp65 BCL4 clono 1 BV1 SVYGGAGNSPL 1.6 0.00866
clono 2 BV1 SYPGGNTI 1.3 0.01797
clono 3 BV3 SFLGYTEA 1.1 0.01174
clono 4 BV8 SSVNEA 1.1 0.00646
clono 5 BV8 SSAGGAVYGY 1.2 0.02039
clono 6 BV9 SLLLGTAAEA 1.1 0.00313
clono 7 BV14 RLLAGGRSAQ 2.5 0.00608
clono 8 BV3 SFSSPGQGSTDTQ 2.3 0.01285
clono 9 BV8 SSVLEA 1.1 0.01002
clono 10 BV8 SLVGGVDGY 1.2 0.03013
clono 11 BV8 SIMDYGY 1.2 0.03125
clono 12 BV13 SAVTGAVDQPQ 1.5 0.01642
clono 13 BV13 SYFYYEQ 2.7 0.00251
clono 14 BV13 SYSTGTAYGY 1.2 0.00289
clono 15 BV13 SPKTGVPYEQ 2.7 0.02146
BCL6 clono 16 BV8 SSANYGY 1.2 0.01505
clono 17 BV13 SRQTGAAYGY 1.2 0.00617
clono 18 BV13 SYATGTAYGY 1.2 0.00530
A2/EBV-BMFL1 BCL4 clono 1 BV2 RDRTGNGY 1.2 0.005131
clono 2 BV2 RDSVGNGY 1.2 0.002706
clono 3 BV2 RDRVGNGY 1.2 0.001934
clono 4 BV2 RDSTGNGY 1.2 0.004689
clono 5 BV2 RVEPGNGY 1.2 0.009871
clono 6 BV4 VGTGGTNEKL 1.4 0.014417
clono 7 BV4 VGYGGTNEKL 1.4 0.013503
clono 8 BV4 VGSGGTNEKL 1.4 0.045620
clono 9 BV16 SQSPGGTQ 2.5 0.009123
clono 10 BV16 SQSPGGEA 1.1 0.003469
clono 11 BV16 SQSPGGTS na 0.003878
clono 12 BV18 SPPAVSYEQ 2.7 0.016529
clono 13 BV2 DGY 1.2 0.017560
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Supplemental Table 2. List of antibodies used in this study. 
 
  
Name Company Catalog no Clone no
APC anti-CD28 BD Pharmigen 559770 CD28.2
FITC anti-CD45RA BD Pharmigen 561882 Hl100
FITC anti-CD107a BD Pharmigen 555800 H4A3
PerCPCy5.5 anti-IL2 BD Pharmigen 560708 MQ1-17H12
APC anti-IL13 BD Pharmigen 561162 JES10-5A2
PE-Cy7 anti-IFNγ BD Pharmigen 557844 4S.B3
A700 anti-TNFα BD Pharmigen 557996 MAb11
PE-Cy7 anti-CD5 BD Pharmigen 348810 L17F12
APC anti-CD137 BD Pharmigen 550890 4B4-1
PE anti-VLA-1 BD Pharmigen 559596 SR84
APC anti-VLA-4 BD Pharmigen 561794 MAR4 .
BrV421 anti-PD1 BD Pharmigen 562516 EH12.1
APC-A750 anti-CD8 Beckman Coulter A94683 B9.11
Pacific-blue anti-CD8 Beckman Coulter A82791 B9.11
FITC anti-CD8beta Beckman Coulter IM2217U 2ST8.5H7
PE-Cy7 anti-CD8alpha Beckman Coulter 737661 SFCI21Thy2D3
PE anti-pan-TCRab Beckman Coulter A39499 IP26A
PE-Cy7 anti-CCR7 Biolegend 353226 G043H7
PE anti-IL4 Biolegend 500810 MP4-25D2
BrV421 anti-CD28 Biolegend 302930 CD28.2
A488 anti-PD1 AbD Serotech MCA2628A488 MlH4
APC anti-TIGIT eBioscience 17-9500-42 MBSA43
FITC anti-LAG-3 Enzo ALX-804-806F-C100 17B4
PE anti-TIM-3 R&D systems FAB2365P 344823
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Supplemental Figure 1: Ex vivo detection of antigen-specific CD8 T cells using pMHC-
based reagents and analysis of blood samples used to generate self/tumor- and virus-
specific CD8 T cell clones.  (A) Comparison of A2/MelanA26-35-specific staining from 
PBMCs obtained from melanoma patients (LAU1129 and LAU1164) using PE-labeled 
pentamers, streptamers, multimers and NTAmers. Gating was done on live CD14-/CD16-
/CD19-/CD3+ lymphocytes. The valence of pMHC reagents is indicated in brackets, as well 
as percentages of positively stained cells. FMO (fluorescence minus one). (B) CD8 and 
multimer staining of CD8-enriched PBMCs from melanoma patients LAU618 (A2/Melan-
A26-35), LAU155 (A2/NY-ESO-1157-165) and healthy donor BCL4 (A2/pp65495-504 or 
A2/BMFL1259-267). (C) CCR7, CD45RA and CD28 staining of the corresponding multimer-
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specific (R1) and total CD8 T cell (CD8t) populations. Percentages of positively stained cells 
are indicated. Melan-A/specific CD8 T cell clones (from patient LAU618) exhibited an 
EM/CD28+/- phenotype, while NY-ESO-1-specific T cell clones (from patient LAU155) 
presented mostly an early-differentiated EM/CD28+ phenotype. EBV/BMFL1-specific CD8 T 
cell clones were predominantly EM/CD28+, whereas CMV/pp65-specific clones mostly 
exhibited a differentiated EMRA/CD28- phenotype. 
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Supplemental Figure 2: In vitro analysis of TCR dissociation-rates versus functional 
avidities of self/tumor- and virus-specific CD8 T cell clones. Representative (A) NTAmer-
dissociation curves, (B) killing-, (C) CD107a degranulation-, IFNγ-, TNFα-, IL-2-, IL-4- and 
IL-13-production titration curves and (D) proliferation analysis (by CFSE fluorescence 
histograms) obtained for A2/Melan-A26-35-specific CD8 T cell clones from patient LAU618, 
defined as slow (n = 6, blue lines) or fast (n = 6, grey lines) TCR off-rates. Non-divided and 
divided T cells are represented as plain and empty peaks, respectively. 
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Supplemental Figure 3: Relationship between TCR dissociation-rates, functional avidity 
and maximal function capacity of self/tumor- and virus-specific CD8 T cell clones. 
Correlations between EC50 values from (A) IL-4- and (B) IL-13-production titration assays, 
and NTAmer-derived TCR dissociation-rates (koff). (C) Correlations between Bmax values 
from killing, CD107a-degranulation, IFNγ-, TNFα-, IL-2-, IL-4- and IL-13-production 
titration assays, or percentages of granzyme-B expressing T cells, and NTAmer-derived TCR 
dissociation-rates (koff). (A-C) Each data-point represents an A2/Melan-A26-35- (derived from 
patient LAU618, !), A2/NY-ESO-1157-165- (patient LAU155, "), A2/pp65495-504- or 
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A2/BMFL1259-267- (healthy donor BCL4, #) specific individual T cell clone. Non-functional 
clones are represented in grey boxes. The number of clones displaying function n, as well as 
Spearman’s correlation (two tailed, α = 0.05) coefficient R and p values are indicated. Color-
coded and black lines are indicative of regression fitting and 95% confidence intervals, 
respectively. (D) Bmax values from killing, CD107a-degranulation, IFNγ-, TNFα-, IL-2-, IL-4- 
and IL-13-production titration assays, or granzyme-B expression, of early-differentiated 
effector-memory EM/CD28+ or late-differentiated EM/CD28- A2/Melan-A26-35-specific T cell 
clones derived from patient LAU618. Data are depicted as box (25th to 75th percentiles) and 
whisker (10th to 90th percentiles) with the middle line representing the median. Numbers of 
clones n, as well as Mann-Whitney (two tailed) derived p values are indicated. Of note, upon 
high peptide-dose stimulation (at Bmax, maximal response), differentiated EM/CD28--
derived CD8 T cell clones displayed higher granzyme-B expression, cytotoxic and IFN-γ 
production capacity, but a lower ability to produce IL-2, IL-4 or IL-13 than memory 
EM/CD28+ T cells. 
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Supplemental Figure 4: Functional avidities according to the functional assay or the 
antigenic specificity of CD8 T cell clones. Comparison of functional avidity (EC50) from 
killing-, CD107a degranulation-, IFNγ-, TNFα- and IL-2-production of A2/Melan-A26-35- 
(derived from melanoma patient LAU618, n = 30), A2/NY-ESO-1157-165- (patient LAU155, n 
= 32), A2/pp65495-504- or A2/BMFL1259-267- (healthy donor BCL4, n = 30 and 26, 
respectively) specific CD8 T cell clones classified according to (A) the functional assay and 
(B) the antigenic-specificity. Data are depicted as box (minimum to maximum) with the 
middle line representing the mean. The representative TCR-BV clonotype diversity of each 
antigenic specificity is as following; LAU618/Melan-A, 77%; LAU155/NY-ESO-1, 43%; 
BCL4/pp65, 57%; BCL4/BMFL1, 67%. 
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Supplemental Figure 5: CD5 expression according to the TCR-dissociation off-rate 
parameter and antigenic specificity of self/tumor- and virus-specific CD8 T cell clones. 
CD5 surface staining was obtained at baseline (no antigen-specific stimulation) from 
representative antigen-specific CD8 T cells of (A) slow or (B) fast NTAmer-based off-rates. 
Data are depicted according to the antigenic specificity (A2/Melan-A26-35-, A2/NY-ESO-1157-
165-, A2/pp65495-504- and A2/BMFL1259-267 antigens). Geometric fluorescence means (gMFI) 
are indicated. 
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Supplemental Figure 6: TCR dissociation-rates according to the antigenic specificity 
and ex vivo differentiation status. Representative (A) NTAmer-dissociation staining and (B) 
corresponding fitting curve obtained for A2/Melan-A26-35- (!), A2/NY-ESO-1157-165- ("), 
A2/pp65495-504- (!) and A2/BMFL1259-267- (") specific CD8 T cell clones, defined as 
average TCR off-rates. koff and t1/2 derived values are indicated. (C) NTAmer-derived TCR 
dissociation-rates (koff) of early-differentiated effector-memory EM CD28+ (left panel) versus 
late-differentiated EM/EMRA CD28- (right panel) clones specific for (i) A2/Melan-A26-35 
(from vaccinated melanoma patients LAU618, LAU627 and LAU818), (ii) A2/NY-ESO-1157-
165 (from patients LAU50 and LAU155 with naturally occurring tumor-specific T cell 
responses) or (iii) the persistent herpes viruses A2/pp65495-504 or A2/BMFL1259-267 (from 
healthy donors BCL4 and BCL6), categorized according to their antigenic specificity. Data 
are depicted as box (25th to 75th percentiles) and whisker (10th to 90th percentiles), with the 
middle line representing the median. Antigen specificity is depicted according to specific 
colored codes and symbols. Numbers of clones n, as well as Kruskal-Wallis test (α = 0.05) 
derived p values are indicated. Significant differences between the A2/Melan-A26-35- and the 
A2/NY-ESO-1157-165-specific groups were obtained by a Mann Whitney test (two tailed). 
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Supplemental Figure 7: Correlations between TCR dissociation rates versus pMHC 
multimer staining versus functional avidity of CD8 T cell clones. (A) Correlations 
between NTAmer-derived TCR dissociation rates (koff), NTAmer surface staining levels 
(gMFI) and killing avidity values (EC50) obtained from independent assays (n = 4 to 9) for 
A2/Melan-A26-35-specific CD8 T cell clones, defined as slow (n = 6, plain symbols) or fast (n 
= 6, empty symbols) TCR off-rates. Each symbol/clone is represented as average ± SD. The 
number of clones (n), as well as Spearman’s correlation (two tailed, α = 0.05) coefficients R 
and p values are indicated. Lines are indicative of linear regression fitting. Representative (B) 
NTAmer-dissociation and (C) killing-titration curves obtained at day 10 (D10), 15 (D15) and 
20 (D20) following non-specific stimulation (by PHA and irradiated feeder cells) of 
A2/Melan-A26-35-specific CD8 T cell clones, defined as slow (n =6, plain symbols and solid 
lines) or fast (n = 6, empty symbols and dotted lines) TCR off-rates. Average and SD 
percentages are depicted, as well as the corresponding fitting curves and koff or EC50 derived 
values. 
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ABSTRACT  23 
Efficient T cell responses rely on TCR-pMHC binding avidity that controls essential T cell 24 
functions. Yet, whether the TCR-ligand avidity is a determining factor for the clonal evolution 25 
of virus antigen-specific CD8 T cells, and how this process is determined in CMV against EBV 26 
latent infection, remains largely unknown. Here, we quantified TCR-pMHC off-rates on large 27 
libraries of well-characterized virus-specific TCRab clonotypes isolated from six healthy 28 
donors over a period of 15 years. Within CMV-specific T cell repertoires, we observed the 29 
progressive contraction of clonotypes of higher TCR-pMHC avidity and lower CD8 binding 30 
dependency during chronic antigen exposure. Interestingly, we identified a unique 31 
transcriptional signature preferentially expressed by high-avidity T cell clonotypes, including 32 
the inhibitory receptor LILRB1. Surface expression of LILRB1 was also found to be elevated 33 
in the declining clonotypes when compared to the expanding clonotypes, correlating with 34 
enhanced proliferative capacity upon LILRB1 blockade. This was not the case for the EBV-35 
specific T cell clonal composition and distribution, that once established, displayed an 36 
unprecedented stability for at least 15 years. Taken together, these findings reveal an overall 37 
long-term avidity decline of CMV- but not EBV-specific T cell clonal repertoires, highlighting 38 
the differing role played by TCR-ligand avidity over the course of these two latent herpesvirus 39 
infections. Our data suggest that LILRB1 represents a key checkpoint regulator that limits the 40 
life expectancy of high-avidity CMV-specific T cell clonotypes. We conclude that the 41 
mechanisms regulating the long-term outcome of CMV- and EBV-specific memory CD8 T cell 42 
clonotypes in humans are distinct.  43 
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 3 
INTRODUCTION 44 
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are common persistent viruses, 45 
infecting, depending on geographical location, 60-90% and over 95% of the human adult 46 
population, respectively. Primary CMV and EBV infection is associated with a robust T cell-47 
specific immune response, followed by the establishment of a lifelong latency. In healthy 48 
individuals, herpesviruses are generally well controlled, through a fine balance between viral 49 
determinants and host immune surveillance, that usually allows immunocompetent individuals 50 
to remain asymptomatic throughout their lives. Yet, these viruses remain a major cause of 51 
morbidity and mortality in immunocompromised individuals (1, 2). 52 
The maintenance of memory CD8 T cell responses during CMV and EBV latent infection has 53 
been shown to differ in terms of frequency, phenotype and function. For instance, the number 54 
of EBV-specific memory CD8 T cells generally remains stable over time in healthy carriers (3, 55 
4), while CMV-specific T cells persist in larger numbers and even slowly accumulate with 56 
ageing, in a process named “memory inflation” (5-7). Moreover, CD8 T cells specific for EBV 57 
mostly display a T cell central-memory (TCM) phenotype and are thus less differentiated than the 58 
predominantly effector-memory (TEM) CMV-specific T cell pool, that typically harbor a more 59 
mature phenotype (8, 9). At the functional level, CMV-specific T cells produce cytokines (i.e. 60 
IFNg, TNFa) and effector mediators (i.e. perforin, granzyme B), and show constitutive 61 
cytolytic activity, sharing features common among acute effector cells (8, 10-12). It is 62 
becoming increasingly clear that repetitive exposure to antigen is a key determinant of memory 63 
T cell inflation during CMV latent infection. Indeed, CMV is characterized by intermittent 64 
reactivation from latency, inducing a low-level persistent infection, which subsequently 65 
impacts on the virus-specific CD8 T cell response (13). In contrast, EBV reactivation during 66 
latency is thought to occur only occasionally, with virus-specific T cells showing no sign of 67 
inflation/expansion comparable to CMV infection (14). While the factors that drive and 68 
maintain these large populations of CD8 T cells are known to diverge between specific herpes 69 
viruses (14), there is still a continued need to improve our knowledge about the course of latent 70 
CMV and EBV infections and their control by long-term immune responses. 71 
The T cell repertoires (TCRs) of CMV- and EBV-specific CD8 T cells during viral infection 72 
and latency have been extensively studied over the past two decades (15). Initial skewing of the 73 
TCR repertoire towards the HLA-A2 restricted epitope derived from the CMV protein pp65 74 
has been observed following primary infection and during CMV reactivation (16, 17), resulting 75 
in progressively limited clonal diversity through the latency phase (9, 18). In the EBV context, 76 
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 4 
early reports have shown that highly dominant T cell clonotypes present during the primary 77 
phase in acute infectious mononucleosis patients were poorly represented in the long-term, as 78 
they were often overtaken or replaced by others (19, 20). Nevertheless, longitudinal studies 79 
have also revealed that the clonal repertoire against latent CMV and EBV infections, once 80 
established, remained stable and did not evolve for at least several years (9, 17, 21-24). 81 
However, the maximal time span analyzed in those studies was 5 years, whereas CMV and 82 
EBV immune responses persist for decades and small changes in the TCR repertoire may only 83 
be observed over longer periods of time. Along this line, Miles et al. (25) have previously 84 
reported the long-term persistence of single CD8 T cell clonotypes specific for the HLA-85 
B*0801/FLR and HLA-B*4405/EEN epitopes for 18 and 11 years, respectively, in two EBV-86 
positive donors. Collectively, following primary infection and initial TCR repertoire focusing, 87 
herpes virus-specific T clonal repertoires appear to be stably maintained for at least several 88 
years (21). 89 
Despite major efforts, the parameters underlying the selection and long-term maintenance of 90 
virus-specific CD8 T cell subpopulations remain poorly understood. Competition for antigen at 91 
the level of the APC (26), as well as between virus-specific T cells (27), have been shown to 92 
favor clonal dominance during memory inflation induced by murine CMV (MCMV) infection. 93 
Other studies have implicated a dominant role for the immunoproteasome (28) and for the viral 94 
gene expression context (29) in defining T cell immunodominance against MCMV. A very 95 
recent report found that the inflationary T cell pool is mainly composed of high avidity CD8 T 96 
cells that outcompete lower avidity T cells (30). This last observation is in agreement with the 97 
assumption that TCR-pMHC avidity represents a major determinant of the TCR repertoire 98 
selection and dominance in human CMV-specific CD8 T cell responses (9, 16-18, 23). In 99 
addition, investigations of TCR repertoire evolution during aging have shown an accumulation 100 
of CMV-specific CD8 T cells of lower avidity or functional potential in elderly individuals (31, 101 
32). On the other hand, a dominant CMV/pp65-specific TRBV clonal signature of high avidity 102 
has been described in elderly individuals, implying that long-lasting infection does not preclude 103 
the establishment of repertoires with increased avidities (33). 104 
One of the main limitations in addressing the question on the impact of TCR-pMHC avidity on 105 
T cell clonal evolution is that the above-mentioned studies determined avidity using soluble 106 
pMHC multimers or functional assays (i.e. specific T cell reactivity was analyzed against 107 
increasing antigen concentrations). It is only recently that the precise quantification of TCR 108 
binding avidity by NTAmers (34, 35) or Streptamers (36), which provide more reliable tools to 109 
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 5 
determine avidity-based TCR repertoire shaping, has become possible (15, 37). Another major 110 
restriction lies in the fact that antigen-specific CD8 T cell clonotypes are commonly assessed 111 
at the TCR-Vb chain (i.e. TRBV) level without including complete TCRab repertoire analyses. 112 
Finally, long-term TCR clonal repertoire and overall avidity evolution have often been 113 
restricted to cross-sectional studies comparing individuals of different age groups. 114 
Here, we combined TCRab clonotypic repertoire with quantitative TCR-pMHC dissociation 115 
rate (i.e. off-rate or koff) analyses to characterize the TCR clonal evolution between CMV 116 
(HLA-A2/pp65495-503) versus EBV (HLA-A2/BMFL1280-288) latent infection in longitudinal 117 
studies over a period of 15 years. Specifically, we investigated the degree to which this process 118 
is determined by TCR-pMHC binding avidity in both viral models. Our findings reveal a 119 
progressive long-term avidity decline of CMV- but not EBV-specific memory CD8 T cell 120 
clonotype repertoires. This was associated with the preferential expression of the checkpoint 121 
regulator LILRB1/CD85j in high-avidity CMV-specific TCRab clonotypes. These data 122 
highlight a critical role played by TCR avidity-driven repertoire evolution in the long-term 123 
outcome of CMV-specific compared to EBV-specific CD8 T cell responses in healthy 124 
individuals.  125 
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MATERIALS & METHODS   126 
Healthy donors and ethics statement 127 
Leukapheresis were collected from seven healthy individuals latently infected with the CMV 128 
and/or EBV viruses (BCL1, BCL2, BCL4, BCL6, BCL7, BCL8 and BCL9) in 2002, as 129 
described previously (9) and defined as time-point Tn. Blood samples from the same individuals 130 
(except BCL8) were collected 15 years later in 2017, defined as Tn+15y. No clinical data were 131 
available on their acute infection in the past, but all individuals remained in excellent health 132 
during the 15 years of follow-up. Peripheral blood mononuclear cells (PBMCs) centrifuged in 133 
Ficoll-Hypaque (Pharmacia) were cryopreserved in 10% DMSO and stored in liquid nitrogen 134 
until further use. This study was reviewed and approved according to the relevant regulatory 135 
standards from the ethical commission of the University of Lausanne (Lausanne, Switzerland). 136 
All healthy donors gave written informed consent. 137 
Generation of virus-specific CD8 T cell clones and direct ex vivo single cell sorting 138 
Thawed PBMCs were positively enriched using anti-CD8-coated magnetic microbeads 139 
(Miltenyi Biotec), stained in PBS, 0.2% BSA, and 5 mM EDTA with PE-labeled HLA- A*0201 140 
multimers loaded with native EBV/BMFL1280-288 (GLCTLVAML) or CMV/pp65495-503 141 
(NLVPMVATV) peptide (Peptide and Tetramer Core Facility, CHUV/UNIL/LICR, Lausanne, 142 
Switzerland) at 4°C for 45 minutes, followed by cell surface marker APC-A750 anti-CD8 143 
(Beckman Coulter) at 4°C for 30 minutes. Virus-specific CD8 T cells (CD8+multimer+) were 144 
then sorted on a FACSAria (BD Biosciences) flow cytometer as single cells for ex vivo T cell 145 
repertoire analyses or as 300-1000 cells for in vitro cloning. For the latter sorting, T cells were 146 
further cloned by limiting dilution and expanded in RPMI 1640 medium (Gibco) supplemented 147 
with 8% human serum, 150 U/ml human recombinant IL-2 (a gift from GlaxoSmithKline), 1 148 
µg/ml PHA (Sodiag), and 1×106/ml 30-Gy-irradiated allogeneic PBMCs as feeder cells. 149 
Antigen-specific CD8 T cell clones were expanded by periodic (every 20-25 days) 150 
restimulation with PHA, irradiated feeder cells and recombinant human IL-2, or cryopreserved 151 
in 10% DMSO (Sigma-Aldrich) and stored in liquid nitrogen until further use. 152 
TCR clonotype repertoire sequencing 153 
Extensive TRBV-CDR3 and TRAV-CDR3 analysis were performed on in vitro-generated T cell 154 
clones as well as on ex vivo sorted single T cells (9, 38). In brief, single cells were incubated 155 
with a lysis/reverse transcription (RT) mix and cDNA preparation mix before undergoing 156 
global cDNA amplification as detailed previously (38). T cell clones (2x104 cells) were directly 157 
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processed through direct cell lysis and cDNA synthesis without undergoing the global cDNA 158 
amplification procedure. Each cDNA sample was then subjected to individual PCR using a set 159 
of previously validated forward primers specific for the different known TRBV or TRAV gene 160 
subfamilies and two reverse primers specific for the corresponding C-beta or C-alpha gene 161 
segments (9). PCR products of interest were sequenced from the reverse primer (Fasteris SA). 162 
Clonotypes were defined as T cell clones sharing the same TRBV-CDR3 and TRAV-CDR3 163 
amino acid sequences. Clonotypic primers for dominant TRBV-CDR3 sequences were validated 164 
and used in clonotypic PCRs for the determination of clonotype frequencies, as described (9). 165 
TCR sequences were analyzed using SnapGene (v.4.1.9 GSL Biotech) and described according 166 
to the ImMunoGeneTics (IMGT) nomenclature (39). 167 
Ex vivo TRBV family and clonotype repertoire analyses 168 
CD8-enriched T cells from PBMCs were initially stained with CMV-specific or EBV-specific 169 
multimers as described above, followed by cell surface marker APC-A750, FITC or APC anti-170 
CD8 (Beckman Coulter) and antibodies against the different identified TRBV families as 171 
indicated in the Supplemental Table 1 for 30 minutes at 4°C. Samples were acquired on a LCRII 172 
cytometer (BD Biosciences) and analyzed using FlowJo 10.4.2 software (v.10.4.2, Tree Star). 173 
The frequency of CMV-specific TRBV clonotypes was also assessed for each ex vivo TRBV 174 
family identified by flow cytometry from donors BCL4 and BCL6. Briefly, antigen-specific 175 
CD8 T cells, which stained positive for a given TRBV family were sorted, in vitro cloned and 176 
TRBV-CDR3 sequenced as described above. 177 
NTAmer staining and dissociation kinetic measurements 178 
NTAmers (Peptide and Tetramer Core Facility, CHUV/UNIL/LICR, Lausanne, Switzerland) 179 
are dual-labeled pMHC multimers built on NTA-Ni2+-His-tag interactions (40) and were used 180 
for dissociation kinetic measurements as previously described (34, 35). Individual virus-181 
specific CD8 T cell clones or bulk virus-specific CD8 T cell populations expanded following 182 
short-term in vitro stimulation (during 20-25 days) with PHA and irradiated feeder cells were 183 
stained for 45 minutes at 4°C in PBS, 0.2% BSA and 5 mM EDTA with virus-specific 184 
NTAmers, in which the HLA-A*0201 molecules were loaded with native EBV/BMFL1280-288 185 
or CMV/pp65495-503 peptides. We also used NTAmers prepared with CD8 binding-deficient 186 
HLA-A*0201 monomers (i.e. NTA CD8-null) bearing the D227K/T228A mutations in the 187 
HLA α3 domain (34). NTAmer staining was assessed at 4°C on a LSRII cytometer (BD 188 
Biosciences). Following 30 seconds of baseline acquisition, imidazole (100 mM) was added 189 
and Cy5 fluorescence was measured during the following 10 minutes. Data were analyzed using 190 
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 8 
the kinetic module of FlowJo software (v.9.7.6, Tree Star) and modeled (1-phase exponential 191 
decay) using Prism software (v.7, GraphPad). 192 
CD107a degranulation and intracellular cytokine staining 193 
HLA-A*0201-positive TAP-deficient T2 cells were pulsed for 1 hour at 37°C with serial 194 
dilutions of native EBV/BMFL1280-288 or CMV/pp65495-503 peptides, washed, and incubated 195 
with virus-specific CD8 T cell clones at an E/T ratio of 1:2 for 6 hours in the presence of FITC 196 
anti-CD107a (BD Pharmingen) and brefeldin A (10 µg/ml, Sigma-Aldrich). EBV/BMFL1280-197 
288 peptide was preincubated for 1 hour at room temperature with the disulfide-reducing agent 198 
TCEP (2 mM, Pierce Biotechnology). Cells were then stained in PBS, 0.2% BSA and 5 mM 199 
EDTA with Pacific Blue anti-CD8α (Beckman Coulter) at 4°C for 30 minutes, fixed in PBS 200 
1% formaldehyde, 2% glucose, and 5 mM NaN3 for 20 minutes at room temperature, and finally 201 
stained in PBS, 0.2% BSA, 5 mM EDTA and 0.1% saponin (Sigma-Aldrich) with PE-Cy7 anti-202 
IFNγ and A700 anti-TNFα (BD Pharmingen) for 30 minutes at 4°C before acquisition on a 203 
LSRII (BD Biosciences) cytometer. Percentages of CD107a/cytokine-positive T cells were 204 
analyzed using FlowJo software (v.10.4.2, Tree Star). EC50 values were derived by dose-205 
response curve analysis (log[agonist] versus response) using Prism software (v.7, GraphPad). 206 
Chromium release cytolytic assay 207 
Chromium release cytolytic assays were performed as following; 51Cr-labeled HLA-A*0201-208 
positive TAP-deficient T2 cells were pulsed with serial dilutions of native EBV/BMFL1280-288 209 
or CMV/pp65495-503 peptides, and incubated with virus-specific CD8 T cell clones at an E/T 210 
ratio of 10:1 for 4 hours. EBV/BMFL1280-288 peptide was preincubated for 1 hour at room 211 
temperature with the disulfide-reducing agent TCEP (2 mM, Pierce Biotechnology). 212 
Percentages of specific lysis were calculated as 100 × (experimental – spontaneous 213 
release)/(total – spontaneous release). EC50 values were derived by dose-response curve 214 
analysis (log[agonist] versus response) using Prism software (v.7, GraphPad).  215 
Surface marker modulation assay 216 
Virus-specific CD8 T cell clones were incubated for 24 hours in the absence or presence of 217 
HLA-A*0201 unlabeled multimers loaded with native EBV/BMFL1280-288 (1 µg/ml) or 218 
CMV/pp65495-503 (0.01 µg/ml) peptides. Cells were then stained in PBS, 0.2% BSA, 5 mM 219 
EDTA and 0.2% NaN3 with A700 anti-CD137 and BV421 anti-PD-1 (Biolegend) at 4°C for 30 220 
minutes and acquired on a LSRII flow cytometer (BD Biosciences). Vivid Aqua (Invitrogen) 221 
was used to discriminate live/dead cells. The level of expression of each marker (geometric 222 
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 9 
mean fluorescence intensity [gMFI]) was analyzed using FlowJo software (v.10.4.2, Tree Star) 223 
and their modulation was calculated as (gMFI of stimulated cells)/(gMFI of unstimulated cells). 224 
RNA sequencing analysis 225 
CD8-enriched from PBMCs were stained with CMV-specific multimers followed by cell 226 
surface marker APC-A750, FITC or APC anti-CD8 (Beckman Coulter) and antibodies against 227 
the different identified TRBV families as described above (Suppl. Table 1). CMV/TRBV-228 
specific CD8 T cells were then sorted on a FACSAria (BD Biosciences) flow cytometer in 229 
RNAlater Stabilization Solution (Invitrogen). Total RNA from the ex vivo sorted cells (between 230 
300 to 8000 cells) was extracted using the RNeasy Micro Kit (Qiagen) according to the 231 
manufacturer’s protocol. RNA-sequencing libraries were prepared using the Clontech 232 
SMART Seq v4 Ultra Low RNA kit (Clontech Laboratories, Inc.) and sequencing was 233 
performed on the Illumina HiSeq 2500. Library preparation, sequencing and analyses were 234 
performed by the Lausanne Genomic Technologies Facility (UNIL, Lausanne, Switzerland) as 235 
described in detail in the Supplemental Data section.  236 
NanoString analysis 237 
Total RNA from CMV-specific CD8 T cell clonotypes of high versus low TCR binding avidity 238 
was extracted using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. 239 
The NanoDrop spectrophotometer (Thermo Scientific) was used to quantify the RNA. Cell 240 
lysates were directly analyzed for the expression of 770 immune-related genes (human 241 
PanCancer immune profiling panel) by the NanoString nCounter System and data were further 242 
processed using the NanoString nSolver analysis software (v.4) by normalizing with 243 
housekeeping genes. 244 
Surface marker expression analysis 245 
Virus-specific CD8 T cell clones were stained in PBS, 0.2% BSA, 5 mM EDTA and 0.2% NaN3 246 
with APC anti-LILRB1/CD85j (eBioscience), PE-CF594 anti-CD57 (BD Horizon), and BV421 247 
anti-PD-1 (Biolegend) at room temperature for 30 minutes and acquired on a LSRII flow 248 
cytometer (BD Biosciences). Vivid Aqua (Invitrogen) was used to discriminate live/dead cells. 249 
The level of expression of each marker (geometric mean fluorescence intensity [gMFI]) was 250 
analyzed using FlowJo software (v.10.4.2, Tree Star). 251 
In vitro blocking experiments 252 
For T cell proliferation assays, 30-Gy-irradiated HLA-A*0201-positive PBMCs were pulsed 1 253 
hour at 37°C with the native CMV/pp65495-503 (10-8M) peptide, washed, and incubated with 254 
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CellTraceViolet-stained CMV-specific CD8 T cell clones (Invitrogen) at an E/T ratio of 1:1 in 255 
RPMI 1640 medium (Gibco) supplemented with 8% human serum and 50 U/ml human 256 
recombinant IL-2 (GlaxoSmithKline) in the presence of monoclonal IgG2B mouse anti-human 257 
LILRB1 (CD85j, ILT-2) antibody or an IgG2B isotype control (5 µg/mL, R&D Systems). After 258 
3 days, cells were stained in PBS with Near-IR Vivid (Invitrogen) at 4°C for 30 minutes before 259 
acquisition on a LSRII (BD Biosciences) cytometer. Percentages of divided cells were analyzed 260 
using the proliferation module of FlowJo software (v.10.4.2, Tree Star). 261 
For CD107a degranulation and intracellular cytokine staining assays, CMV-specific CD8 T cell 262 
clones were incubated for 48 hours in the presence of monoclonal IgG2B mouse anti-human 263 
LILRB1 antibody or an IgG2B isotype control (5 µg/mL, R&D Systems). Clones were then 264 
incubated with 30-Gy-irradiated HLA-A*0201-positive PBMCs previously pulsed 1 hour at 265 
37°C with the native CMV/pp65495-503 (10-8M) peptide, at an E/T ratio of 1:2, in the presence 266 
of FITC anti-CD107a (BD Pharmingen) and brefeldin A (10 µg/ml, Sigma-Aldrich). After 6 267 
hours, T cell clones were assessed for CD107a degranulation and intracellular cytokine 268 
production as described above. 269 
Statistical analyses  270 
Data were analyzed using Prism software (v.7, GraphPad) by nonparametric Mann-Whitney 271 
test, Kruskal-Wallis test (α = 0.05), Wilcoxon matched-pairs signed rank test and Spearman 272 
correlations as indicated throughout the manuscript. All P values were derived using two-tailed 273 
tests and P < 0.05 were considered significant.  274 
Results 
 86 
 
	  
 
 11 
RESULTS 275 
Characteristics of the healthy donors 276 
Here, we performed a comprehensive longitudinal study of the TCR-pMHC binding avidities 277 
(i.e. off-rates) on well-defined virus-specific CD8 T cell clonotype repertoires from six healthy 278 
donors latently infected with (i) both CMV and EBV (BCL4 and BCL9), (ii) CMV only (BCL6 279 
and BCL1) or (iii) EBV only (BCL7 and BCL2). Blood was first withdrawn in 2002 (defined 280 
as Tn) when donors had an average age of 30 years (+/- 10 years) and 15 years later in 2017 281 
(defined as Tn+15y) (Fig. 1A, Supp. Table 2). The proportion of CMV-specific (HLA-282 
A*0201/pp65495-503) and EBV-specific (HLA-A*0201/BMFL1280-288) populations within total 283 
CD8 T cells over time was monitored by ex vivo fluorescent multimer staining (Fig. 1B, Supp. 284 
Table 2). No consistent pattern of frequency evolution was found among CMV-specific CD8 T 285 
cells, as that of donor BCL6 increased with time (from 1.06% to 4.08%), while the other three 286 
individuals showed reduced frequencies across the two time-points with some donor-related 287 
variations (between 0.14% to 0.97%). EBV-specific CD8 T cell populations were globally more 288 
stable during the period of 15 years, with a maximum frequency variation of 0.15% (Fig. 1B, 289 
Supp. Table 2). 290 
TCR clonotype frequencies determined by in vitro T cell cloning strongly correlate with 291 
direct ex vivo TCR b-chain and single-cell clonotype analyses 292 
For detailed analyses of complete TCRab repertoires including TCR-pMHC binding avidity 293 
characterization, large panels of in vitro-generated CMV-specific CD8 T cell clones were 294 
generated by single cell sorting from the four healthy individuals latently infected with CMV. 295 
The clonal composition was analyzed based on the TRBV-CDR3 and TRAV-CDR3 gene 296 
sequence ((9, 38), Supp. Table 3). Importantly, for each individual, the cloning procedure from 297 
samples obtained at Tn and Tn+15y was performed alongside, in the same experiment. To validate 298 
the repertoires represented by the in vitro-generated clones, we used a panel of TCRβ chain-299 
specific (i.e. TRBV) antibodies combined with multimers for staining of PBMCs directly ex 300 
vivo (Supp. Fig. 1). Robust correlations were obtained with highly similar relative frequencies 301 
of co-dominant TRBV families as determined by both approaches and at the two time-points 302 
(Fig. 1C). CMV-specific T cells positive for each TRBV family from donors BCL4 and BCL6 303 
were further sorted, in vitro cloned and sequenced for the TCR-CDR3 gene motif. More than 304 
95% of all TRBV family-recovered clones bore the corresponding TRBV-CDR3 clonotype (Fig. 305 
1D), demonstrating that for CMV-specific T cell populations, direct ex vivo TRBV family 306 
staining is a robust indicator of clonotype frequency. In addition, highly comparable 307 
Results 
 87 
 
	  
 
 12 
proportions of individual TCR clonotype signatures were found when using a direct ex vivo 308 
sorted single-cell approach (Fig. 1E), in agreement with previous studies (9, 38, 41). Altogether, 309 
these results indicate that our in vitro cloning strategy did not introduce major repertoire biases 310 
and allows the high-resolution molecular characterization of the TCR clonotype repertoire in 311 
individual virus-specific CD8 T cell sub-populations. 312 
CMV-specific TCRab clonotype dominance varies over time 313 
We next assessed the evolution of the TCRab clonal repertoire composition and dominance 314 
patterns over the observation period of 15 years. In line with our previous observations (9), 315 
CMV-specific CD8 T cell repertoires were highly restricted, with the presence of 2 to 6 316 
dominant or sub-dominant clonotypes (Fig. 1F). All clonotypes identified in the peripheral 317 
blood of the four healthy donors at the early time-point were also found 15 years later (Fig. 1F), 318 
indicating a remarkable long-term persistence of a restricted clonal repertoire. Yet, some of 319 
these clonotypes were found to decrease in frequency from Tn to Tn+15y (clonotypes depicted by 320 
grey arcs), whereas others increased (i.e. clono 3, 7, 9 and 11) with time or remained relatively 321 
stable (clono 4, 12, 13, 14, and 15). This implies a preferential selection of certain clonotypes 322 
over others throughout the course of persistent CMV infection in healthy donors. This 323 
observation was particularly evident in donors BCL4, BCL6 and BCL1. In contrast, the TCR 324 
clonotype composition of BCL9 remained relatively stable over the 15 years, with only two 325 
clonotypes, representing 20% of the repertoire, showing frequency variation over time (clono 326 
10 and clono 11; Fig. 1F). Similar changes in frequency were found when analyzing CMV-327 
specific populations at the ex vivo TRBV-chain family level (Supp. Fig. 1B). 328 
EBV-specific TCRab clonotype dominance and evolution remains highly stable over 329 
extended periods of time 330 
The TCRab clonotype signature of the EBV/BMFL1-specific CD8 T cell repertoire in four 331 
healthy individuals, with donors BCL4 and BCL9 sharing T cell responses against CMV/pp65, 332 
was determined at Tn and Tn+15y. EBV-specific repertoires obtained from single T cells 333 
generated by in vitro cloning again showed comparable proportions of TRBV family usage by 334 
ex vivo anti-TRBV staining, resulting in a high correlation coefficient (Fig. 2A). Despite 335 
presenting a diverse clonotype composition with 10 to 25 dominant or subdominant clonotypes 336 
per donor (Supp. Table 4), EBV-specific T cell repertoires were highly biased in their TRBV 337 
and TRAV family usage, in agreement with previous studies (9, 18, 19, 42, 43). Notably, the 338 
TCR clonotypes that dominated EBV-specific T cell responses preferentially used BV20, 339 
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BV29, BV2, BV14 and BV6 as well as AV5 and AV12-1 gene segments (according to IMGT’s 340 
nomenclature; Fig 2B, Supp. Table 4). In sharp contrast to CMV-specific T cell responses, and 341 
despite a high degree of polyclonality, the EBV clonal repertoires showed a remarkable stability 342 
during the observation period of 15 years, with only minor changes or fluctuations in their 343 
clonotype frequency between the time-points and for each healthy individual (Fig. 2C). 344 
CMV-specific T cell clonotypes that expand over time express TCRs of lower binding 345 
avidity than those that decrease 346 
To better evaluate how CMV-specific CD8 T cell repertoires evolve during latent infection, we 347 
defined three groups of clonotypes based on their frequency changes over time (Fig. 1F, Supp. 348 
Fig. 1B), i.e. decreasing, increasing/expanding and stable clonotypes, the latter regrouping 349 
clonotypes with frequency variation lower than 5% (Fig. 3A). In donor BCL6, for whom we 350 
had two additional time-points (i.e. Tn+4y and Tn+16y), we observed that the relative frequency 351 
increase or decrease of a specific clonotype was a gradual and continuous process during the 352 
follow-up (Fig. 3B, left panel). As low-avidity CMV-specific CD8 T cells that re-express 353 
CD45RA were reported to accumulate in elderly donors with aging (32), we next sought to 354 
determine whether differences in TCR binding avidity between CMV-specific T cell clonotypes 355 
could account for the changing patterns of dominance found in healthy donors throughout the 356 
course of latent infection. Quantitative TCR-pMHC dissociation rates (i.e. koff) were assessed 357 
by two-color reversible NTAmers (NTA) (34, 40) and applied to several clones of each 358 
identified CMV-specific TCRab clonotype. Interestingly, as shown in Figure 3C, clonotypes 359 
that declined in frequency over time (i.e. decreasing clonotypes) mostly displayed relatively 360 
slow off-rates (i.e. low koff/high binding avidity) ranging between 0.015 s-1 and 0.0011 s-1, while 361 
increasing clonotypes generally showed fast off-rates (i.e. high koff/low binding avidity), with 362 
the exception of clono 11 from BCL9 of higher binding avidity. Clonotypes with relatively 363 
stable frequencies over the 15 years exhibited variable off-rates (from 0.05 s-1 to 0.0007 s-1). 364 
Importantly, on average, CMV-specific T cell clonotypes that expanded over time bore TCRs 365 
of significantly lower binding avidity (i.e. high koff) compared to those that decreased (Fig. 3D). 366 
Enrichment of CMV-specific T cell clonotypes with reduced functional avidity and higher 367 
CD8 binding dependency over time 368 
We recently reported that the TCR-ligand off-rate is a stable and reliable biomarker, very useful 369 
for assessing ex vivo antigen-specific CD8 T cell responses (35). We tested the robustness of 370 
this parameter by comparing off-rates from CMV-specific T cell clones expressing the same 371 
TCRab clonotype, but isolated from blood samples at different time-points. For instance, each 372 
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identified CMV-specific T cell clonotype derived from donor BCL6 between Tn and Tn+15y 373 
revealed a highly comparable and stable koff value (Fig. 3B, right panel), in contrast to its 374 
frequency variation observed over time (Fig. 3B, left panel). Furthermore, we observed a strong 375 
positive correlation between koff rates obtained at Tn and Tn+15y from the four CMV-positive 376 
individuals studied (Fig. 3E). Similar data (Supp. Fig. 2) were found when assessing off-rates 377 
using mutated NTAmers, that were deficient for CD8 binding to pMHC (i.e. CD8-null NTA). 378 
These observations demonstrate that for a given TCRab clonotype, the TCR-pMHC off-rate 379 
remains highly conserved over extended periods of time, while this was not the case for the 380 
clonotypic prevalence. 381 
To further investigate the parameters driving clonal evolution, we studied the CD8 binding 382 
contribution to the overall TCR-pMHC avidity on the different identified CMV-specific 383 
TCRab clonotypes using CD8 binding-deficient NTAmers. Of note, T cell clonotypes that were 384 
highly CD8 binding-dependent could not be stained by mutated NTAmers, thus making 385 
dissociation rate measurements technically impossible to record. These non-binder clones are 386 
depicted in the grey lower box (Fig. 3F). We found that 100% of the CMV-specific CD8 T cell 387 
clonotypes that decreased over time were CD8 binding-independent (Fig. 3G), as all clonotypes 388 
were able to bind the CD8-binding deficient NTAmers with a relatively high avidity (mean koff 389 
of 0.022 s-1) (Fig. 3F). On the other hand, 75% of increasing clonotypes were CD8 binding-390 
dependent, again with the exception of clono 11 from BCL9, which was CD8 binding-391 
independent (Fig. 3F and 3G). Importantly, each TCR clonotype subgroup (i.e. decreasing, 392 
increasing and stable) revealed a similar TCR-pMHC off-rate threshold defining CD8 binding 393 
dependency (koff > 0.0106 s-1; Fig. 3C and 3F). Collectively, these data indicate that TCR off-394 
rates and CD8 binding dependency have a clear impact on the clonal dominance over time 395 
within CMV-specific CD8 T cell repertoires, with the preferential long-term enrichment of 396 
clonotypes of fast TCR-pMHC off-rates and greater dependency on CD8 coreceptor binding 397 
(i.e. low binding avidity; Fig. 3H). Conversely, CMV-specific clonotypes with slow TCR off-398 
rates and reduced CD8 binding dependency (i.e. high binding avidity) were those that declined 399 
in frequency over the 15 years. 400 
We also assessed whether this enrichment of low avidity clonotypes over time had an impact 401 
on the functional quality of CMV-specific CD8 T cell repertoires. As expected (35), T cell 402 
clonotypes of low binding avidity presented decreased functional avidity (i.e. EC50) for CD107a 403 
degranulation as well as a trend for reduced killing capacity compared to the high avidity ones 404 
(Fig. 3I). They produced less TNFα and IFNγ cytokines and were less susceptible to antigen-405 
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specific activation as shown by the diminished expression of PD-1 following peptide 406 
stimulation (Fig. 3I). These results indicate that CMV-specific T cell clonotypes of fast TCR 407 
off-rates and increased CD8 binding dependency displayed reduced functional capacity. 408 
TCR binding avidity and CD8 binding dependency of EBV-specific T cell clonotypes are 409 
associated with particular TRBV family usage 410 
To evaluate the impact of TCR binding avidity on EBV-specific CD8 T cell responses, we next 411 
measured koff rates using WT (i.e. NTA) and CD8 binding-deficient (i.e. CD8-null NTA) 412 
NTAmers on several clones of each individually identified TCRab clonotype (Figure 4). In 413 
line with the data obtained for CMV clonotypes, similar koff were found for the same EBV-414 
specific TCRab clonotypes between Tn and Tn+15y by WT (Fig. 4A) and mutated NTAmers 415 
(Fig. 4B). Despite their great stability in terms of frequency (Fig. 4C) over the 15 year period, 416 
the different TCR clonotypes covered a large range of binding avidities and CD8 binding-417 
dependency rates between single healthy donors (Fig. 4D and F, Supp. Fig 3). Strikingly, TCR 418 
binding avidity and CD8 binding-dependency were closely related to distinct TRBV family 419 
usage, but to a weaker extent to TRAV (Supp. Fig. 3E). Specifically, TRBV29 clonotypes 420 
(depicted as red symbols) displayed significantly faster TCR off-rates (mean koff of 0.038 s-1) 421 
and were largely CD8 binding-dependent compared to TRBV20 clonotypes (shown as blue 422 
symbols) of slower TCR off-rates (mean koff of 0.0075 s-1) and increased CD8 binding-423 
independency (Fig. 4E and G). TRBV2, TRBV14 and TRBV6 clonotypes presented TCRs of 424 
intermediate dissociation rates, (mean koff of 0.010 s-1) and between 33% to 67% were CD8 425 
binding-independent (Fig. 4E and G). These differences in TCR binding avidity between EBV-426 
specific T cell clonotypes and related to particular TRBV families were, to some degree, further 427 
observed at the functional avidity level. Specifically, TRBV29 clonotypes produced slightly 428 
less CD107a and cytokines (IFNg; TNFa), and were less able to kill target cells than TRBV20 429 
clonotypes (Fig. 4H). No major differences were found when assessing fold-change of PD-1 430 
expression upon peptide stimulation. In summary, these data indicate that TCR-pMHC-CD8 431 
binding avidity differentially impacts on the clonotype evolution of CMV- versus EBV-specific 432 
CD8 T cell responses during latent infection over extended periods of time. 433 
Decline in overall avidity of CMV- but not EBV-specific memory CD8 T cell repertoires 434 
over time 435 
We hypothesized that the enrichment of CMV- but not EBV-specific T cell clonotypes of low 436 
TCR binding avidities observed between Tn and Tn+15y would lead to an overall decline in TCR 437 
avidity of the CMV-specific repertoire. To address this question, we estimated the overall koff 438 
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at the viral epitope-specific CD8 T cell population level for the six healthy donors at Tn and 439 
Tn+15y (Figure 5). Due to the limited numbers of ex vivo antigen-specific T cells, sorted total 440 
CMV-specific or EBV-specific CD8 T cells were first non-specifically expanded during short-441 
term in vitro cultures before being assessed for their clonal composition by TRBV family 442 
staining. We found strong correlations with the TRBV frequencies obtained by in vitro cloning, 443 
confirming that no major bias was introduced by this strategy (Fig. 5A). We then performed 444 
off-rate measurements with NTAmers on CMV-specific bulk T cells from Tn and Tn+15y samples 445 
and observed faster dissociation rates at the later time-point, revealing a significant decrease in 446 
the overall TCR binding avidity over time in three out of four donors (i.e. BCL4, BCL6 and 447 
BCL1) (Fig. 5B and C). Off-rates from BCL9 samples were highly heterogenous (Fig. 5C) due 448 
to the presence of two distinct NTAmer staining-based dissociation sub-populations (Fig 5B), 449 
preventing accurate dissociation fitting and computation. Nonetheless, when we compared the 450 
proportion of CMV-specific T cells representative of the slower dissociation curves between 451 
the two time-points (Fig. 5B, BCL9, see FACS-gated region), there was also a significant 452 
decline in the percentage of these slow dissociating cells over time (Fig. 5D). 453 
In most cases, EBV-specific ex vivo generated bulk T cell populations were not representative 454 
of the clonal repertoire (data not shown), likely due to the high clonotype diversity of EBV-455 
specific repertoires (Fig. 2). Yet, EBV-specific bulk repertoire compositions from donor BCL7 456 
correlated well with the clonal ones (Fig. 5E), thus allowing direct overall avidity assessment 457 
by NTAmers. For this donor, we observed a high stability of the overall off-rates obtained 458 
between Tn and Tn+15y (Fig. 5E). We next used indirect methods to estimate the overall TCR 459 
binding avidity of EBV-specific repertoires during the observation period of 15 years. First, in 460 
donors BCL2 and BCL9, we assessed NTAmer-based koff of 60 in vitro generated EBV-specific 461 
CD8 T cell clones for each time-point without further clonotype characterization or selection, 462 
thus representing an unbiased repertoire, and observed no significant differences in their global 463 
TCR off-rates over time (Fig. 5F). Moreover, we reconstituted the overall repertoire avidity of 464 
each EBV-positive donor by in silico pooling of the koff values obtained for most of the 465 
identified TCRab clonotypes according to their respective prevalence. Again, no significant 466 
difference in the global TCR off-rates (i.e. koff) was found between both time-points in any of 467 
the EBV-positive donors (Fig. 4G). In contrast, similarly reconstituted off-rates of CMV-468 
specific T cell repertoires displayed a comparable overall decline over time as observed by 469 
direct NTAmer-based avidity measurements (data not shown). 470 
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Altogether, these observations show that the overall TCR-pMHC binding avidities of the EBV-471 
specific CD8 T cell response were highly stable over time, in contrast to those comprising the 472 
CMV-specific repertoire, which were significantly reduced over the 15 year period. 473 
Preferential accumulation of LILRB1 gene expression in high avidity CMV-specific T cell 474 
clonotypes over time 475 
To gain further insight into the mechanisms underlying the selection of low avidity clonotypes 476 
over time in long-term CMV-specific CD8 T cell responses, we performed a global 477 
transcription profiling by RNA sequencing on ex vivo sorted CMV/TRBV-specific sub-478 
populations of three CMV-positive donors at Tn and Tn+15y. We decided to exclude BCL9 from 479 
these screening analyses because this particular donor presented a more diverse clonotype 480 
repertoire that was stable over time, contrasting with the preferential accumulation of low 481 
binding avidity clonotypes observed in the other donors (Fig. 1 and 3). As demonstrated in Fig. 482 
1D, the TRBV-specific sub-populations were highly representative of each clonotype, with the 483 
exception of the TRBV6-5-specific sub-population from BCL6, composed of two clonotypes 484 
(clono 5 and 6) but sharing similar biological characteristics (i.e. high TCR binding avidity and 485 
decreasing frequency over time). As depicted by volcano plots (Fig. 6A) and hierarchical 486 
clustering (Fig. 6B, Supp. Fig. 4A), more differentially expressed genes were found over time 487 
(i.e. Tn versus Tn+15y) than between high (i.e. slow off-rates) versus low (i.e. fast off-rates) TCR 488 
binding avidity clonotypes. Nonetheless, hierarchical clustering highlighted the presence of 9 489 
genes that were found to be upregulated in high avidity CMV-specific CD8 T cell clonotypes 490 
when compared with low TCR binding avidity ones (Fig. 6B). Interestingly, one of these 491 
upregulated genes encoded for the inhibitory receptor LILRB1 (CD85j/ILT-2/LIR-1), which 492 
expression on CD8 T cells has been shown to increase with age and in the context of chronic 493 
CMV infection (44, 45). Moreover, LILRB1 was not only significantly upregulated in high 494 
avidity CMV-specific clonotypes but also at the later Tn+15y time-point (Fig. 6C). Consistently, 495 
the highest LILRB1 gene expression was also found in those CMV-specific T cell clonotypes 496 
defined as decreasing based on their reduced frequencies over time and mainly consisted of 497 
high avidity T cells at both time-points (Fig. 6D). In contrast, expanding TCRab clonotypes 498 
displayed globally lower normalized LILRB1 expression. Finally, similar data were obtained 499 
when gene expression analyses by NanoString were performed on two representative CMV-500 
specific CD8 T cell clones of different clonotypes from BCL4, i.e. a high avidity/decreasing 501 
clonotype (clono 1) and a low avidity/increasing clonotype (clono 3) (Fig. 7A). LILRB1 was 502 
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among the top genes whose expression was significantly elevated among the high avidity 503 
clonotypes, both at rest and upon CMV/pp65-specific-stimulation (Fig. 7A). 504 
Differential impact of LILRB1 blockade on proliferation versus cytokine production of 505 
LILRB1high expressing CMV-specific CD8 T cell clones 506 
To further explore the role of differential LILRB1 expression on CMV-specific TCRab 507 
clonotype evolution, we examined LILRB1 surface expression by flow cytometry in our panel 508 
of in vitro-generated CMV-specific CD8 T cell clones, including donor BCL9. Compatible with 509 
mRNA data, levels of LILRB1 were found to be significantly increased in high avidity 510 
TCRab clonotypes from all CMV donors when compared to low avidity ones, as well as in 511 
clonotypes from Tn+15y compared to those derived from Tn (Fig. 7B). Comparable trends were 512 
observed when we focused our analysis on donor BCL9 alone (Supp. Fig. 4B). We further 513 
found that those clonotypes that underwent contraction over time (i.e. high TCR binding 514 
avidity) expressed higher levels of LILRB1 than the increasing/expanding ones (i.e. low TCR 515 
binding avidity; Fig. 7C). LILRB1 expression was also associated with enhanced levels of the 516 
marker of senescence CD57, while PD-1 expression was reduced (Fig. 7D and E). Stable 517 
clonotypes showed intermediate levels of LILRB1, CD57 and PD-1 expression, when 518 
compared to increasing and decreasing clonotypes (Supp. Fig. 4C, D and E). Finally, various 519 
EBV-specific CD8 T cell clonotypes expressed comparable low levels of LILRB1, 520 
independently of their preferential TRBV family usage (Fig. 7F), consistent with a previous 521 
study (46). 522 
Lastly, we evaluated the biological significance of LILRB1 expression on proliferation, 523 
CD107a degranulation and cytokine production of LILRB1high expressing CMV-specific T cell 524 
clones upon incubation with a LILRB1 blocking antibody or an isotype control. LILRB1 525 
blockade induced an increase in the frequency of dividing cells, while it had no major effect on 526 
CD107a degranulation or on cytokine (IFNγ+TNFα+) production following pp65-specific 527 
stimulation (Fig. 7G). Together, our data are in line with recent findings showing that LILRB1 528 
characterizes a population of senescent but not exhausted CMV-specific effector CD8 T cells 529 
(44). Moreover, we propose that LILRB1 may play a regulatory role by inhibiting the expansion 530 
of CMV-specific CD8 T cell clonotypes of higher TCR binding avidity.  531 
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DISCUSSION 532 
CD8 T cells play a central role in controlling latent CMV and EBV-mediated infections. In this 533 
regard, both herpes viruses provide attractive models to study the parameters associated with 534 
the generation and maintenance of long-lived antigen-specific memory T cells. TCR-pMHC 535 
avidity has been investigated by several groups, including ours (9, 16-18), and has been 536 
proposed as a key parameter underlying TCR clonal selection and dominance in human CD8 T 537 
cell populations specific for persistent DNA viruses. Nonetheless, its precise impact on TCR 538 
clonal repertoire evolution in longitudinal studies as well as in a comparative clonal repertoire 539 
analysis against the two herpes viruses has not previously been investigated. Here, we addressed 540 
the questions of whether TCR-ligand avidity can directly drive the long-term maintenance of 541 
particular TCRab clonotypes and how this process is determined in latent CMV versus EBV 542 
infection. Using specifically designed reversible fluorescent pMHC multimeric complexes, we 543 
performed a comprehensive study of quantitative TCR-pMHC off-rates combined with 544 
individual virus-specific TCRab clonotypes in six CMV- and/or EBV-positive healthy donors, 545 
followed over a period of 15 years. Our data revealed the progressive loss of CMV/pp65 CD8 546 
T cell clonotypes of high avidity (i.e. slow off-rates, reduced CD8 binding dependency) during 547 
long-term antigen exposure (Fig. 3 and 5), which was associated with the preferential 548 
expression of LILRB1/CD85j in those cells (Fig. 6 and 7). This was not the case for 549 
EBV/BMFL1-specific CD8 T cell repertoires, in which the clonal composition and distribution 550 
(i.e. dominant versus sub-dominant, slow versus fast TCR off-rates, CD8 binding-independent 551 
versus -dependent) are kept highly stable for at least 15 years. Together, these findings indicate 552 
that TCR-pMHC-CD8 binding avidity is a determining factor driving the clonal evolution of 553 
long-lasting CMV- but not EBV-specific memory CD8 T cell responses in humans. 554 
Our observations could in part be explained by differences in the nature of these viruses during 555 
latent infection. EBV reactivation and replication in B cells occurs only sporadically, leading 556 
to intermittent cycles of T cell rest and stimulation, in contrast to CMV, which may be 557 
considered more as a smoldering chronic infection (47). There is growing evidence that CMV 558 
undergoes low-level viral replication, which potentially impacts the virus-specific CD8 T cell 559 
response (13). Specifically, the expansion of CMV-specific CD8 T cells, namely those sharing 560 
an effector-memory phenotype could be the consequence of repetitive antigen stimulation (48). 561 
With the exception of donor BCL6, we did not observe a significant increase in CMV/pp65-562 
specific CD8 T cells over the observation period of 15 years (Fig. 1). It is possible that our 563 
study performed on middle-aged individuals (45 +/- 10 years) was still set too early in the 564 
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course of the latent phase to visualize CMV-specific T cell inflation/expansion, as observed in 565 
elderly individuals (7). The majority of CD8 T cells specific for CMV were effector-566 
differentiated TEM (CD28neg) or TEMRA and retained an activated phenotype (CD27low CD127low 567 
CD57high and Granzyme Bhigh) in contrast to the memory-differentiated TCM or TEM (CD28pos) 568 
phenotype displayed by EBV-specific T cells ((8, 9, 49); Fig. 7). Importantly, fluctuations 569 
within the CMV-specific clonotype composition were observed over time, contrasting with the 570 
striking stability observed among EBV-specific CD8 T cell clonotypes. Altogether, these data 571 
further emphasize the presence of distinct features in the CD8 T cell responses elicited by these 572 
two herpes viral infections, which could to some extent be related to differing mechanisms of 573 
viral latency (14). 574 
At present, it still remains to be elucidated whether the remarkable stability in the clonal 575 
composition and evolution of EBV-specific repertoires is a global characteristic of EBV-576 
specific T cell responses or only of responses against the EBV epitope studied here (i.e. HLA-577 
A2/BMFL280-288). Since HLA-A2/BMLF1280-288 is an epitope from the early protein BMLF1 578 
essentially expressed during the acute phase of infection, the stability of the observed clonotype 579 
repertoires over extended periods of time could potentially be explained by the relative absence 580 
of epitope expression during the latent phase. Nonetheless, TCR clonotype composition and 581 
distribution against HLA-A2/BMLF1280-288 were also highly preserved during transient 582 
immunological perturbations after non-myeloablative chemotherapy (41) or following lung 583 
transplant under immunosuppression in the presence of EBV reactivation (42). Moreover, long-584 
lasting dominance of EBV-specific TCRab clonotypes against two latent epitopes, with no 585 
changes in the T cell hierarchy for at least 18 years has been previously reported (25). 586 
Collectively, these observations, including our own study (Fig. 2), are consistent with the 587 
concept that TCRab clonotype responses against EBV, once established, show steady 588 
repertoires over these long periods. Strikingly, CMV-specific T cell repertoires are also 589 
maintained stable during several years ((21, 41); Fig. 3B), but extending the studied period to 590 
15 years revealed signs of contraction of the clonal repertoire (Fig. 1). This latter observation 591 
was especially apparent for three out of the four studied donors, and suggest that distinct 592 
mechanisms regulate the long-term outcome of memory CMV- versus EBV-specific CD8 T 593 
cell repertoires in healthy individuals. 594 
Schober and colleagues (15) recently proposed different theoretical models of TCR repertoire 595 
evolution during latent CMV infection, and to which degree this process is controlled by TCR-596 
pMHC binding avidity. One model hypothesizes an initial accumulation of high-avidity virus-597 
Results 
 96 
 
	  
 
 21 
specific T cells during the early phase of latency, followed by the succession of clones of lower 598 
TCR binding avidity over the course of latent infection (50). During this clonal evolution, T 599 
cells of higher TCR binding avidity are progressively lost after replicative senescence due to 600 
critical telomere length shortening (51, 52). Compatible with this model, we demonstrated the 601 
preferential selection and expansion of CMV-specific clonotypes of lower TCR avidity and 602 
higher CD8 binding dependency, compared to those that had contracted after 15 years (Fig. 3). 603 
Consequently, an overall avidity decline was also observed at the CMV epitope-specific 604 
population (Fig. 5). Another study, comparing donors of different age-groups, showed that low 605 
avidity CMV-specific CD8 T cells largely contributed to the expanded T cell pool found in 606 
older subjects (32). A recent report in the context of MCMV infection (30) revealed that during 607 
the acute and early phase of latent infection (i.e. 100 days), low avidity CD8 T cells were 608 
replaced by higher avidity CD8 T cells. Nonetheless, similar to human studies, longer 609 
observation periods in mice might be required to reveal the contraction of high avidity clones. 610 
In summary, our longitudinal analysis largely supports the model of a T cell repertoire skewing 611 
towards an overall lower avidity over the course of latent CMV infection, as reported in other 612 
settings of chronic antigen exposure (53, 54). This is in contrast to the highly conserved overall 613 
TCR binding avidities found in EBV-specific CD8 T cell repertoires over 15 years (Fig. 5), 614 
fitting an alternative model (15) which assumes that a TCR hierarchy according to TCR binding 615 
avidity is established during the initial response and is kept constant over longer periods. 616 
Presently, it would be interesting to compare a larger array of CMV- and EBV-specific epitopes 617 
to fully appreciate the impact of TCR-ligand avidity on the long-term clonal evolution of 618 
TCRab repertoires against herpes viruses. 619 
Robust techniques allowing for the large-scale ex vivo assessment of TCR-pMHC binding 620 
kinetics at the surface of live T cells have proven technically challenging until recently. Using 621 
NTAmers, we demonstrated that the koff parameter represents a powerful biomarker by which 622 
the functional potency of antigen-specific CD8 T cell responses can be directly evaluated (34, 623 
35) and graded to better characterize their impact on the efficacy of therapeutic vaccines (55). 624 
To our knowledge, the use of NTAmers on well-identified virus-specific TCRab clonotypes as 625 
shown in this study revealed, for the first time, the differential impact of TCR-pMHC binding 626 
kinetics on long-term TCR clonal evolution during CMV/pp65 versus EBV/BMFL1 latent 627 
infection. In vitro cloning by limiting dilution followed by TCR sequencing currently remains 628 
the method of choice to determine TCRab clonotype sequences simultaneously with TCR-629 
pMHC kinetic measurements at the individual T cell level. Importantly, in vitro cloning data 630 
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corresponded well to ex vivo TRBV staining followed by sorted single clonotype sequencing 631 
analyses (Fig. 1 and 2). Consequently, this strategy yields an accurate representation of the 632 
clonotype prevalence when studying epitope-specific populations with skewed clonotype 633 
repertoires, as is the case for CMV or EBV latent infection (9, 19, 38, 41). Only one report 634 
could successfully assess individual TCR-pMHC affinity (based on micropipette adhesion 635 
frequency) simultaneously with its corresponding TCR sequence in a high throughput manner 636 
(56). Nonetheless, the success rate in recovering paired TCRab sequences was still restricted 637 
to 20-50% (56), consistent with the technical limitations in determining TCRab sequence 638 
frequencies by other ex vivo single-cell RNA-Seq approaches (reviewed in (57, 58)). Moreover, 639 
no study has thus far been performed on frozen human samples, therefore precluding 640 
longitudinal analyses. Whilst highly promising, combined single cell TCR-pMHC affinity and 641 
sequencing technologies still warrant further refinement before becoming widely applicable for 642 
the immune profiling of particular TCRab clonotypes in a straightforward manner at any time 643 
and body location. 644 
Another finding is that the TCR-pMHC dissociation rate further represents a robust and stable 645 
determinant for a given TCRab clonotype. For instance, we found highly comparable off-rate 646 
(i.e. koff) values for any studied representative of a given CMV-specific clonotype over time 647 
(Tn versus Tn+15y; Fig. 3). This contrasted to the biological differences observed at the clonotype 648 
level with changes in prevalence (Fig. 3) and in gene expression profiling (Fig. 6 and Supp. 649 
Fig. 4B) over the study period. Similar data were found for off-rates from EBV-specific TCRab 650 
clonotypes obtained at both time-points (Fig. 4). These observations are in agreement with 651 
previous studies showing highly conserved NTAmer-based off-rates, independently of the 652 
activation state (35) or the differentiation stage (55) of antigen-specific CD8 T cells. In addition, 653 
Nauerth and coworkers (59) elegantly demonstrated that the TCR is the main driver of 654 
measured off-rates by reporting similar off-rate values between T cell clones and TCR-655 
transduced Jurkat cells. 656 
Studies performed during immune aging have provided key insights in the processes involved 657 
in the long-lasting persistence of memory virus-specific CD8 T cell responses (reviewed in 658 
(60)). Such as, the preferential accumulation of the inhibitory receptor LILRB1 on T cells 659 
specific for CMV has been proposed as one of the phenotypic hallmarks of aging (45, 61, 62). 660 
LILRB1 recognizes a wide range of classical and non-classical MHC class I molecules, 661 
including UL18, a human CMV-encoded MHC class I homologue, previously shown to bind 662 
LILRB1 with very high affinity (63). Recently, it has been proposed that LILRB1 may function 663 
Results 
 98 
 
	  
 
 23 
as a checkpoint regulator in CD8 T cell differentiation and ageing (44). Notably, blocking 664 
LILRB1 binding enhanced the proliferative capacity of CMV-specific CD8 T cells without 665 
altering their cytokine production (44). Here, extending on these observations, we demonstrated 666 
the preferential upregulation of LILRB1 in ex vivo sorted CMV-specific TCRab clonotypes of 667 
high avidity as well as during latent infection after 15 years (Fig. 6). Consequently, clonotypes 668 
that underwent clonal contraction (i.e. decline in frequency) and which mainly comprised high-669 
avidity T cells, were also those that expressed the highest levels of LILRB1 at both time-points 670 
(Tn and Tn+15y). At the protein level, LILRB1 surface expression was also found to be increased 671 
in declining CMV-specific T cell clonotypes, correlating with partial proliferative recovery 672 
upon LILRB1 blockade (Fig. 7). This was associated with enhanced expression of the 673 
senescence marker, CD57, but not of PD-1. In contrast, low and similar LILRB1 expression 674 
were observed in all EBV-specific CD8 TCRab clonotypes (Fig. 7). In agreement with these 675 
findings, others have reported that CMV-specific T cells often maintain cytotoxic and cytokine-676 
producing functions, in contrast to exhausted T cells, but can show various signs of senescence 677 
(reviewed in (48, 64, 65)). 678 
Collectively, our data reinforce the key role driven by TCR binding avidity in tailoring CMV- 679 
but not EBV-specific clonal evolution during long periods of viral latency. We further propose 680 
that LILRB1 acts as an inhibitory checkpoint receptor, specifically by limiting the expansion 681 
of high avidity clonotypes over the course of latent CMV infection. In the context of CMV 682 
infection, repetitive exposure to antigen is a key determinant for memory inflation, and 683 
therefore regulatory mechanisms that can brake CD8 T cell expansion are likely beneficial (13). 684 
Such mechanisms include regulatory T cells and anti-inflammatory cytokine production, which 685 
might otherwise lead to the extensive proliferation of highly antigen-sensitive T cells (i.e. TCR 686 
of high binding avidity), possibly overwhelming the global T cell pool. Supporting this notion, 687 
LILRB1 could therefore provide another mechanism by which memory inflation of certain 688 
CMV-specific TCRab clonotypes might be tightly regulated during lifelong latent infection, 689 
while preserving the global functional T cell repertoire.  690 
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FIGURE LEGENDS 691 
Figure 1. Frequencies of circulating CMV-specific CD8 TCRab clonotypes in healthy 692 
donors over time. A, Schematic representation of donor sampling. Blood samples from six 693 
CMV- and/or EBV-positive healthy donors were analyzed at early (Tn) and late (Tn+15y) time-694 
points during latent infection. B, Frequencies of CMV (HLA-A2/pp65)- and EBV (HLA-695 
A2/BMFL1)-specific cells within total ex vivo CD8 T cells over time as determined by the 696 
corresponding peptide/HLA-A2 multimers. C, Correlations of CMV-specific TRBV-family 697 
frequencies between ex vivo TRBV-staining versus in vitro single cell cloning, in BCL4, BCL6, 698 
BCL1 and BCL9 at Tn and Tn+15y. D, Frequencies of color-coded CMV-specific clonotypes per 699 
TRBV family for BCL4 and BCL6. Specific TRBV-CDR3 clonotypes were determined 700 
following FACS-sorting of positive TRBV family staining and TRBV-CDR3 sequencing. E, 701 
Correlation of TRBV-based clonotype frequencies between in vitro single cell cloning and ex 702 
vivo sorted single CMV-specific T cells from BCL6 and BCL8 at Tn. C and E, Linear 703 
regression analysis with 95% confidence intervals. F, Quantification of co-dominant CMV-704 
specific TCRab clonotypes at Tn and Tn+15y. Results are presented as percentages of color-705 
coded clonotype frequencies by in vitro single-cell cloning and TRBV/TRAV-CDR3 analyses. 706 
Unique clonotypes are defined as “others” and depicted in white. Over time decreasing CMV-707 
specific T cell clonotypes are highlighted by grey arcs. Number of clones n are indicated. 708 
Figure 2. Frequencies of circulating EBV-specific CD8 TCRab clonotypes in healthy 709 
donors over time. A, Correlation of EBV-specific TRBV-family frequencies between ex vivo 710 
TRBV-staining versus in vitro single cell cloning in BCL2 and BCL9 at Tn and Tn+15y (by linear 711 
regression analysis with 95% confidence intervals). B, Cumulative frequencies of preferential 712 
TRBV family usage within EBV-specific clonotypes at Tn as assessed by in vitro single cell 713 
cloning. C, Quantification of co-dominant EBV-specific TCRab clonotypes at Tn and Tn+15y. 714 
Results are depicted as percentages of T cell clonotypes classified according to their TRBV 715 
family by in vitro single-cell cloning and TRBV/TRAV-CDR3 analyses. Preferential TRBV 716 
family usage is highlighted by colored arcs. Unique clonotypes are defined as “others” and 717 
depicted in white. Number of clones n are indicated. 718 
Figure 3. Monomeric TCR-pMHC dissociation rates and CD8 binding dependency of 719 
CMV-specific TCRab clonotypes in healthy donors over time. A, Relative frequencies of 720 
each CMV-specific TCRab clonotype at Tn and Tn+15y defined as decreasing (left panel), 721 
increasing (middle panel) or stable (right panel) clonotypes based on their frequency evolution 722 
over time from BCL4, BCL6, BCL1 and BCL9. B, Relative frequencies (left panel) and TCR-723 
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pMHC dissociation rates by wild-type NTAmers (koff, right panel) of each color-coded CMV-724 
specific TCRab clonotype from donor BCL6 at the indicated time-points. C and F, TCR-725 
pMHC off-rates (koff) by wild-type NTAmers (C, NTA) or mutated NTAmers (F, CD8null 726 
NTA) on a representative selection of CMV-specific CD8 T cell clones of each color-coded 727 
TCRab clonotype. CD8null NTA non-binder clones are represented in the grey boxes. The 728 
dotted line represents the threshold of CD8 binding dependency. D, Dissociation rates (koff) of 729 
decreasing, increasing and stable TCRab clonotypes. Data are representative of 5 pooled clones 730 
of each clonotype and are depicted as box (25th and 75th percentiles) and whisker (min to max) 731 
plots with the middle line indicating the median. Kruskal-Wallis test-derived (α = 0.05) P values 732 
are indicated with ** P < 0.01. E, Correlation of TCR-pMHC off-rates (koff) by wild-type 733 
NTAmers (NTA) obtained from identical TCRab clonotypes between Tn and Tn+15y (by linear 734 
regression analysis with 95% confidence intervals). G, Proportions of CD8 binding-735 
independent TCRab clonotypes from decreasing, increasing and stable sub-groups, based on 736 
mutated NTAmer assays (see Fig. 3F). H, Proportions of CD8 binding-dependent TCRab 737 
clonotypes within CMV-specific CD8 T cell populations at Tn and Tn+15y. I, EC50 values from 738 
CD107a degranulation, IFNg and TNFa production and killing capacity derived from co-739 
culture assays using CMV-negative HLA-A2+ T2 target cells pulsed with graded concentrations 740 
of native CMV (NLV-pp65495-503) peptide and fold-increase in PD-1 expression upon CMV 741 
(NLV-pp65495-503)-specific stimulation. Data are representative of pooled CMV-specific CD8 742 
T cell clones (n = 35 to 59) categorized as high (slow off-rates, reduced CD8 binding 743 
dependency) versus low (fast off-rates, increased CD8 binding dependency) binding avidity. 744 
Significant differences between groups by Mann-Whitney test (two tailed); * P < 0.05 and ** P 745 
< 0.01. 746 
Figure 4. Monomeric TCR-pMHC dissociation rates and CD8 binding dependency of 747 
EBV-specific TCRab clonotypes in healthy donors over time. A and B, Correlations of 748 
TCR-pMHC dissociation rates (koff) by wild-type NTAmers (A, NTA) or mutated NTAmers 749 
(B, CD8null NTA) obtained from identical TCRab clonotypes between Tn and Tn+15y (by linear 750 
regression analysis with 95% confidence intervals). C, Relative frequencies of each EBV-751 
specific color-coded TCRab clonotype and classified according to their TRBV family at Tn 752 
and Tn+15y from BCL4, BCL7, BCL2 and BCL9. D and F, TCR-pMHC off-rates (koff) were 753 
assessed by wild-type NTAmers (D, NTA) or mutated NTAmers (F, CD8null NTA) on a 754 
representative selection of EBV-specific T cell clones of each TCRab clonotype grouped per 755 
color-coded TRBV family usage. CD8null NTAmer non-binder clones are represented in the 756 
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grey boxes. E, TCR-pMHC off-rates (koff) of EBV-specific TCRab clonotypes classified 757 
according to their preferential TRBV family usage. Data are depicted as box (25th and 75th 758 
percentiles) and whisker (min to max) plots with the middle line indicating the median. P value 759 
by Kruskal-Wallis test-derived (α = 0.05) with **** P < 0.0001. G, Proportions of CD8-760 
independent clonotypes TCRab classified according to their TRBV family, based on mutated 761 
NTAmer assays (see Fig. 4F). H, EC50 values from CD107a degranulation, IFNg and TNFa 762 
production and killing capacities performed in co-culture assays using EBV-negative HLA-A2+ 763 
T2 target cells pulsed with graded concentration of native EBV (BMFL1280-288) peptide and fold 764 
increase in PD-1 expression upon EBV (BMFL1280-288)-specific stimulation. Data are 765 
representative of pooled EBV-specific CD8 T cell clones (n = 37 to 45) categorized according 766 
to their preferential TRBV family usage. 767 
Figure 5. Overall monomeric TCR-pMHC dissociation rates on total CMV- and EBV-768 
specific CD8 T cell populations over time. A, Correlation of CMV-specific TRBV-family 769 
frequencies between in vitro single cell cloning and TRBV-staining on ex vivo expanded CMV-770 
specific bulk T cell populations from BCL4, BCL6, BCL1 and BCL9 at Tn and Tn+15y (by linear 771 
regression analysis with 95% confidence intervals). B, Representative FACS-based wild-type 772 
NTAmer dissociation curves obtained from ex vivo expanded CMV-specific bulk populations 773 
at Tn and Tn+15y. Imidazole was added after 30s of baseline recording. Insets show the gating 774 
region used to estimate the proportion of CMV-specific T cells of slower off-rates in donor 775 
BCL9. C, Dissociation rate (koff) values derived from ex vivo expanded CMV-specific bulk 776 
populations at Tn and Tn+15y. Data are representative of pooled values from 1 to 4 independent 777 
experiments with the middle line indicating the mean value. P values by Mann-Whitney test 778 
(two tailed) with ** P < 0.01 and *** P < 0.001 and by Kruskal-Wallis test (α = 0.05) with * P < 779 
0.05 and ** P < 0.01. D, Percentage of slow dissociating CMV-specific bulk cells from BCL9 780 
at Tn and Tn+15y based on the quantification of slow FACS-gated dissociation curves (see Fig. 781 
5B, BCL9). P values by Mann-Whitney test with ** P < 0.01. E, Data as described for A (top 782 
left), B (bottom panel) and C (top right) for EBV-specific bulk populations from donor BCL7. 783 
F, TCR-pMHC off-rate (koff) values from 60 in vitro generated EBV-specific T cell clones 784 
without further clonotype characterization or selection at Tn and Tn+15y. G, Overall repertoire 785 
avidity of each donor by in silico pooling of koff data for most identified EBV-specific TCRab 786 
clonotypes according to their prevalence at Tn and Tn+15y. C, E and F, ns; non significant. 787 
Figure 6: Gene expression of ex vivo sorted CMV-specific TRBV-based clonotypes. A, 788 
Volcano plots showing differentially expressed genes between Tn and Tn+15y (left panel) and 789 
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between high- and low-avidity (right panel) CMV-specific CD8 clonotypes. Each red dot 790 
represents an individual gene with a False Discovery Rate (FDR) < 0.1 (horizontal dotted line). 791 
B, Heatmap plot based on the 19 differentially expressed genes between high- and low-avidity 792 
CMV-specific clonotypes FDR < 0.1). Normalized expression level was transformed (DESeq2 793 
function rlog), center and variance scaled by gene. Red indicates overexpression and blue 794 
underexpression relative to the gene mean expression. C, Direct comparison of LILRB1 795 
expression (as normalized counts) between low- and high-avidity CMV-specific clonotypes 796 
(left panel) and between Tn and Tn+15y (right panel). D, LILRB1 expression (normalized counts) 797 
in decreasing (in blue) and increasing (in red) CMV-specific clonotypes at Tn and Tn+15y. C-D. 798 
The middle line indicating the mean and P values by Mann-Whitney test (two tailed) with * P 799 
< 0.05 and ** P < 0.01. A-D. Gene expression data were generated by RNA sequencing on ex 800 
vivo sorted CMV/TRBV-specific sub-populations from CMV-positive BCL4, BCL6 and BCL1 801 
at Tn and Tn+15y. 802 
Figure 7: Surface expression of LILRB1 and functional effect of LILRB1 blockade on 803 
CMV-specific CD8 TCRab clonotypes. A, Nanostring-based gene expression on two 804 
representative CMV-specific TCRab clonotypes from BCL4, i.e. a high avidity/decreasing 805 
clonotype (clono 1) versus a low avidity/increasing clonotype (clono 3), at resting and upon 806 
CMV/pp65-specific stimulation. Data are presented as gene expression ratio of clono 1/clono3. 807 
B, Baseline surface expression levels (geometric mean fluorescence intensity [gMFI]) of 808 
LILRB1 in high- and low-avidity CMV-specific clonotypes and in clonotypes from Tn and 809 
Tn+15y. C-E, Representative FACS-based staining (left panels) and baseline surface expression 810 
levels (gMFI) (right panels) of LILRB1 (C), CD57 (D) and PD-1 (E) in decreasing (in blue) 811 
and increasing (in red) CMV-specific clonotypes at Tn and Tn+15y. B-E, Data are representative 812 
of a selection of pooled clones and are depicted as box (25th and 75th percentiles) and whisker 813 
(min to max) plots with the middle line indicating the median. P values by Mann-Whitney test 814 
(two-tailed) with * P < 0.05 and ** P < 0.01. F, Baseline surface expression levels (gMFI) of 815 
LILRB1 in EBV-specific TCRab clonotypes classified according to their TRBV family. G, 816 
Frequencies of CFSE-labeled divided T cell clones (top left) and of CD107a- and IFNg+TNFa+-817 
expressing T cell clones (bottom panels) after CMV pp65-specific stimulation in the presence 818 
of anti-LILRB1 or an isotype control antibody. P values by Wilcoxon matched-pairs signed 819 
rank test (two-tailed) with ** P < 0.01; ns, non significant.   820 
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SUPPLEMENTAL DATA  
 
SUPPLEMENTAL MATERIALS AND METHODS 
RNA sequencing analysis 
Purity-filtered reads were adapters and quality trimmed with Cutadapt (v.1.8, (1)). Reads 
matching to ribosomal RNA sequences were removed with fastq_screen (v.0.11.1). Remaining 
reads were further filtered for low complexity with reaper (v.15-065, (2)). Reads were aligned 
against Homo sapiens.GRCh38.92 genome using STAR (v.2.5.3a, (3)). The number of read 
counts per gene locus was summarized with htseq-count (v.0.9.1, (4)) using Homo 
sapiens.GRCh38.92 gene annotation. Quality of the RNA-seq data alignment was assessed 
using RSeQC (v.2.3.7, (5)). The effect TCR avidity and time were tested in R (v.3.4.0) using 
the likelihood ratio test implemented in the DESeq2 package (6). A linear model with the TCR 
binding avidity (low and high avidity), the time-point (Tn, 2002 and Tn+15y, 2017) and the 
donors (BCL1, BCL4, BCL6) was compared to reduced models with (i) the TCR avidity factor 
removed or (ii) the time-point factor removed. Parameters ‘cooksCutoff’ and 
‘independentFiltering’ were set to ‘false’. 
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Supplemental Table 1. List of TRBV antibodies 
 
*TCR Vb-chain according to Arden’s nomenclature (7).  
 
 
Supplemental Table 2. Biological characteristics of the studied healthy donors 
 
 
 
Supplemental Table 3. CMV-specific TCRab clonotypes from healthy donors 
 
  
Name* IMGT nomenclature Company Catalog # Clone
Pe-Vio770 anti-Vβ1 TRBV9 Miltenyi 130-110-020 REA662
APC-Vio770 anti-Vβ2 TRBV20 Miltenyi 130-110-098 REA654
FITC anti-Vβ3 TRBV28 Beckman Coulter IM2372 CH92
FITC anti-Vβ4 TRBV29 Beckman Coulter B07084 WJF24 
FITC anti-Vβ8 TRBV12 Beckman Coulter IM1233 56C5.2
APC anti-Vβ9 TRBV3 Invitrogen 17-4899-41 AMKB1-2
FITC anti-Vβ13.1 TRBV6-5 Invitrogen 11-5792-41 H131
APC anti-Vβ14 TRBV27 Miltenyi 130-108-738 REA557
FITC anti-Vβ22 TRBV2 Beckman Coulter IM1484 IMMU546
* TCR Vβ according to Arden's nomenclature
Donors 1st sample 2nd sample Virus-
specificity 
studiedID Sexe Age %CMVin CD8+ T cells
%EBV
in CD8+ T cells Age 
%CMV
in CD8+ T cells
%EBV
in CD8+ T cells
BCL1 F 25.9 0.21 0.12 41.2 0.07 0.09 CMV
BCL2 M 39.1 na 0.38 54.6 na 0.45 EBV
BCL4 F 29.9 2.11 0.27 44.7 1.14 0.12 CMV and EBV
BCL6 F 37.0 1.06 0.21 51.3 4.08 nd CMV
BCL7 M 27.1 0.08 1.16 42.1 na 1.29 EBV
BCL8 F 28.6 3.07 0.24 na na na CMV
BCL9 M 20.0 1.99 0.45 35.3 1.82 0.33 CMV and EBV
Donor Clonotype IMGT BV Arden CDR3β BJ IMGT AV Arden CDR3α AJ TCR avidity
BCL4 Clono 1 TRBV27 14 RLLAGGRSAQ 2.5 TRAV24 18 EGGNQF 49 High
CMV Clono 2 TRBV3-2 9S2 SLLLGTAAEA 1.1 TRAV24 18 IAGNQF 49 HIgh
Clono 3 TRBV9 1 SVYGGAGNSPL 1.6 TRAV14 6 KNFNKF 21 Low
Clono 4 TRBV28 3 SFLGYTEA 1.1 TRAV3 16 YYGQNF 26 Low
BCL6 Clono 5 TRBV6-5 13S1 SRQTGAAYGY 1.2 TRAV24 18 NTGNQF 49 High
CMV Clono 6 TRBV6-5 13S1 SYATGTAYGY 1.2 TRAV24 18 NTGNQF 49 High
Clono 7 TRBV12-3/4 8S1/2 SSANYGY 1.2 TRAV35 25 PRETSYDKV 50 Low
BCL1 Clono 8 TRBV9 1 SVVGLWTDTQ 2.3 TRAV14 6 PMKTSYDKV 50 High
CMV Clono 9 TRBV12-3/4 8S1/2 SSANYGY 1.2 TRAV35 25 EPENSGGSNYKL 53 Low
BCL9 Clono 10 TRBV7-3 6 SLMALGAGANVL 2.6 na High
CMV Clono 11 TRBV28 3 SFQGYTEA 1.1 na High
Clono 12 TRBV9 1 SPLGGAGLADTQ 2.3 TRAV14 6 REGIIQGAQKL 54 Low
Clono 13 TRBV27 14 SLTPGSPGSPL 1.6 na High
Clono 14 TRBV6-5/1 13 SPTTGTGYFGY 1.2 TRAV24 18 NTGNQF 49 High
Clono 15 TRBV6-5 13 SLVSGSGSYGY 1.2 TRAV24 18 NTGNQF 49 High
BCL8 Clono 16 TRBV6 13 SSVSGGASNEQ 2.1 TRAV3 16 NYGNML 39 na
CMV Clono 17 TRBV24-1 15 SDPLTASYEQ 2.5 TRAV29 2 GSQGNL 42 na
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Supplemental Table 4. EBV-specific TCRab clonotypes from healthy donors 
  
Donor Clonotype IMGT BV Arden CDR3β BJ IMGT AV Arden CDR3α AJ
BCL4 2 clono 1 TRBV20 2 RDRIGNGY 1.2 TRAV5 15 DNNARL 31
EBV 2 clono 2* TRBV20 2 RDRTGNGY 1.2 TRAV5 15 DNNARL 31
2 clono 3 TRBV20 2 RDSVGNGY 1.2 TRAV5 15 DNNARL 31
2 clono 4 TRBV20 2 RDRVGNGY 1.2 TRAV5 15 DNNARL 31
2 clono 5 TRBV20 2 RDSTGNGY 1.2 TRAV5 15 DNNARL 31
4 clono 1 TRBV29 4 FQEASYGY 1.2 TRAV29 21 SGGSQGNL 42
4 clono 2** TRBV29 4 VGTGGTNEKL 1.4 TRAV5 15 STGKL 37
4 clono 3 TRBV29 4 VGYGGTNEKL 1.4 TRAV5 15 STGKL 37
4 clono 4 TRBV29 4 VGSGGTNEKL 1.4 TRAV5 15 DNNARL 31
4 clono 5 TRBV29 4 TPGQLMETQ 2.5 TRAV5 15 TLGNTGKL 37
16 clono 1 TRBV14 16 SQSPGGTQ 2.5 TRAV5 15 SPPSSASKI 2
18 clono 1 TRBV18 18 SPPAVSYEQ 2.7 TRAV29 21 IHNQAGTAL 15
BCL7 2 clono 1 TRBV20 2 RDTIGNGY 1.2 TRAV5 15 DNNARL 31
EBV 2 clono 2*** TRBV20 2 RVGVGNTI 1.3 TRVA5 15 DNNARL 31
2 clono 3 TRBV20 2 RDRVGNTI 1.3 TRAV5 15 DQSPRV 31
2 clono 4* TRBV20 2 RDRTGNGY 1.2 TRAV5 15 DNNARL 31
2 clono 5 TRBV20 2 RSETGNTI 1.3 TRAV5 15 DNNARL 31
2 clono 6 TRBV20 2 RGSVGNTI 1.3 TRAV5 15 DSNARL 31
2 clono 7 TRBV20 2 RIGVGNTI 1.3 TRAV5 15 DNNARL 31
2 clono 8 TRBV20 2 RDRVGNGY 1.2 TRAV5 15 DVNARL 31
2 clono 9 TRBV20 2 RDETGNGY 1.2 TRAV5 15 DNNARL 31
2 clono 10 TRBV20 2 WDREVMGGNTI 1.3 TRAV5 15 TSSASKI 3
4 clono 1 TRBV29 4 VGSGGTNEKL 1.4 TRAV5 15 SIGKL 34
4 clono 2 TRBV29 4 TTGSGDRGA 1.1 TRAV5 15 DRYSTL 11
4 clono 3 TRBV29 4 VEGLTYNEQ 2.1 TRAV12-2 2S1 ITGGTYKY 40
4 clono 4 TRBV29 4 VGEGGTNEKL 1.4 TRAV5 15 SIGKL 37
4 clono 5 TRBV29 4 VEDSLWGAGDEKKASTDTQ 2.3 TRAV9-2 22 NGGFKT 9
4 clono 6** TRBV29 4 VGTGGTNEKL 1.4 TRAV5 15 STGKL 37
22 clono 1 TRBV2 22 TSGQISPSAI 1.3 TRAV12-1 2S3 NGGDSSYKL 12
22 clono 2 TRBV2 22 TAGGTLPGEQ 2.7 TRAV12-1 2S3 NGMDSSYKL 12
22 clono 3 TRBV2 22 SGGQVAPSEQ 2.1 TRAV12-1 2S3 NGEDSSYKL 12
22 clono 4 TRBV2 22 SSGSVAPGEL 2.2 TRAV12-1 2S3 NGRDSSYKL 12
22 clono 5 TRBV2 22 SSLEVSPSEQ 2.7 TRAV12-1 2S3 NGKDSSYKL 12
22 clono 6 TRBV2 22 TSGTVAPGEQ 2.7 TRAV12-1 2S3 NGMDSSYKL 12
BCL2 2 clono 1 TRBV20 2 RDEVSGSWNEQ 2.1 TRAV9-2 22 SGDRDDKI 30
EBV 2 clono 2 TRBV20 2 RDQTGNGY 1.2 TRAV5 15 DNNARL 31
2 clono 3 TRBV20 2 RDREFGNTI 1.3 TRAV5 15 DSNARL 31
2 clono 4*** TRBV20 2 RVGVGNTI 1.3 TRAV5 15 DNNARL 31
4 clono 1 TRBV29 4 VGTGGTNEKL 1.4 TRAV5 15 SVGKL 8
4 clono 2 TRBV29 4 VEDSIAGFTDTQ 1.4 TRAV9-2 22 NGGFKT 9
4 clono 3 TRBV29 4 VGQGGTNEKL 1.4 TRAV5 15 SSSVGY 40
22 clono 1 TRBV2 22 SEGAVAPGEQ 2.7 TRAV12-1 2S3 NGMDSSYKL 12
22 clono 2 TRBV2 22 TDPRLLPGEQ 2.7 TRAV12-1 2S3 NGADSSYKL 12
22 clono 3 TRBV2 22 SVGEILPGEQ 2.7 TRAV12-1 2S3 NGRDSSYKL 12
13 clono 1 TRBV6-5 13 KTGTGNEKL 1.4 TRAV5 15 PNNAGNML 39
13 clono 2 TRBV6-5 13 PPMGTPNYGY 1.2 TRAV5 15 DNNARL 31
13 clono 3 TRBV6-5 13 SEWTGYQPQ 1.5 TRAV29 21 SGGGADGL 45
BCL9 13 cl.1 TRBV6-5 13 TPDVNTEA 1.1 TRAV5 15 SMDGYAL 41
EBV 16 cl.1 TRBV14 16 SQSPGGTQ 2.5 TRAV5 15 SRETAL 15
16 cl.2 TRBV14 16 SQSPGGIQ 2.4 TRAV5 15 GGADGL 45
22 cl.1 TRBV2 22 SPPGLAPNEQ 2.1 TRAV12-1 2 NGKDSSYKL 12
22 cl. 2 TRBV2 22 SGGRVAPGEL 2.2 TRAV12-1 2 NGRDSSYKL 12
22 cl. 3 TRBV2 22 SDGAVAPNEQ 2.1 TRAV12-1 2 NGRDSSYKL 12
22 cl.4 TRBV2 22 SEGQVWPGEL 2.2 TRAV12-1 2 NGMDSSYKL 12
6 cl.1 TRBV7-3 6 SSGGNIDTQ 2.3 na
12 cl.1 TRBV10-3 12 KSFRHRYSE 2.3 TRAV5 15 DNNARL 31
7 cl.1 TRBV4-2 7 SQDGAGGLGEQ 2.1 TRAV12-1 2 NIPNDYKL 20
*, **, ***: Public αβ TCR clonotypes
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SUPPLEMENTAL FIGURE LEGENDS 
Supplemental Figure 1. Frequencies of ex vivo CMV-specific TRBV family-based CD8 T 
cell clonotypes from healthy donors. A, Representative FACS dot plots obtained after ex vivo 
labeling with anti-TRBV family antibodies on CMV+CD8+ T cells from BCL4, BCL6, BCL1 
and BCL9. Percentages of positively stained cells are indicated. B, Quantification of dominant 
CMV-specific TRBV-family based T cell clonotypes at Tn and Tn+15y for each healthy donor. 
Results are depicted as percentages of color-coded TRBV family frequencies by ex vivo TRBV 
family-based staining. TRBV-unlabeled CMV-specific T cells are depicted in white. 
Supplemental Figure 2. Monomeric TCR-pMHC dissociation rates of CMV-specific CD8 
TCRab clonotypes over time. A, Correlation of monomeric TCR-pMHC dissociation rate 
(koff) values by mutated NTAmers (CD8null NTA) obtained from identical TCRab clonotypes 
between Tn and Tn+15y (by linear regression analysis with 95% confidence intervals). B, TCR-
pMHC dissociation rate (koff) by mutated NTAmers (CD8null NTA) of each color-coded 
CMV-specific TCRab clonotype from donor BCL6 at the indicated time-points. 
Supplemental Figure 3. Monomeric TCR-pMHC dissociation rates and CD8 binding 
dependency of EBV-specific CD8 TCRab clonotypes per healthy donor. A-D, TCR-pMHC 
dissociation rates (koff) by wild-type NTAmers (NTA) or mutated NTAmers (CD8null NTA) 
on a representative selection of EBV-specific T cell clones of each color-coded TCRab 
clonotype from the four healthy donors. Unique clonotypes are defined as “others” and 
depicted in grey. CD8null NTAmer non-binder clones are represented in the grey boxes. E, 
TCR-pMHC dissociation rates (koff) by wild-type NTAmers (NTA) of EBV-specific TCRab 
clonotypes classified according to their preferential TRAV family usage. A representative 
selection of EBV-specific T cell clones of each TCRab clonotype is shown. Data are depicted 
as box (25th and 75th percentiles) and whisker (min to max) plots with the middle line indicating 
the median. Kruskal-Wallis test-derived (α = 0.05) P values are indicated with * P < 0.05. 
Supplemental Figure 4: Gene and surface molecule expression in CMV-specific CD8 
TCRab clonotypes. A, Heatmap plot of 52 differentially expressed genes between CMV-
specific clonotypes at Tn versus Tn+15y (FDR < 0.1). Normalized expression level was 
transformed (DESeq2 function rlog), center and variance scaled by gene. Red indicates 
overexpression and blue underexpression relative to the gene mean expression. Gene 
expression data were generated by RNA sequencing on ex vivo sorted CMV/TRBV-specific 
sub-populations of CMV-positive BCL4, BCL6 and BCL1 donors at Tn and Tn+15y. B, Baseline 
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surface expression levels of LILRB1 (gMFI) in high- and low-avidity CMV-specific 
clonotypes and in clonotypes from Tn and Tn+15y from donor BCL9. C-E, Baseline surface 
expression levels (gMFI) of LILRB1 (C), CD57 (D) and PD-1 (E) in decreasing (in blue), 
increasing (in red) and stable (grey) CMV-specific TCRab clonotypes at Tn and Tn+15y. Data 
are representative of a selection of pooled clones and are depicted as box (25th and 75th 
percentiles) and whisker (min to max) plots with the middle line indicating the median. 
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Couturaud et al. 
Supplemental Figure 3
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Discussion 
1. Impact of TCR binding avidity on CD8 T cell function among different 
antigenic specificities 
1.1. T cell-based therapies against malignant and infectious diseases 
Recent success in T cell-based immunotherapy strategies have demonstrated the therapeutic 
potential of tumor- and viral-specific T cells. Among these, therapeutic vaccination aims to 
generating and/or boosting a strong and persistent immune response to destroy tumor or 
infected cells. Vaccination relies on the identification of immunogenic antigens, and can be 
delivered in the form of peptide or protein vaccine, or via viral or DNA-based vectors. In the 
tumor context, a large number of clinicals trials have demonstrated that this 
immunotherapeutic approach is feasible and safe. However, most phase 3 clinical trials have 
not shown significant clinical benefit [264]. These failures were in part due to the advanced 
metastatic state and to the strong immunosuppressive environment of the targeted cancers. 
Indeed, therapeutic vaccines against non-metastatic prostate cancer have shown enhanced 
CD8 T cell infiltration [265] and partial clinical efficacy [266]. In addition, the identification of 
neo-antigens has opened the door for novel vaccine strategies. In this context, the reinfusion 
of autologous dendritic cells pulsed with autologous whole-tumor cell lysate in the patient, has 
shown promising results in the treatment of ovarian cancer with the specific amplification of 
T cells directed against previously recognized and unrecognized neo-epitopes [267]. In the 
context of viral infection, numerous therapeutic vaccines for patients with CMV-infected 
allografts, either stem cell or solid organ, have been developed and evaluated. While no vaccine 
has yet been licensed [268], several candidates in clinical trials have shown promising results 
[269-271]. 
Another immunotherapeutic strategy is to restore the functional capacities of exhausted T cells 
through the administration of antibodies targeting inhibitory receptors or their ligands. 
Impressive results in cancer patients have been obtained using immune checkpoint blockade 
targeting immunosuppressive molecules like PD-1, PD ligand-1 (PDL-1) or CTLA-4. These 
treatments have all led to significant improvement of clinical outcome in metastatic melanoma 
patients [272, 273]. 
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Finally, adoptive transfer of patient- or donor-derived T cells is of significant interest for the 
treatment of cancer or viral infection following stem cell or solid organ transplants. Adoptive 
cell transfer was initially developed by Rosenberg et al. more than 30 years ago for the treatment 
of melanoma [274]. More recently these treatments have been modernized with the 
development of genetically modified T-cells expressing chimeric antigen receptors (CARs) 
which have shown encouraging clinical results despite potential high toxicity [275, 276]. In the 
context of viral infection, the isolation of virus-specific T cells from a healthy donor and 
subsequent infusion into an immunocompromised patient to control the reactivation of 
persistent pathogens such as CMV or EBV has been investigated in many patients [277]. While 
conventional antiviral agents have limited efficacy with frequent reactivation after cessation of 
treatment as well as significant toxicity, several clinical trials have established the safety and 
efficacy of adoptive transfer of CMV- or EBV-specific T cells to control those infections [152, 
153, 278, 279]. All these strategies rely on the identification and/or the robust activation of 
powerful T cells to efficiently fight against cancer or infected cells. Hence, there is a strong 
need to define those parameters that characterize potent T cells and how to assess them in 
order to further improve current therapies and to reach significant clinical benefit in a larger 
proportion of treated patients.  
1.2.  Identifying high-quality individual CD8 T cells 
Since T cells play a major role in immune protection against cancer and infection, and are at 
the forefront of the development of immunotherapies, it is important to determine which T 
cell properties are essential to predict in vivo efficacy. In this regard, the functional capacity of 
T cells has been widely used as a correlate of protection. Indeed, it is now commonly accepted 
that CD8 T cells of higher functional avidity (defined as the peptide concentration mediating 
half-maximal activity, EC50) confer superior viral protection or anti-tumor responses than T 
cells of lower functional avidity. However, the assessment of ex vivo functional avidity (i.e. 
specific T cell responses when exposed to increasing antigen concentrations) often requires a 
large number of cells and remain laborious and time consuming. It is also quite clear that 
significant variability of EC50 exists depending on the laboratory protocols and reagents used 
to assess them [70]. In addition, in the present study we showed that the T cell activation state 
(Manuscript 1, Figure 6) has a significant impact on the functional avidity, thus introducing 
additional experimental bias. Indeed, in line with previous studies [280, 281], we observed a 
gradual increase of functional avidity with time after in vitro re-stimulation (up to 20 days) for 
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identical individual clones. This was consistent with the increased expression of TCRαβ and 
the co-receptor CD8αβ as well as the very late antigen-1 (VLA-1) (Manuscript 1, Figure 6). The 
latter is known to be up regulated following several days of T cell stimulation [282] and to 
interact with collagen to increase TCR-mediated proliferation and cytokine secretion [283, 284] 
as well as to activate signaling pathways that promote cell survival [285]. This increase in 
functional avidity also correlated with a reduced expression of CD28 and the inhibitory 
receptors lymphocyte-activation gene-3 (LAG-3) and T cell immunoreceptor with Ig and ITIM 
domains (TIGIT) (Manuscript 1, Figure 6). 
Finally, we observed a large variability in the peptide dose required to reach the EC50 for a 
given antigen specificity depending on the chosen functional readout (Manuscript 1, Figure 1 
and Supp. Figure 4), reflecting different activation thresholds (cytotoxicity < cytokine 
production). These observations reinforce the need to identify a robust T cell-based biomarker 
that would allow for the rapid and efficient screening and identification of tumor- and viral-
specific cytolytic T cells of high potential for immunotherapy. In this respect, TCR-pMHC 
binding avidity has been proposed as a potential candidate since it controls numerous aspects 
of T cell biology such as T-cell activation, differentiation, and functional efficacy (reviewed in 
[255]). So far technical limitations are the major reason why the TCR-pMHC binding avidity is 
still infrequently determined in research or patient monitoring, or in the selection of T cells 
used for adoptive cell therapy. Indeed, pMHC multimers (“tetramers”) are biased by their 
multivalent nature and accurate measurements of TCR-pMHC binding parameters (i.e. 2D 
surface-based kinetics), while offering important membrane-associated kinetic insights, are not 
well suited for the high-throughput characterization of living antigen-specific CD8 T cells 
(reviewed in [94]). To overcome these limitations, reversible multimers have been recently 
developed which allow for the accurate measurements of monomeric TCR-pMHC 
dissociation-rates directly on CD8 T cells and on a wide avidity spectrum [99, 108].  
1.3. TCR-pMHC binding avidity is a robust and stable biomarker of CD8 T cell 
potency 
Using reversible multimers NTAmers, our group recently demonstrated that TCR-pMHC 
dissociation rates robustly correlate with those obtained by SPR [108]. Moreover, the half-lives 
determined by NTAmers accurately correlated to the killing capacity (i.e. EC50) of tumor-
specific T cell clones that were isolated from patients with melanoma [108] as well as following 
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therapeutic vaccination [109]. In a viral setting using a microscopy and reversible Streptamer-
based assay, Nauerth et al. [99] have shown that virus-specific CD8 T cells bearing TCRs of 
high avidity were associated with improved function (i.e. killing capacity) and conferred better 
protection against Listeria monocytogenes infection in mice.  
Here we performed a comprehensive study of TCR-pMHC off-rates combined with multiple 
functional assays on large representative libraries of human self/tumor- and non-self/virus-
specific CD8 T cell clones (n > 600). We demonstrated that TCR-pMHC off-rates accurately 
predict CD107a degranulation, cytokine production, cell proliferation, stimulatory/inhibitory 
receptor expression (Manuscript 1, Figure 1 and 3), polyfunctionality (Manuscript 1, Figure 2), 
as well as in vivo anti-tumor activity (Manuscript 1, Figure 4). These data confirm that the TCR-
pMHC off-rate is a major determinant controlling CD8 T cell function. Our findings are of 
particular scientific and practical importance as we also found that the TCR-ligand dissociation-
rate is a highly stable biomarker, independent of the activation state of the cell and its 
assessment is highly reproducible for a given clone between different experiments. These 
features are advantageous compared with frequently used functional assays or multimer 
staining intensity (Manuscript 1, Figure 6). Together, these data show the potential of TCR-
pMHC dissociation-rate measurements as a broadly applicable research method and as a highly 
promising biomarker to determine the potency of specific-T cells for immunotherapy. 
1.4. Therapeutic implications: impact of peptide vaccines on TCR-pMHC 
binding avidity 
Within the scope of cancer immunotherapy, and as shown above, TCR-ligand avidity 
represents a powerful and robust biomarker that can be used to monitor and study vaccine 
trials with the aim to determine the treatment regimen that offers the best clinical efficacy in 
patients.  In this regard, NTAmer-based TCR-pMHC off-rates have recently been used by our 
group to accurately characterize the quality of vaccination-induced self/tumor–specific T cell 
responses in melanoma patients. First, Gannon et al. [109] found differences in the TCR-pMHC 
binding avidity of Melan-A specific clones depending on the type of Melan-A26-35 peptide used 
for vaccination. Specifically, they observed the selective enrichment of clones with increased 
TCR-pMHC binding avidity and stronger tumor reactivity following vaccination with the 
native Melan-AMART-126–35 peptide compared to those derived from patients vaccinated with the 
analog Melan-AMART-126–35 (A27L) peptide [109], despite the latter having a 10-fold increased 
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binding to HLA-A2  compared to the natural peptide [286]. Secondly, during my PhD thesis 
work, I took part in a project which aimed to evaluate the impact of the analog Melan-AMART-
126–35 (A27L) peptide and CpG-B adjuvant dosage on the induction of tumor-specific CD8 T cell 
responses in melanoma patients in relation to TCR binding avidity and functional potency 
(Carretero-Iglesia L, Couturaud B et al., manuscript in preparation). Indeed, as antigenic 
peptides are poorly immunogenic by themselves, they are administrated in conjunction with 
strong adjuvants such as the TLR9-mediated agonist CpG B-ODN 7909 and oil emulsion (i.e. 
incomplete Freund adjuvant, IFA) to generate a robust immune response [48, 287]. Such 
vaccines have been shown to generate functionally competent T cells in vivo [47, 288] and to 
correlate with favorable clinical outcome [289].   
Here (Carretero-Iglesia L, Couturaud B et al., manuscript in preparation), we found that 
increased peptide dose vaccine (i.e. 0.5 mg) promoted the more rapid selection (after only 4-
vaccines) of Melan-A-specific CD8 T cells of enhanced TCR binding avidity (i.e. measured by 
NTAmer-based dissociation rates and frequency of CD8 binding-independent clones assessed 
using CD8-null NTAmers) and functional avidity. Comparable results were achieved with 
lower peptide doses (i.e. 0.1 mg) but required additional serial vaccinations (i.e. 8-vaccines), 
independently of the CpG-B dose (2-2.6 mg vs 1-1.3 mg). Finally, and in line with our results 
in Manuscript 1, strong correlations between dissociation rates measured by NTAmers and 
functional capacity were observed for vaccine-induced CD8 binding-dependent tumor-specific 
T cell clones. In contrast, these correlations were lost in the CD8 binding-independent group 
due to the increased proportion of higher avidity clones, despite sharing similar functional 
avidities to many clones bearing TCRs of lower avidity. This suggests that vaccine-induced 
CD8 T cell clones bearing high avidity TCRs reach a plateau of maximal response (Carretero-
Iglesia L, Couturaud B et al., manuscript in preparation). These results are in line with several 
studies showing that T cell activation and function are limited to a given TCR-pMHC 
affinity/avidity window, both in pathogen and tumor-specific T cell responses (reviewed in 
[94, 290]). Above a given TCR-pMHC affinity/avidity threshold in the upper part or beyond 
the natural TCR affinity range, T cell functionality does no longer correlate to TCR-pMHC 
affinity or off-rate [114, 117, 118, 290-295]. This phenomenon could in part explain our 
observation (Manuscript 1, Figure 1) of weaker, although statistically significant, correlations 
between TCR binding and functional avidity displayed by virus-specific T cells compared to 
tumor-specific T cells. Indeed, the overall virus-specific repertoire is of higher TCR-pMHC 
binding avidity compared to the tumor-specific repertoire.  
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In summary, TCR binding avidity represents a robust biomarker for the high-throughput 
assessment of tumor-specific CD8 T cell responses following therapeutic peptide vaccination. 
1.5. TCR-pMHC binding avidity varies according to the antigenic specificity of 
CD8 T cells 
One of the great advantages of the NTAmer technology is the possibility to accurately assess 
a wide spectrum of TCR binding avidities on living CD8 T cells (reviewed in [94]). Indeed, 
unlike the equivalent Streptamer technology which is limited to the analysis of non-self/virus-
specific T cells of high TCR binding avidity due to the lag time (60 sec) in the switch from 
multimeric to monomeric form, NTAmer complexes dissociate in just a few seconds and allow 
the analysis of, for example, tumor-specific CD8 T cells of lower TCR avidity. Using this 
powerful technology, we were able to directly compare large T cell clonotype repertoires (n > 
300) across four different antigenic specificities. Comparison of off-rates for antigens of 
different origin revealed significantly slower off-rates (i.e. low koff/high avidity TCRs) against 
non-self/viral antigens (i.e. CMV/pp65 and EBV/BMFL1) compared to self/tumor antigens 
(Melan-A and NY-ESO-1) (Manuscript 1, Figure 5). These results were in line with previous 
studies showing that while non-self/pathogen specific T cells covered a large range of TCR 
affinities [111], they are generally of high avidity [54, 55] (Figure 12). Of note, nonetheless, 
non-self-specific CD8 T cells of very low affinity have been shown to significantly participate 
in the immune response against pathogens [111]. Specifically, low affinity T cells exit the 
lymphatic system and enter blood circulation earlier than high avidity ones, and are thus 
essential for the early control of infection [111]. However, high affinity T cells expand more 
during the acute phase of infection, thus dominating the peak of the acute response and during 
memory, as observed in our study. On the other hand, self/tumor-specific T cells are generally 
of low TCR avidity (Figure 12), which can be explained by mechanisms of central and 
peripheral tolerance. Indeed, most tumor antigens are expressed in the thymus thus leading to 
the negative selection of thymocytes with high TCR affinity/avidity for those antigens [296]. 
In addition, self/tumor-specific T cells can be eliminated in the periphery through mechanisms 
of peripheral tolerance [297]. Nonetheless, a fraction of cytotoxic T cells reactive to 
self/tumors antigens with low TCR–pMHC affinity/avidity evade these mechanisms and are 
found in the periphery [298-301]. Despite being of low TCR avidity, these tumor-reactive T 
cells are capable of eliminating cancer cells [302, 303]. However, low avidity T cells generally 
need a stronger signal to be activated and do not exhibit extensive expansion, thus highlighting 
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the necessity to find better strategies to efficiently and sustainably activate tumor-specific T 
cells for immunotherapy [304, 305]. 
   
 
 
 
 
Figure 12: Representative TCR-pMHC binding affinity/avidity according to the antigenic 
specificity of CD8 T cells. A. CD8 T cells specific for non-self/pathogen cover a large range of TCR affinities/avidities 
with a large proportion (depicted as dark blue gradients) of cells bearing intermediate to high affinity/avidity TCRs (depicted 
as orange-red arcs). B. Self/tumor-specific T cells are mainly of low TCR affinity/avidity (depicted as yellow arcs) which can 
be explained by mechanisms of central and peripheral tolerance.  C. Neoantigen-specific T cells are more likely to escape thymic 
negative selection, as neoantigens are “non-self like” epitopes, thus potentially having a higher proportion of high affinity/avidity 
TCRs compared to tumor-specific T cells. Adapted from Hebeisen et al. 2015 [94]. 
 
Moreover, we showed for the first time a significant difference in the TCR-pMHC binding 
avidity among different types of tumor antigens, with TCRs of cancer testis NY-ESO-1-
specific T cells having a stronger binding to their pMHC than TCRs of differentiation antigen 
Melan-A-specific T cells from healthy individuals or unvaccinated melanoma patients 
(Manuscript 1, Figure 5). Yet, several clones of slower off-rates could still be detected, 
indicating the presence of rare self/Melan-A specific T cells of high binding avidity within the 
endogenous unvaccinated repertoire. We could have hypothesized that a large proportion of 
Melan-A specific CD8 T cells would be of high avidity as a recent study reported that medullary 
thymic epithelial cells express a truncated Melan-A transcript, lacking the expression of the 
immunodominant 26–35 epitope, thus precluding clonal deletion of specific CD8 T cells to 
this antigen during central tolerance [306]. This particular thymic expression in part explains 
the unusually high frequency of naive A2/Melan-A26-35–specific CD8 T cells observed in 
melanoma patients as well as in healthy donors [307-309]. In addition, Melan-A multimer+ T 
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cells have been shown to be highly cross-reactive with several self- and pathogen-specific 
epitopes thus further increasing the size of the subset of Melan-A-specific naive T cells [310]. 
Nonetheless, differentiation antigens such as Melan-A are not highly tumor specific, as they 
are expressed in both tumor cells and normal tissues (e.g. healthy melanocytes), thus 
presumably leading to the deletion of high affinity Melan-A-specific T cells in blood circulation 
by peripheral tolerance mechanisms. Nevertheless, several clones with enhanced TCR binding 
avidity could still be detected in vaccinated melanoma patients (Manuscript 1, Figure 5), 
indicating the presence of rare self/Melan-A-specific CD8 T cells that are selected upon 
vaccination, in line with a previous study [311]. These results highlight the relevance of 
therapeutic vaccination approaches to enhance the quality of the tumor-specific T cell 
repertoire. Contrary to Melan-A, cancer testis antigens such as NY-ESO-1 are strictly tumor-
specific. Although these antigens are naturally expressed in trophoblastic cells and male germ 
cells, they do not lead to auto-immune responses because in the healthy state these cells are 
devoid of HLA class I molecules and cannot present antigens to T cells [312]. These results 
further highlight the importance of optimizing the choice of tumor antigens for the 
development of cancer-based immunotherapies. 
1.6. Perspectives for immunotherapy 
The ability to accurately measure the TCR-pMHC binding avidity of tumor-specific T cells 
could be of great potential for cancer immunotherapy. Specifically, NTAmer technology is an 
easy-to-use approach that can be readily standardized to identify rare naturally occurring tumor-
specific TCRs of high avidity in order to use them for adoptive cell transfer and/or T cell 
engineering. In addition, it is of particular interest to investigate the TCR-pMHC avidity of 
neoantigen-specific CD8 T cells. These exclusively tumor-specific T cells are more likely to 
escape thymic negative selection [313] and are, thus, potentially of high TCR avidity (Figure 
12) [314] while being unlikely to drive immune tolerance. Moreover, CD4 and CD8 neoantigen-
specific T cells have been associated with favorable clinical outcome in several human cancer 
types (reviewed in [315]). 
TCR-pMHC avidity has long been underestimated as a clinically relevant biomarker due to 
technical limitations for its precise assessment. Here, we demonstrated that NTAmer-based 
TCR-pMHC off-rate parameters represent a powerful biomarker to characterize in vitro and in 
vivo CD8 T cell potency within antigen-specific CD8 T cell responses.  Nonetheless, a high-
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throughput method to identify high avidity T cells at the single cell level, directly ex vivo, with 
minimal manipulation and with the potential to recover the sample for amplification and/or 
genetic engineering before re-employment for treatment is still lacking. In that regard, Soler et 
al. [316] recently developed a label-free 2D affinity analysis of TCR-pMHC by employing a 
multiparametric Surface Plasmon Resonance (MP-SPR) biosensor functionalized with artificial 
cell membranes. Another approach consists in the single cell serial determination of 2D TCR-
pMHC affinity (based on micropipette adhesion frequency) and TCR clonotyping [256].  Such 
promising technological progress is of significant interest and clinical importance for the near 
future.  
2. Impact of TCR-ligand binding avidity on the persistence of viral-
specific CD8 T cell clonotypes over time 
2.1. T cell responses in chronic infections 
Contrary to acute infections where the virus is eliminated, chronic infections are characterized 
by the persistence of a certain level of viremia. The long-term persistence of chronic infections 
may manifest itself in different ways, from chronic infection with high and sustained viremia 
(e.g., hepatitis B and C virus or HIV), to infections with periodic reactivation (e.g., herpes 
simplex virus, VZV or EBV), or to low but continuous chronic infections such as CMV [197]. 
Gaining insight into the development of memory T cell responses against these viruses and 
their fine regulation is of fundamental interest to better understand how the human immune 
system works, as well as of medical importance for the development of preventive and 
therapeutic treatments such as viral vaccines. For this purpose, animal models of chronic 
infections such as lymphocytic choriomeningitis virus (LCMV) or MCMV are highly valuable 
tools as they allow for the tight control of many parameters such as the time of infection, the 
viral load or co-infections, and allow analyses of all organs [317]. Nonetheless, mice can 
generally only be studied for a maximum period of several months, while chronic infections in 
humans may persist for several decades. In addition, recent studies have shown that laboratory 
pathogen free mice used in many studies are not ideal models to mimic real life infections [318] 
as they lack differentiated memory cells [319], as well as physical and psychosocial natural 
stressors [320] that could have an impact on chronic infections and their regulation. Therefore, 
gaining better insight into CD8 T-cell responses to persistent infections in humans is of utmost 
importance. 
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In this regard, T cell immune responses against CMV and EBV have been widely investigated 
over the last two decades. These herpes viruses are genetically stable agents with double 
stranded DNA genomes that co-exist with their infected host in a finely orchestrated balance. 
The high prevalence of these infections in the world (reaching 100% in some populations) and 
their important contribution to mortality in immunosuppressed individuals, as well as the key 
role of T cells in controlling these latent infections, make them attractive models to study long-
term immune responses. Moreover, during latency, EBV is thought to sporadically reactivate 
and replicate in B cells, leading to intermittent cycles of T cell rest and stimulation, while CMV 
could be considered more as a smoldering chronic infection. This difference in biology 
provides an interesting setting to compare the impact of continuous T cell stimulation versus 
resting memory T cells with infrequent stimulation, on the evolution of TCRαβ repertoires 
over time. 
In this study (see Manuscript 2), we compared the TCRαβ clonal evolution between CMV 
(A2/pp65) and EBV (A2/BMFL1) latent infections in a human longitudinal study (over a 
period of 15 years). Specifically, we aimed at investigating the degree to which this process is 
determined by TCR-pMHC binding avidity in both viral models. Our findings reveal a 
progressive long-term avidity decline of CMV- but not EBV-specific memory CD8 T cell 
clonotype repertoires. This was associated with the preferential expression of the checkpoint 
inhibitor LILRB1 in high-avidity CMV-specific T cell clonotypes. These data highlight the 
critical role played by TCR avidity-driven repertoire evolution in the long-term outcome of 
CMV-specific, compared to EBV-specific, CD8 T cell responses in healthy individuals. 
2.2. TCRαβ clonotype repertoire assessments 
TCR repertoire analyses are challenging due to the immense diversity and complexity of the 
TCR alpha-beta chain that composes each TCR, and especially the CDR3 region, but also due 
to several technical limitations. In humans, most analyses are done from a few hundred 
milliliters of blood and ignore the T cell repertoires found in lymphoid organs or tissues, thus 
leading to an incomplete picture of overall TCR usage.  
A direct and pioneering approach to characterize TCR repertoire usage is the use of TRBV-
specific antibodies combined to virus- or tumor-specific multimers [257, 321]. This method 
has been widely exploited [90, 213, 322, 323], even if it only assesses the BV usage and does 
not reveal the level of heterogeneity at the clonotype level. Nonetheless, it can be used as a first 
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screening analysis as well as a tool to validate clonal repertoires assessed by other methods. In 
our study, we used this technology for the latter purpose (Manuscript 2, Figure 1C and 2A) and 
found a strong correlation between the percentage of cells ex vivo stained with specific TRBV 
antibodies and the percentage of TRBV clonotypes assessed by in vitro cloning. Indeed, in vitro 
cloning by limiting dilutions followed by sequencing of the TCRs of the generated clones is an 
alternative and more precise approach to study TCR repertoires as it allows sequence 
determination for paired TCR α and β chains for each clone. Nowadays, it is still one of the 
methods of choice to characterize TCRαβ repertoires. One drawback of this approach is the 
potential bias introduced by the different capacity of each clone to proliferate or not during in 
vitro culture. In addition, this method is not sufficiently powerful and high-throughput to 
estimate a complete TCR repertoire diversity. Nonetheless, to study epitope-specific 
populations with skewed repertoires composed of a maximum of a few dozen dominant 
clonotypes, this method has shown robust results [90, 324]. Here, we observed a strong 
correlation between repertoires assessed by the in vitro cloning strategy and both ex vivo TRBV 
staining and ex vivo sorted-single cell sequencing (Manuscript 2, Figure 1C-E and 2A). Finally, 
a significant advantage of the generation of in vitro clones is the possibility to precisely assess 
TCR-pMHC binding avidity on living T cells. Together, in vitro cloning by limiting dilution 
followed by TCR sequencing is a robust method to determine TCRαβ clonotype sequences 
and TCR-pMHC kinetic measurements simultaneously at the individual T cell level. 
A major breakthrough in TCR repertoire analyses was the development of high-throughput 
sequencing techniques that allow for the sequencing of millions of DNA molecules in parallel. 
While being very informative on the TCR diversity in healthy individuals [13, 325, 326] or in 
the tumor setting [327], these techniques have several limitations especially for the quantitative 
analysis of the TCR clonal repertoire due to inconsistent PCR efficiency, PCR and sequencing 
errors or the impact of the level of TCR expression (reviewed in [328]). In addition, only the 
TCR β chain is generally sequenced thus not giving information about the α/β pairing. It is 
only very recently that high-throughput sequencing for paired α and β chains has started to 
become possible with the development of single cell sequencing (reviewed in [329, 330]). 
Several groups have used full-length single-cell RNA-sequencing with TCR reconstruction 
methods to study T cell clonality and fate [331-334]. Others have used tag-based strategies 
where a “barcode” is introduced during the reverse transcription reaction thus “tagging” the 
whole cDNA of a single cell [335-337].  These methods increase the high-throughput potential 
as all tagged-cDNAs can be pooled and prepared together for sequencing. Nonetheless, they 
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are less informative and sensitive compared to full-length strategies. These state-of-the-art 
technologies have so far only been used by a few research groups and not on frozen human 
samples, thus precluding longitudinal studies. Moreover, only one group has successfully 
assessed single cell 2D TCR-pMHC affinity (based on micropipette adhesion frequency) 
simultaneously with TCR sequencing in a high-throughput manner [256]. In addition, so far 
this technology recovered the paired TCRαβ sequence in only 20% to 50% of cases. Whilst 
highly promising, these techniques need refinement to become more accessible and widespread 
in the coming years and to succeed classical in vitro cloning approaches.  
2.3. TCR off-rate is a stable biomarker for a given TCRαβ clonotype 
We showed that NTAmer-based TCR off-rates are highly stable for the same Melan-A-specific 
CD8 T cell clones in intra- and inter-experimental measurements (Manuscript 1, Fig. 6). In 
addition, off-rate measurements for a given clone at different time-points post-stimulation 
were highly stable when compared to functional assays (Manuscript 1, Fig. 6), in line with a 
previous study by Nauerth et al. [99] characterizing given CMV/pp65-specific clones using 
Streptamer technology. Using this approach, they further demonstrated that koff data of two 
CMV/IE1-specific clones were highly similar to the koff data obtained from Jurkat-76 cells 
transduced with the TCR α and β chains isolated from the clones. Gannon et al. [109] further 
demonstrated the robustness of the reversible NTAmer-based technique to analyse tumor-
specific T cell clones from early- (EM28+) and late- (EM28-) differentiation subsets bearing 
the same TCRαβ. Highly similar off-rates between T cell subsets were again found, 
independently of the differentiation status of the T cell clones. Together these results indicate 
that the TCR is the main driver of TCR-pMHC binding avidity with only marginal impact of 
other cell-specific parameters such as the differentiation state or cell activation background.  
In our second study (Manuscript 2), we strengthened this concept as we found highly 
comparable off-rate measurements for a given virus-specific TCRαβ clonotype (Manuscript 2, 
Fig.3 and Supp. Fig. 3), indicative of the strong stability of TCR off-rates for a given clonotype. 
Moreover, while a given clonotype displayed significant biological differences over time, i.e. 
between Tn and 15 years later (i.e. Tn+15y), as shown by ex vivo RNA sequencing (Manuscript 2, 
Fig. 6A and Supp. Fig. 4A), NTAmer-based off-rates were again highly conserved. Indeed, 
strong positive correlations were observed between NTAmer-based off-rates from EBV- and 
CMV-specific T cell clones bearing the same TCRαβ obtained at Tn and Tn+15y from the six 
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studied healthy donors, both with wild-type (WT)- and CD8null-NTAmers (Manuscript 2, Fig. 
3B, E, Supp. Fig2A and Fig. 4 A, B). Collectively, these data demonstrate that the TCRαβ is a 
highly stable determinant of the TCR-pMHC structural/binding avidity of living CD8 T cells 
measured by reversible multimers. 
2.4. TRVB but not TRAV usage of EBV-specific T cells is linked to different 
TCR avidity 
Here, we characterized the TCR repertoire diversity and composition of EBV- and CMV-
specific CD8 T cell repertoires from 6 healthy donors. In line with previous studies [90, 91, 
199, 202, 203, 205] , in A2/EBV-BMFL1-specific CD8 T cell repertoires, we observed the 
preferential usage of some TRBV families, i.e. TRBV20, TRBV29, TRBV2 and to a lesser 
extent TRBV6 and TRBV14 (Manuscript 2, Fig. 2). There was also a marked preferential usage 
of TRAV families with, in all EBV-positive donors combined, 34 clonotypes out of 57 using 
TRAV5 with a recurrent TRAV5-DNNARL-AJ31 motif, followed by 14 clonotypes using 
TRAV12-1 with the frequent motif TRAV12-1-NGxDSSYKL-AJ12. Moreover, we identified 
three public TCR sequences defined by identical α/β TCRs shared between different healthy 
donors (Manuscript 2, Supp. Table 4). On the other hand, A2/CMV-pp65-specific repertoires 
did not show striking TRBV usage preference even though several TCR clonotypes bearing 
TRBV6-5 and TRBV12 gene segments were each identified in two different healthy individuals 
(Manuscript, Supp. Table 3). TRAV usage was more biased with the preferential usage of 
TRAV18 observed in 3 out of 4 individuals (Manuscript, Supp. Table 3), with a recurrent 
TRAV18-xxGNQF-AJ49 motif. Finally, while we did not identify “true” CMV-specific α/β 
public TCRs, we found an identical β chain, i.e. TRBV12-SSANYGY-BJ1.2, in two donors, 
that has previously been described by others [91, 202, 205]. The less stringent TCR bias in the 
CMV-specific response compared to EBV can in part be explained by highly restricted 
repertoires with only a few dominant clonotypes in each individual. 
 TCR bias can arise for various different reasons. The peptide accessibility in the MHC 
could bias the selection of naive T cells bearing TCRs with conserved structural motifs. 
Specifically, peptides deeply encapsulated in the MHC groove in a featureless conformation 
may select restricted TCRs with specific structural pattern [338], while protruding peptides 
would drive the selection of a broader TCR diversity (reviewed in [339]). However, TCR bias 
cannot be exclusively attributed to a featureless pMHC, as we observed striking TCR bias of 
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the A2/EBV-BMFL1 specific response despite it being a protuberant peptide [340]. Indeed, it 
has been shown that the commonly observed biased TRAV5 and TRBV20 gene usage in the 
A2/EBV-BMFL1 specific response is related to unique residues encoded only by these genes 
which lead to specific pMHC contacts [340]. Finally, antigen-driven selection and amplification 
of clones bearing TCRs of high avidity/affinity based on a particular pMHC recognition model 
may occur. In this context, Gras et al. [219] demonstrated that the immunodominance of a high 
avidity TCR (based on CD8null multimer staining and multimer dissociation assay) [205] in the 
pp65/CMV-specific response could be explained by the fact that it forms tight contacts with 
3 peptide residues and one HLA-A*0201 amino acid, and is thus of high structural 
complementarity with the entire peptide. However, this cannot be the main parameter driving 
TCR bias as we and others [205] observed the preferential selection of TCRs covering a large 
range of TCR-pMHC avidities. Many other factors can have an impact on TCR selection and 
bias such as convergent recombination, bias in TCR α and β chain pairing for optimal 
interaction with MHC or an individual’s MHC haplotype (reviewed in [341]). The number of 
parameters impacting TCR selection and their synergy renders the understanding of 
mechanisms underlying TCR usage bias very challenging. 
In our study we also demonstrated in four EBV-positive healthy donors that TCR-pMHC 
binding avidity and CD8-binding dependency measured by NTAmers and CD8null NTAmers, 
respectively, were closely related to distinct TRBV family usage but to a weaker extent to TRAV 
usage (Manuscript 2, Fig. 4, Supp. Fig. 3). Indeed, substantial TCR avidity differences were 
observed between the two highly dominant TRBV families, with TRBV20 clonotypes bearing 
significantly higher avidity TCRs (slower off-rates) and being mainly CD8-binding independent 
compared to TRBV29 clonotypes which were generally of low avidity (fast off-rates) and largely 
CD8-binding dependent (Manuscript 2, Fig. 4). These differences in TCR binding avidity 
related to particular TRBV families were to some extent further reflected at the functional 
avidity level. Specifically, TRBV29 clonotypes produced slightly less CD107a and cytokines 
(IFNg; TNFα), and were less able to kill target cells than TRBV20 clonotypes (Manuscript 2, 
Fig. 4H). These functional analyses could in part be biased by the relatively broad avidity range 
of each TRBV family, precluding the assessment of clear functional differences. Nonetheless, 
these data are in line with the strong positive correlation observed between TCR-pMHC 
binding avidity and functional capacities at the clonal level in our first manuscript (Manuscript 
1, [254]). On the other hand, the highly dominant TRAV5 and TRAV12 families were not 
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associated with distinct TCR-pMHC binding avidity and clones bearing such TCRs covered a 
large range of avidity (Manuscript 2, Supp. Fig. 3E). Together, we have shown that in 
EBV/BMLF1-specific responses, the TCR-pMHC binding avidity was linked to preferential 
TRBV but not TRAV usage and had no impact on clonotype prevalence over time which was 
found to be highly stable, independent of the clonotypes’ TCR avidity.  
2.5. Virus-specific TCRαβ clonal repertoire over time 
Previous longitudinal studies have reported that the clonal repertoire specific for CMV and 
EBV infections, once established, did not evolve for at least several years [91, 198, 216, 217, 
342, 343]. Nonetheless, the maximal time span analyzed in those studies was 5 years, whereas 
CMV and EBV immune responses persist for decades and small changes in the TCR repertoire 
may only be observed over longer periods of time. To gain deeper insight into the persistence 
and/or evolution of EBV- and CMV-specific CD8 T cell clonal repertoires over extended 
periods of time, we analyzed the TCRαβ clonotype composition and selection of large panels 
of CMV- and EBV-specific CD8 T-cell clones from our cohort of chronically infected healthy 
donors over a period of 15 years. 
2.5.1. Differences between EBV- and CMV-specific clonal repertoires 
EBV-specific responses studied in four healthy donors revealed a remarkable stability in the 
clonal repertoire composition and distribution between the two time-points, suggesting that, 
once established, EBV-specific repertoires are kept strikingly constant over time (Manuscript 
2, Fig. 2C). Whether this clonal repertoire stability is a global characteristic of EBV-specific 
responses or only of responses against the studied EBV epitope, i.e. A2/BMLF1280-288, remains 
to be elucidated. Indeed, A2/BMLF1280-288 is an epitope from the early protein BMLF1 of the 
lytic cycle. Immediate early and early protein-derived epitopes are preferentially expressed on 
the infected cell surface during the acute phase of EBV infection and lead to the amplification 
of T cells specific for those epitopes. During the latent phase, highly restricted latent gene 
expression in infected cells avoids immune detection by minimizing antigen exposure [127]. 
The remarkable stability of the EBV-specific CD8 T cell repertoire observed here could be due 
to the absence of targeted-epitope expression in healthy donors during the latent phase. 
Nonetheless, Miles et al. [92] also demonstrated the persistence of single CD8 T cell clonotypes 
against two latent epitopes, i.e. HLA B*0801/FLR and HLA B*4405/EEN, for 18 and 11 
years, respectively, in two healthy individuals.  
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In the four CMV-positive healthy donors, we observed that CMV-specific TCRαβ repertoire 
composition was also maintained, but fluctuations in the clonotypes’ distribution were still 
observed over the 15 year observation period (Manuscript 2, Fig. 1F). Indeed, preferential 
selection of certain clonotypes over others occurred throughout the course of persistent CMV 
infection. This phenomenon was especially apparent in three donors (BCL4, 6 and 1), while 
the CMV-specific TCR repertoire analysis of donor BCL9 showed a relatively more stable 
repertoire with only two clonotypes out of seven showing frequency variation over time 
(Manuscript 2, Fig. 1F). These findings suggest that distinct mechanisms regulate the long-term 
outcome of memory CMV versus EBV-specific CD8 T cell repertoires.  
These two contrasting models of repertoire evolution over long periods time during the latent 
phase of EBV- and CMV-specific memory CD8 T cell responses could, in part, be due to 
differences in the biology of the two viruses. Indeed, as represented in figure 13, during latency, 
EBV reactivation and replication in B cells occurs only sporadically, leading to cycles of T cell 
rest and stimulation thus maintaining a pool of functional CD8 T cells over time [197]. On the 
contrary, CMV latent infection is thought to be characterized by a continuous low level of 
transcriptional activity leading to the constant stimulation of CD8 T cells with infrequent rest 
[196, 197]. While we did not observe a significant increase of CMV+ cells in the CD8 T cell 
compartment of our donors over time, the continual CD8 T cell stimulation observed in CMV 
responses is thought to be the main driver of memory inflation observed in chronic CMV 
infection, and will be discussed in detail in the section 2.5.3. 
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Figure 13: Model of CMV- and EBV-specific CD8 T cell response dynamics. Representative kinetics of 
(A) CMV- and (B) EBV-specific CD8 T cells during the acute and latent phases of infection. A. CMV latent infection is 
characterized by regular transcriptional activity leading to continuous T cell stimulation and the memory inflation of some 
CMV-specific CD8 T cells. B. EBV reactivation events are only sporadic, leading to the maintenance of a constant pool of 
CD8 T cells over time. Adapted from Torti, Oxenius 2012, Wherry, Ahmed 2004, and O’Hara G et al. 2012 [171, 196, 
197]. 
 
2.5.2. Role of TCR avidity in CMV-specific clonal selection 
Despite major efforts, the parameters underlying the long-term maintenance or the selection 
of some virus-specific CD8 T cell clones during the latent phase of infection remain poorly 
understood. TCR avidity/affinity has been investigated by several groups, including ours  [91, 
202, 342, 344], and proposed as a major determinant of TCR repertoire selection and 
dominance in CMV-specific CD8 T cell responses. Nonetheless, its precise impact on long-
term TCR clonal repertoire evolution in healthy individuals has so far not been investigated. 
Recently, Schober et al. [345] proposed three theoretical models for the evolution of CMV-
specific CD8 T cell clonotype repertoires during latency, according to TCR-pMHC binding 
avidity. The first one assumes that a TCR hierarchy according to TCR avidity is established 
during the initial response with an avidity maturation similar to secondary T-cell responses, and 
it is subsequently stably maintained over long periods of time (Figure 14, model A). However, 
an alternative hypothesis is that CMV-specific T cell clones bearing high avidity TCRs are 
continuously preferentially selected over time as shown in the second model (Figure 14, model 
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B). Finally, as Davenport et al. [220] have already proposed, a third model hypothesizes an initial 
accumulation of high-avidity virus-specific T cells followed by the succession of clones of lower 
TCR avidities due to the proliferative senescence of high avidity T cells by frequent antigenic 
stimulation (Figure 14, model C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Models of TCR avidity-dependent repertoire evolution during CMV latency. During CMV 
latency, a TCR repertoire hierarchy according to TCR avidity could be established and then maintained in a state of equilibrium 
(model A), or lead to the continued selection of high avidity clones over time (model B). Alternatively, high avidity clones could 
by more prone to proliferative senescence after an initial accumulation, and thus be succeeded by clones with lower avidity TCRs 
over time (model C). Adapted from Schober et al. 2018 [345]. 
 
In our study, we took advantage of NTAmer and CD8null NTAmer based off-rate 
measurements to assess the impact of TCR-ligand avidity on the evolution of clonal repertoires 
specific for latent herpes viruses over extended periods of time (i.e. 15 years). We observed, at 
the clonal level, the preferential selection and expansion over time of clonotypes of relatively 
lower TCR-pMHC avidity and higher CD8 binding dependency compared to clonotypes that 
tended to decrease in frequency over time (Manuscript 2, Fig. 3). Consequently, at the 
CMV+CD8+ population level, we also observed a significant overall avidity decline over time 
(Manuscript 2, Fig. 5). These results are in line with the third model proposed by Schober et al. 
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stochastic, the degree of determinism vs. stochasticity is still a mat-
ter of debate when it comes to T- cell fate during an in vivo epitope- 
specific T- cell response.99,100 Currently, there might be stro ger 
arguments for a dominance of stochastic features during this pro-
cess. Many examples not only from complex composite systems in 
physics,98 but also the generation of the TCR repertoire itself show 
stochasticity.100 I portantly, stochastic behavior of epitope- specific 
T cells on the single- cell level can still lead to predictable T- cell re-
sponses on the overall population level, for example, through the in-
tegration of a defined developmental framework that applies for all 
individual cells.93,100,101 Feedback loops of signal integration, spati-
otemporal control, and stochastic gene expression of environmental 
cues are additional examples which can explain how T- cell responses 
can be stochastic on the level of individual cells, but still robust and 
predictable on the overall population level.102
3.5 | Probability modulation through immune 
response regulators
The c mbinati  of “protection assurance” with the “flexibility to 
react against virtually any foreign target with phenotypic plastic-
ity”103,104 is a fascinating and highly complex biological task, which 
makes it difficult to assign unique effects to individual regulators of 
immune responses. Each regulator should be regarded as a “modu-
lator of probability” affecting the overall outcome of the immune 
response. Importantly, the degree of observable “determinism” 
that a single regulator contributes to a T- cell response depends not 
only on the strength of influence, but also on the degree of redun-
dancy with which this regulator is present in the responding T- cell 
population.101
A classic example from probability theory illustrates this phe-
nomenon: if one rolls a regular 6- faced die once, the outcome 
is highly variable (predictions will only be correct in 1/6 cases). 
However, biological systems are often characterized by redundancy. 
The more redundantly a certain event occurs, the more predictable 
the overall outcome is going to be. If the result “6” should occur with 
>95%	confidence	at	least	once,	one	has	to	roll	17	unloaded	dice	(1−
(5/6)17 = 0.955). If dice are loaded so that the probability to obtain 
the result “6” is 2/6, one needs to roll only 8 dice to have a >95% 
chance	to	roll	a	“6”	at	least	once	(1−(4/6)8 = 0.961). This means that 
strong regulators increase chances to observe a certain effect even 
if the level of redundancy is low, but that weak regulation can also 
exert a detectable effect when the degree of redundancy is suffi-
ciently high.
Sizes of epitope- specific T- cell populations are relatively well 
predictable in standardized mouse models, where many factors 
(such as MHC haplotype, age, antigen dose, mouse housing con-
ditions) can be controlled. This argues for a significant level of re-
dundancy as far as the composition of the naive TCR repertoire is 
concerned. In fact, given the variability observed for single T- cell- 
derived immune responses it appears likely that a certain level of re-
dundancy within the naive TCR repertoire is physiologically relevant, 
to guarantee for “robust” and efficient T- cell responses in the case 
of antigen ncounter.
However, this applies only to the epitope- specific T- cell population 
as a whole; the progeny size of a single low avidity T cell has been de-
scribed to be just as variable as the progeny size of a single high- avidity 
CD8+ T cell.96,97 Thereby, it is most likely that single- cell variability 
exceeds the impact of modulation hardwired through TCR avidity. 
Recently, the mean progeny size derived from monoclonal populations 
of CD4+ T cells, exposed to high vs low avidity TCR ligation, was found 
to differ by approximately 10- fold. However, the progeny size derived 
from single CD4+ T cells, harboring identical TCRs and exposed to high 
avidity TCR ligation only, varied across a 200- fold range.
As illustrated in Figure 2 for primary T- cell responses, the above- 
summarized findings and models allow certain predictions of cor-
relations between TCR avidity and progeny size expanded from a 
polyclonal source of naive epitope- specific precursor cells. For 
F IGURE  3 TCR avidity- dependent 
repertoire evolution during CMV latency. 
During CMV latency, the TCR repertoire 
may show avidity maturation similarly 
to secondary T- cell responses (Figure 2), 
which ends in a state of equilibrium 
(model A) or becomes continuously 
accentuated (model B). Alternatively, 
high- avidity T cells vanish after initial 
avidity maturation (eg, due to proliferative 
senescence) and are succeeded by clones 
with lower avidity TCRs [Colour figure can 
be viewed at wileyonlinelibrary.com]
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[345] (Figure 14) and are supported by studies that have investigated TCR repertoire evolution 
during aging, by comparing groups of individuals of different ages, and revealed an 
accumulation of lower avidity CMV-specific CD8 T cells [221, 222]. Together, our data and 
others [221, 222] indicate a T cell repertoire skewing towards an overall lower avidity over 
extended periods of time and during aging in CMV chronic infection. This was strikingly 
contrasting with EBV-specific repertoires which were highly stable in terms of repertoire 
composition and distribution, as well as in overall avidity (Manuscript 2, Fig. 5). Indeed, EBV-
specific repertoire evolution fits with the 1st model proposed by Schober et al. [345] (Figure 14, 
model A), which assumes that clones bearing TCRs covering a large range of affinities are 
selected during the primary response and early during the latent phase and are subsequently 
stably maintained over long periods of time. 
2.5.3. CMV memory inflation 
CMV-specific immune responses have been largely investigated in recent decades for their 
particular capacity to accumulate over time in hosts, in a phenomenon called memory inflation. 
In our study, we did not observe clear signs of T cell expansion as only one donor, BCL6, 
showed an increase in the frequency of CMV/pp65+ cells in the pool of CD8 T cells over time 
(Manuscript 2, Fig. 1). Several studies [156, 346], but not all [347, 348], have observed that both 
major CMV immunodominant proteins, pp65 and IE1, can drive the accumulation of antigen-
specific T cells in humans with aging. Nonetheless, our observation could in part be explained 
by the pattern of expression of the studied epitope, pp65, compared with IE1, during latency 
[348-350]. Indeed, immediate early proteins such as IE1 are the first proteins to be expressed 
during latent CMV replication and even the only one in some instances as CMV replication has 
been shown to be arrested before early proteins are made in monocytic precursor cells [351]. 
As a result, IE1-specific T cells would be the first to be activated and to kill infected cells before 
the production of early and late proteins such as pp65. Therefore, pp65-specific T cells may be 
less prone to constant stimulation and more dependent on productive CMV reactivation. The 
importance of the targeted epitope in memory inflation has been extensively studied in mice, 
where it has been shown that its location in the CMV genome and its ability to be processed 
by the constitutive proteasome of infected cells influence the degree of memory inflation 
(reviewed in [352]). In addition, in humans, memory inflation has been particularly described 
in populations over 60 years old [156, 353] while the studied CMV positive healthy donors here 
had an average age of 45 years (+/- 10 years) at the time of the second sample collection 
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(Manuscript 2, Supp. Table 2). Thus, one hypothesis is that in our setting it is too early in the 
course of the latent phase to observe significative T cell expansion/inflation.  
Importantly, it should be noted that whether CMV memory inflation really occurs in humans 
is still a matter of debate (reviewed in [354]). While several studies observed an accumulation 
of CMV-specific T cells in humans, others have shown no such accumulation. These 
discrepancies could be link to several parameters such as (i) the choice of the studied epitope-
specific response, (ii) the setting, i.e. longitudinal versus cross-sectional studies and the lack of 
knowledge of when primary hCMV infection occurred, (iii) the method (ex vivo multimer 
staining or quantitative functional assay) or (iv) the readout (absolute number or frequency of 
virus-specific T cells). Additional long-term longitudinal studies with the precise quantification 
of T cells specific for a large array of CMV epitopes in human are still required. 
Nonetheless, in our study, we observed the decline in frequency of clones of higher TCR-
pMHC binding avidity. In addition to the theory of proliferative senescence of high avidity T 
cells previously described (Figure 14, Model C), additional and non-exclusive factors could 
further account for a slow repertoire avidity decline over time in the context of CMV memory 
inflation. For example, it has been shown in mice that the inflationary repertoire is highly 
dynamic with the continuous production of short-lived EM T cells recruited from a pool of 
CM cells [173]. One could hypothesize that naive T cells with high avidity TCRs would generate 
a larger pool of CM T cells during the acute phase thus leading to the maintenance of a 
repertoire of mainly high avidity EM T cells over time. Nonetheless, high avidity CM T cells 
might also have higher chances of differentiating into EM T cells with no further backup of 
memory cells. Thus, high avidity T cells would gradually disappear from the long-term 
maintained memory pool and be replaced by cells of lower TCR avidity. Many other parameters 
such as virus-specific factors have been described to impact the degree of memory inflation 
(reviewed in [352]) and thus potentially the extent of repertoire shift. For instance, a high initial 
viral inoculum and, thus, an increased number of latently CMV-infected cells lead to increased 
memory inflation in mice [355] (Figure 15). In addition, instances of complete CMV 
reactivation or CMV re-infection, even if well controlled by immunocompetent hosts, could 
also significantly impact the repertoire clonal dominance. 
 
Discussion 
 144 
 
 
Figure 15: Parameters driving the degree of MCMV memory inflation. From the virus perspective, the size 
of the initial viral inoculum and the number of latently infected cells impact the extent of memory inflation. From the host 
perspective, the inflationary T cell precursor frequency as well as their TCR avidity for the pMHC can influence the degree of 
memory inflation. Adapted from Welten, Bauman and Oxenius, 2019 [352]. 
 
2.5.4. Mechanisms for overall repertoire avidity decline over time 
To gain further insight into the mechanisms underlying the selection of low avidity clonotypes 
over time in chronic CMV-specific CD8 T cell responses, we performed a global transcription 
profiling by RNA sequencing on ex vivo sorted populations representative of each of the main 
clonotypes isolated at Tn and Tn+15y. BCL9 was excluded from this screening since this 
particular donor presented a more diverse as well as a more stable clonotype repertoire over 
time, in contrast to the preferential accumulation of low binding avidity clonotypes observed 
in the other three donors. Only a limited number of genes were significantly differentially 
expressed between high and low avidity samples as well as between samples from Tn and Tn+15y 
(Manuscript 2, Figure 6, Supp. Fig. 4). One still has to keep in mind that the analyzed cells were 
ex vivo sorted quiescent cells from long term cryopreserved samples, with no in vitro culture nor 
stimulation. Thus, the extraction of good quality RNA and identification of few differentially 
expressed genes was not a foregone conclusion. Interestingly, one of the genes upregulated in 
high avidity clonotypes as well as at late time points encodes for the inhibitory receptor, 
LILRB1 (CD85j/ILT-2/LIR-1). Consistently, clonotypes that decreased in frequency over 
time, which are mainly of high avidity, were also those that expressed higher levels of LILRB1 
compare to clonotypes that increased, at both Tn and Tn+15y.  
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LILRB1 is a receptor expressed in various immune cell types including monocytes, B and T 
cells, NK cells and dendritic cells, but at different levels depending on the cell type [356]. It 
acts as an inhibitory receptor through its cytoplasmic tail which contains several 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that are able to recruit the tyrosine 
phosphatases Src homology region 2 domain-containing phosphatase-1 and -2 (SHP-1 and 
SHP-2) [357]. LILRB1 recognizes MHC class I molecules and interacts with especially high 
affinity with HLA-G molecules [358]. In addition, it binds with high affinity to the hCMV-
UL18 molecule [359], which is an MHC-I homologue expressed by CMV infected cells, and 
which has been proposed to act as a decoy molecule to avoid immune recognition by NK cells 
[360]. Indeed, LILRB1 has been shown to be expressed by CMV-specific CD8 T cells [172, 
263, 353, 361] and its expression has been described to increase with age and to be associated 
with the senescence marker, CD57 [172, 263]. In this context, Gustafson et al. recently showed 
that LILRB1 characterized a population of senescent cells with altered proliferative capacity 
but conserved cytokine production capacities [263]. They proposed LILRB1 as a checkpoint 
regulator to control virus-specific T cell expansion during ageing.  
Expanding on this study, we observed in all CMV-positive donors including BCL9, increased 
LILRB1 expression at the protein level in high avidity CMV-specific clonotypes that decreased 
over time (Manuscript 2, Fig. 7), associated with increased expression of CD57 but not PD-1. 
In addition, by blocking LILRB1 with a specific antibody we were able to increase the 
proliferative potential of LILRB1high clones upon pp65-specific stimulation while no significant 
differences were observed on CD107a degranulation or on IFNγ and TNFα production. 
Collectively, our data suggest that LILRB1 has an important function as an inhibitory 
checkpoint receptor, specifically in controlling the expansion of high avidity clonotypes over 
the course of latent CMV infection (Figure 16). In contrast to CMV-specific T cell clonotypes, 
similar and low LILRB1 expression was found among the different EBV-specific T cell 
clonotypes and was not related to specific TRBV family usage. Collectively, our data reinforce 
the key role of TCR binding avidity in tailoring CMV- but not EBV-specific clonal evolution 
during long periods of viral latency.  
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Figure 16: Representative model of LILRB1 in shaping CMV-specific repertoires over time. 
Expression of the inhibitory receptor LILRB1 by high avidity T cells (i.e. blue cells) could be a mechanism for overall repertoire 
avidity decline over the course of latent CMV infection, specifically by regulating the expansion of high avidity clonotypes. 
 
The role of LILRB1 as an inhibitory checkpoint receptor might be even more pronounced in 
the context of CMV memory inflation. Indeed, as the main factor driving memory inflation 
has been shown to be repetitive antigen exposure [177, 362], one could hypothesize that high 
avidity T cells would be more sensitive to this constant stimulation and thus more susceptible 
to express inhibitory receptors such as LILRB1. This could lead to an even more drastic 
phenomenon of repertoire shift and overall avidity decline over time in the context of memory 
inflation. This hypothesis is in line with the recently published study by Baumann et al. who 
showed in mice that T cells recruited early into the inflationary pool are mainly of high avidity 
[363] (Figure 15), thus being potentially more prone to increased LILRB1 expression in 
response to chronic stimulation and subsequent slow replacement by cells of lower TCR avidity 
over extend periods of time. Nonetheless, whether this mechanism can be observed in short-
lived models such as mice remains unclear. 
In addition to the expression of LILRB1, we could hypothesize that high avidity CMV-specific 
T cells might be more subject to replicative senescence. The increased expression of the marker 
of senescence CD57, but not PD-1, observed in high avidity CMV-specific T cells clonotypes 
(Manuscript 2, Fig. 7) is in line with a senescent phenotype and not an exhausted one. Others 
have also reported that CMV-specific CD8 T cells often maintain effector function, in contrast 
to exhausted T cells [177, 364], but can show signs of replicative senescence due to shortened 
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telomeres [231].  Together, this suggest that CMV-specific CD8 T cells of high TCR avidity are 
more susceptible to become senescent, i.e. high functionality but a decreased proliferative 
potential, than low avidity T cells during CMV latency. This mechanism would be in line with 
the previously presented model (Figure 14, Model C) of replicative senescence of high avidity 
T cells leading to the progressive decline of the overall repertoire avidity, as observed in our 
study. This hypothesis will be investigated in the future by assessing the telomere length of 
CMV+ TRBV+ clonotypes directly ex vivo by quantitative PCR. 
One could imagine that the loss of high avidity CMV-specific T cells in aging with persistent 
CMV infection would be detrimental for the host and would increase the chances of clinically 
dangerous CMV reactivation. On the other hand, mechanisms that dampen immune responses 
might also be highly beneficial. In the context of CMV infection likely characterized as a 
smoldering infection with continuous T cell stimulation, we could imagine that without 
regulatory mechanisms, highly antigen sensitive T cells, i.e. high avidity T cells, would 
extensively proliferate and overwhelm the T cell compartment. Such an outgrowth of only few 
epitope-specific T cells could severely impair CD8-mediated immune responses against other 
pathogens. Expression of inhibitory receptors such as LILRB1 may provide another 
mechanism by which excessive expansion of some virus-specific T cells during lifelong latent 
infection might be tightly regulated, while preserving a global functional repertoire. Along these 
lines and despite being of relatively lower TCR-pMHC binding avidity, we observed that 
clonotypes enriched over time were nonetheless of high functional quality and able to 
efficiently kill target cells, thereby providing long term protection from CMV reactivation or 
re-infection. 
2.6. Perspectives 
In our study, we are able to demonstrate the decline of CMV- but not EBV-specific CD8 T 
cells of high TCR avidity over time. This decline was associated with increased expression of 
the inhibitory receptor LILRB1, both at the gene level by ex vivo RNA sequencing and at the 
protein level in in vitro generated clones. Nonetheless, the assessment of protein expression in 
in vitro maintained clones is often tricky and does not necessarily reflect in vivo expression. In 
vitro culture can induce significant bias depending on the culture conditions, the activation state 
of the cells, or the number of rounds of in vitro stimulation they have been subjected to. In our 
study, although LILRB1 expression profiles in clones were in line with the gene expression 
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assessed by ex vivo RNA sequencing, we observed a great diversity of LILRB1 expression levels 
among clones sharing the same TCRαβ clonotype. This could indicate a bias of culture and 
clone selection and potentially not reflecting the protein expression at the population level. To 
overcome this limitation, we plan to assess the level of LILRB1 expression, as well as CD57 
and PD-1, directly ex vivo on the cell surface of CMV/TRBV-specific populations of selected 
healthy donors at Tn and Tn+15y. These data should further confirm the preferential expression 
of LILRB1 in high avidity CMV-specific T cells in vivo. 
LILRB1 interacts with MHC class I molecules and acts as an inhibitory receptor through 
several ITIM motifs which can transmit inhibitory signals and inhibit the activity of immune 
cells [365]. In the context of CMV, LILRB1 interacts with high affinity with the MHC-I 
homologue UL18 expressed by CMV infected cells and inhibits LILRB1high NK cell function 
[360], thus potentially protecting CMV infected cells from LILRB1high NK cell attack. Based 
on our data, we could speculate a similar role of UL18 expression by CMV-infected cells to 
limit LILRB1high CD8 T cell function. Similarly, LILRB1 is thought to be important for the 
evasion from immune surveillance of HLA-G positive tumor cells [366, 367]. Indeed, HLA-G 
is a high affinity ligand of LILRB1, and elevated expression of both markers in tumor tissue 
has been associated with advanced tumor stage [368]. In addition, HLA-G-LILRB1 signaling 
has been studied in NK cells and shown to inhibit the proliferation and cytotoxic activity of 
infiltrating NK cells in gastric cancer, thus limiting their anti-tumor activity [369]. Finally, 
LILRB1 interaction with the common MHC class I component b2-microglobulin, expressed 
on the cell surface of macrophages and cancer cells, respectively, has been shown to act as a 
“don’t eat” me signal that prevents cancer cell phagocytosis [370]. Together, these studies 
suggest that LILRB1 could be an important immunological target for engaging immune cells 
such as NK cells and macrophages to attack cancer cells. In addition, one could hypothesize 
that LILRB1 expressing tumor infiltrating CD8 T cells would be hindered by tumor cells 
expressing common MHC class I component b2-microglobulin or HLA-G, thus impairing 
efficient T cell-mediated anti-tumor immunity. Thereby, agents directed against the MHC-class 
I-LILRB1 signaling axis might sensitize tumors to immune attack. Nonetheless, MHC-I is 
ubiquitously expressed by normal cells, thus raising questions regarding the safety and 
specificity of potential MHC-1-LILRB1 targeted immunotherapy. Additional studies are 
necessary to better understand the role of LILRB1 in both the viral and tumor contexts, and 
to explore the MHC-l-LILRB1 axis as a target for immunotherapy. 
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